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Cardiovascular disease (CVD) causes a global burden with a death rate of 17.3 million 
per year which is rapidly inclining to an estimated 23.6 million in 2030.1 Atherosclerosis, 
a chronic inflammatory disease of multifactorial origin that may ultimately lead to 
stenosis or atherothrombosis,2, 3 is a dominant contributor to the development of CVD.4 
It is characterized by the development of atherosclerotic lesions consisting of activated 
endothelial cells, lipid accumulation, leukocytes, macrophages, foam cells, connective-
tissue elements, calcified regions and necrotic cores.3, 5 The progressive decrease in lumen 
size caused by the development of these lesions was previously described as the culprit 
that led to cardiovascular events.3 However, it is now believed that this is attributable to a 
decrease in plaque stability, which may lead to rupture followed by thrombus formation on 
the ruptured plaques.6 To this end, an unstable lesion is characterized by a thin, collagen-
poor fibrous cap, decreased smooth muscle cells, increased macrophage infiltration and a 
large necrotic core.5 This type of vulnerable lesion is referred to as a thin-cap fibroatheroma.7 
From a pharmaceutical perspective, several risk factors are currently being targeted in the 
fight against the development of atherosclerosis and the prevalence of CVD. These include 
amongst others; hypertension and high blood cholesterol, more specifically high low-density 
lipoprotein-cholesterol (LDL-C) and low high-density lipoprotein-cholesterol (HDL-C).8 
1. Hypertension
Uncontrolled hypertension is the leading risk factor for CVD.1 Numerous factors including; 
age, ethnicity, family history, genetic factors, lower education and socioeconomic status, 
obesity, smoking, sleep apnea and dietary factors contribute to the development of 
hypertension and several of these factors are modifiable. Nonetheless, according to statistics 
from the American Heart Association, the prevalence of high blood pressure, defined as 
a systolic blood pressure of ≥140 mmHg and a diastolic blood pressure of ≥90 mmHg, or 
taking anti-hypertensive medication, or being diagnosed with hypertension on at least 
two occasions, was as high as 33% for adults aged ≥20 years (extrapolated to 2010 using 
data from the National Health and Nutrition Examination Survey (NHANES) 2007 to 2010).8 
The World Health Organization reported that globally elevated blood pressure caused 
51% of stroke deaths and 45% of coronary heart disease (CHD) deaths.1 The inefficiency 
of the current treatment regimens to reduce these numbers is ascribed not only to lack 
of adherence, but also to failure of treatment strategies to fully neutralize all mechanisms 
involved in hypertension, as well as the activation of feedback mechanisms that counteract 
the treatment effects on blood pressure.9 Therefore, the development of additional anti-
hypertensive treatment options beyond the current ‘gold standard’ therapies, such as 










































inhibitors (ACEi) and angiotensin II type I receptor blockers (ARBs),10 is needed to more 
effectively treat hypertension. 
The renin-angiotensin-aldosterone system (RAAS) plays a crucial role in the regulation 
of blood pressure. Renin secreted by the kidneys cleaves angiotensinogen produced by the 
liver to angiotensin I which is converted by angiotensin converting enzyme to angiotensin II. 
Angiotensin II, in turn binds to angiotensin II receptors leading to arterial vasoconstriction, 
other tubular and glomerular effects, as well as inflammation, hypertrophy and fibrosis.10 
Current treatment strategies that disrupt the RAAS, such as ACEi and ARBs result in 
compensatory increases in angiotensin I or II, as well as in plasma renin activity (PRA).11 
The latter may have further implications since renin was shown to exert angiotensin 
I-independent effects by binding to (pro)renin receptors.10 Moreover, increased PRA has 
been associated with increased mortality rates as a result of myocardial infarction (MI) and 
renal failure.12 The development of direct renin inhibitors emerged as a potential treatment 
strategy to more effectively inhibit the RAAS at the point of origin and at its rate-limiting 
step.13 Aliskiren is the first orally active direct renin inhibitor approved for the treatment 
of hypertension.13 The extent to which aliskiren, administered as monotreatment and in 
combination with current ‘gold standard’ treatment strategies in various patient populations, 
can provide clinical benefit remains to be elucidated. 
2. High blood cholesterol
Cholesterol is a hydrophobic molecule that serves as a structural component in plasma 
membranes and as a precursor for the synthesis of steroid hormones and bile acids.14, 
15 Cholesterol is transported through the circulation in five major classes of lipoprotein 
particles; chylomicrons, very low-density lipoproteins (VLDL), intermediate-density 
lipoproteins (IDL), LDL and HDL.15 Chylomicrons transport dietary lipids after uptake and 
secretion from the intestines and VLDL is secreted from the liver to deliver triglycerides and 
cholesterol to other tissues.
2.1 Low-density lipoprotein-cholesterol
In 1913, Nikolai N. Anitschkow first described the involvement of cholesterol in the 
development of atherosclerosis when rabbits fed a high-cholesterol diet developed 
human-like arterial lesions.16 The recent 100th year anniversary of this discovery is 
worth commemorating given that serum cholesterol contained in LDL particles is now 
well recognized as a primary causal risk factor for CHD as evidenced by experimental, 











































The American Heart Association reported a prevalence of hypercholesterolemia defined 
by TC levels ≥200 mg/dL of 43.4% and by LDL-C levels ≥130 mg/dL of 31.1% (extrapolated to 
2010 using data from NHANES 2007 to 2010).8 The prevalence of high TC and LDL-C levels 
in 2009/2010 was considerably lower compared to 1999/2000, most likely attributable to 
statin use.1 Statins reduce LDL-C up to 55% by inhibiting hydroxy-3-methyl-glutaryl-CoA 
reductase, a rate limiting step in cholesterol biosynthesis.18 Intervention trials provided 
ample evidence that the lowering of LDL-C with statin therapy contributes to a reduction 
of CHD19-21 and recent trials indicated that intensive lipid-lowering with statins may be 
more beneficial in risk reduction than less intensive (or standard) therapy.19 According to 
results from the latter meta-analysis, every 1 mmol/L (40 mg/dL) reduction in LDL-C was 
associated with a 22% reduction in the risk of major vascular events, suggesting that a 2-3 
mmol/L reduction in LDL-cholesterol (LDL-C) would correspond with a 40-50% reduction 
in events. Nonetheless, there remains a substantial residual risk despite statin treatment 
which warrants the development of other treatment options to better protect against CVD, 
especially in combination with statins.
2.1.1 Approved LDL-C-lowering treatment strategies beyond statins 
Despite not sharing the success rate of statin treatment, other LDL-C-lowering treatment 
strategies have been approved for clinical use. These include: bile acid-binding resins, 
cholesterol absorption inhibitors, niacin, peroxisome proliferator-activated receptor 
(PPAR)-α agonists and PPAR-γ agonists.17 In fact, recently the cholesterol absorption inhibitor, 
ezetimibe was the first compound shown to add to the effect of a statin on CVD outcome 
(http://newsroom.heart.org/news/cholesterol-lowering-drug-with-different-action-adds-
to-statins-reduction-of-cardiovascular-risk). 
Bile acid-binding resins and cholesterol absorption inhibitors were developed to inhibit 
cholesterol absorption in the intestine from food and bile.22 Resins reduce the efficiency of 
cholesterol absorption by binding bile acids and therewith decreasing intestinal solubilization 
of lipids, and by binding bile acids resins also increase bile acid synthesis from the precursor 
cholesterol.23 The cholesterol absorption inhibitor, ezetimibe limits cholesterol absorption 
by blocking the function of the transporter Niemann pick C-1-like 1 (NPC1L1). The benefits 
of niacin on plasma lipids were first reported in 1955 and led to the development of niacin 
for therapeutic purposes.24 The lipid-lowering effects of niacin is ascribed to decreased 
free fatty acid (FFA) flux from adipose tissue to the liver, although this reduction in FFAs 
is followed by a rebound effect. Another mechanism described by which niacin decreases 
lipids is by decreasing TG synthesis.25 PPARs are nuclear transcription factors involved in the 
regulation of target gene expression and their effects on glucose and lipid metabolism were 
utilized to develop PPAR agonists for the treatment of hyperglycemia and dyslipidemia.26, 










































VLDL remnants clearance and β-oxidation.28 PPAR-γ agonists mainly mediate glucose 
homeostasis,26 but pioglitazone also weakly activates PPAR-α and, therefore, also has minor 
effects on lipid metabolism.29
2.1.2. Emerging LDL-C-lowering treatment strategies beyond statins
Several other approaches to lower LDL-C are currently being investigated in clinical 
trials, including amongst others: apolipoprotein B inhibition by for example antisense 
oligonucleotides (ASOs), microsomal triglyceride transport protein (MTP) inhibitors, 
proprotein convertase subtilisin kexin type 9 (PCSK9) inhibition by for instance monoclonal 
antibodies, gene-silencing or vaccines and PPAR-δ agonists.17 Some of these treatment 
strategies have already been approved in certain countries.
The ASO against apolipoprotein B, mipomersen inhibits the synthesis of apolipoprotein 
B by binding to the messenger RNA coding for apolipoprotein B-100 and the MTP inhibitor, 
lomitapide inhibits the transfer of triglycerides to apolipoprotein B during formation of 
a mature VLDL particle within hepatocytes. Both compounds, therefore, decrease LDL-C 
by reducing VLDL production and secretion.17 PCSK9 is a serine protease responsible for 
LDL receptor (LDLR) degradation.30 Interestingly, the upregulation of the LDLR after statin 
treatment is accompanied by an upregulation of PCSK9 which in turn promotes LDLR 
degradation.31-33 PCSK9 inhibition has, therefore, emerged as a promising new strategy 
to lower LDL-C, especially in combination with statins. PPAR-δ agonists also improve 
atherogenic lipid profiles by modifying cell fuel preference from glucose to lipids34 and a 
reduction in cholesterol absorption via NPC1L1 has been described as another possible 
mechanism.35 
2.2 High-density lipoprotein-cholesterol 
In the 1970s, Miller & Miller hypothesized that a reduction in plasma HDL concentration 
may accelerate the development of atherosclerosis and ischemic heart disease by impairing 
cholesterol clearance from the arterial wall.36 Besides its major role in reverse cholesterol 
transport, HDL has also been described to have anti-inflammatory, anti-oxidant, anti-
platelet and vasodilatory properties.37 Although the original hypothesis referred to HDL 
particle concentration which could not be measured at the time,37 epidemiological studies 
consistently reported an inverse association between CHD risk and HDL-C.38-40 Results from 4 
prospective epidemiologic studies indicated that an increase of 1 mg/dL (0.03 mM) in HDL-C 
was associated with a 2-3% reduction in CHD risk.41 However, data from genetic studies do 
not support a causal relationship between increased HDL-C and reduced risk of MI42, 43 and 
evidence from large clinical trials is lacking.
The American Heart Association revealed a prevalence of HDL-C levels ≤40 mg/dL of 











































no clinical trial has demonstrated beneficial effects of HDL-C-raising therapies, several HDL-
targeting therapies are still being investigated in clinical trials. 
2.2.1. HDL-C-raising treatment strategies beyond statins
Treatment strategies approved for the treatment of hyperlipidemia, such as niacin and PPAR-α 
agonists (fibrates), that mainly decreases triglycerides with a small LDL-C-lowering effect, 
also increases HDL-C. Other therapies in clinical development primarily aimed to increase 
HDL-C include CETP inhibitors, scavenger receptor B-I (SR-BI) inhibitors and apolipoprotein 
A-I inducers.44 In addition, the effects of novel treatment strategies specifically targeting 
HDL are currently being investigated in clinical trials, including reconstituted and delipidated 
HDL, as well as HDL mimetics, apolipoprotein A-I mimetic peptides and recombinant human 
lecithin cholesterol acyltransferase (LCAT).
Niacin is described to increase HDL-C by increasing apolipoprotein A-I lipidation and by 
decreasing apolipoprotein A-I removal,25, 45 and PPAR-α agonists are shown to increase HDL-C 
by increasing apolipoprotein A-I/II expression and cholesterol efflux from macrophages.26 
In 1989, markedly increased HDL-C led to the discovery of the first mutation in the CETP 
gene in two Japanese subjects.46 CETP facilitates the transfer of cholesteryl esters from 
atheroprotective HDL to atherogenic (V)LDL and has become a target to increase HDL-C.47 
The HDL-C-raising effects of niacin and PPAR-α agonists are also ascribed to a reduction in 
CETP.48, 49 The PPAR-γ agonist, pioglitazone increases HDL-C by weakly activating PPAR-α.29 
PPAR-δ agonists also increase HDL-C and this effect is ascribed to possible mechanisms 
involving apolipoprotein A-II and ABCA1.35 The development of reconstituted and delipidated 
HDL, as well as HDL mimetics, apolipoprotein A-I mimetic peptides and recombinant 
human lecithin cholesterol acyltransferase (LCAT) have emerged as potential approaches 
to improve reverse cholesterol transport.50 In addition, the therapeutic use of recombinant 
apolipoprotein A-I Milano originated from the observation that carriers of this mutation 
have low levels of HDL-C without increased atherosclerosis as observed in patients with 
hypoalhalipoproteinemia.51, 52 It remains to be elucidated whether these novel treatment 
strategies may provide additional clinical benefit beyond current therapies. 
3. Experimental model for human-like lipoprotein metabolism and 
atherosclerosis
To investigate the effects of innovative pharmaceutical interventions in experimental 
atherosclerosis, we used the APOE*3Leiden.CETP mouse model. While normal wild-type 
mice have a very rapid clearance of apolipoprotein B-containing lipoproteins, APOE*3Leiden.










































mimic the slow clearance observed in humans, particularly in patients with familial 
dysbetalipoproteinemia (FD).53 The APOE*3Leiden mouse was initially developed as an 
animal model for FD or type III hyperlipoproteinemia, which is characterized by elevated 
levels of cholesterol and an increased ratio of cholesterol to triglycerides in the VLDL and 
IDL fractions, resulting in the appearance of β-VLDL particles.53, 54 Similar to FD patients, 
APOE*3Leiden and APOE*3Leiden.CETP mice carry a major part of plasma cholesterol in 
the VLDL and VLDL-remnant particles, leading to the formation of β-VLDL particles, which 
further increases after cholesterol feeding. These mice respond in a similar way to statins 
as humans with decreases in the apolipoprotein B-containing lipoproteins up to 55%. In 
addition, APOE*3Leiden.CETP mice express human CETP under control of its natural flanking 
regions,55 a crucial gene involved in HDL metabolism and implicated in the mechanisms by 
which most therapies modulate HDL.49 These mice develop diet-induced atherosclerosis 
and respond to TC/LDL-C-lowering and HDL-C-raising drugs in a human-like manner45, 48, 56-
58 and are, therefore, a suitable model to study the effects of innovative pharmaceutical 
interventions on lipid and lipoprotein metabolism and atherosclerosis development. 
4. Outline of this thesis
The research described in this thesis investigated the effects of innovative pharmaceutical 
interventions in experimental atherosclerosis. Statin treatment is currently the first line 
of defense against CVD. However, the treatment of CVD remains suboptimal due to; (i) 
a residual risk that persists after statin treatment, (ii) failure for some patients to reach 
LDL-C targets despite statin treatment, and (iii) lack of adherence to statin treatment as 
a result of statin intolerance. We, therefore investigated the effects of novel treatment 
strategies administered as monotreatment, but also in combination with statin treatment 
on atherosclerosis development in APOE*3.Leiden.CETP mice, a well-established model for 
lipid metabolism and atherosclerosis. 
Hypertension is a leading risk factor for CVD and is associated with the development 
of atherosclerosis. Aliskiren is the first commercially available, orally active, direct renin 
inhibitor approved for the treatment of hypertension. In chapter 2, we investigated the 
effects of aliskiren administered as monotreatment and in combination with atorvastatin on 
systolic blood pressure, total cholesterol, inflammation markers and atherosclerotic lesion 
size and composition in APOE*3Leiden.CETP mice. 
Cholesterol contained in LDL particles is well recognized as a primary causal risk factor 
for CHD as evidenced by experimental, epidemiological and genetic data. Furthermore, 
intervention trials provided ample evidence that the lowering of LDL-C contributes to 











































reported an inverse association between HDL-C and CHD risk, the benefits of raising HDL-C 
remain less defined. In chapter 3 to 6, we investigated the effects of novel lipid-modifying 
treatment strategies, i.e. LDL-C lowering and/or HDL-C-raising compounds on atherosclerosis 
development in the APOE*3Leiden.CETP mouse model, since these mice respond to both 
LDL-C-lowering and HDL-C-raising compounds in a human-like manner. 
The benefits of niacin on plasma lipids were first described in 1955 and led to the 
development of niacin for therapeutic purposes. In chapter 3, we evaluated the effects of 
niacin alone and in combination with simvastatin on plasma lipid levels and atherosclerotic 
lesion size and composition. To further explore the mechanism by which niacin reduces 
atherosclerosis, we performed additional VLDL production and clearance, as well as reverse 
cholesterol transport experiments. We also conducted statistical analyses to assess the 
contribution of the LDL-C-lowering versus HDL-C-raising effects of niacin on the inhibition 
of atherosclerosis. 
CETP is involved in lipoprotein metabolism by facilitating the transfer of cholesterol 
esters from atheroprotective HDL to atherogenic (V)LDL. In chapter 4, we investigated 
the effects of a broad dose range of the novel CETP inhibitor anacetrapib on CETP activity, 
lipid levels, atherosclerotic lesion size and composition and HDL function. In addition, we 
examined possible additive/synergistic effects of anacetrapib on top of atorvastatin. We 
also performed statistical analyses to evaluate whether the effects of anacetrapib and 
atorvastatin on atherosclerosis development could be explained by either a decrease 
in non-HDL-C or an increase in HDL-C or both. Since lowering of non-HDL-C was a major 
determinant of lesion size, we investigated the mechanism by which anacetrapib decreases 
(V)LDL-C levels in chapter 5.
PCSK9 is a serine protease responsible for LDLR degradation. The upregulation of the 
LDLR after statin treatment is accompanied by an upregulation of PCSK9 which in turn 
promotes LDLR degradation. Inhibition of PCSK9 is, therefore, a potential novel strategy in 
the treatment against CVD, especially in combination with statin treatment. In chapter 6, we 
investigated the effects of 2 dosages of the fully human, monoclonal antibody, alirocumab 
alone and in combination with atorvastatin on hepatic LDLR protein levels, hepatic and 
plasma lipid levels, atherosclerosis development and plaque morphology.  
In chapter 7, we reviewed the effects of established and novel treatment strategies, 
specifically targeting HDL, on inhibition of atherosclerosis development in animals expressing 
CETP, a crucial gene involved in HDL metabolism and implicated in the mechanisms by 
which most therapies modulate HDL. In addition, we conducted a meta-analysis to evaluate 
the potential effects of these treatment strategies on the prevention of clinical events in 
randomized controlled trials. In this systematic review and meta-analysis of preclinical 
studies and clinical trials, we focused specifically on the contribution of non-HDL-C/LDL-C-










































The results obtained in these studies and their clinical relevance are discussed in the 
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Objective Aliskiren is the first commercially available, orally active, direct renin inhibitor 
approved to treat hypertension. The renin-angiotensin system has been shown to be a 
significant contributor to the development of hypercholesterolemia-induced atherosclerosis. 
The aim of this study was to evaluate the anti-atherosclerotic and plaque stabilization effects 
of aliskiren alone and in combination with atorvastatin.
Methods APOE*3Leiden.CETP mice (n=14-17/group) were fed a Western-type diet 
(containing 0.25% cholesterol) alone or were treated with either aliskiren (15 mg/kg/day), 
atorvastatin (3.6 mg/kg/day) or a combination of aliskiren and atorvastatin. Effects on 
systolic blood pressure (SBP), total cholesterol, inflammation markers and atherosclerotic 
size and composition were assessed.
Results Aliskiren reduced SBP (-19%, P<0.001) and atorvastatin reduced total cholesterol 
(-24%, P<0.001). Atherosclerotic lesion area was reduced by aliskiren (-40%, P<0.01), 
atorvastatin (-61%, P<0.001) and the combination treatment (-69%, P<0.001). Aliskiren 
alone and together with atorvastatin decreased the number of T cells in the aortic root area 
(-60%, P<0.01; -41%, P<0.05), as well as macrophage (-64%, P<0.001; -72%, P<0.001) and 
necrotic area (-52%, P=0.071; -84%, P<0.001) in the lesion. Atorvastatin alone and together 
with aliskiren decreased monocyte adherence (-43%, P<0.05; -51%, P<0.01) and monocyte 
chemoattractant protein-1 (both -36%, P<0.01). The combination treatment decreased the 
number of lesions (-17%, P<0.05) and E-selectin (-17%, P<0.05).
Conclusion Aliskiren inhibited atherosclerosis development and improved plaque stability 
alone and in combination with atorvastatin, possibly via a mechanism involving T cells. 
These results suggest a potential benefit of using aliskiren in a clinical setting, particularly in 
combination with statin treatment.













































Atherosclerosis is a chronic inflammatory disease of multifactorial origin that may ultimately 
lead to stenosis or thrombosis.1, 2 It is characterized by the development of atherosclerotic 
lesions consisting of activated endothelial cells, inflamed smooth muscle cells (SMCs), lipid 
accumulation, leukocytes, macrophages, foam cells, connective-tissue elements, calcified 
regions and necrotic cores.2-4
It is well known that hypertension is associated with increased cardiovascular risk and 
progression of atherosclerosis.5-7 Endothelial dysfunction occurs secondary to hypertension 
and/or hypercholesterolemia in the early stages of atherogenesis.8 The effects of increased 
renin-angiotensin system (RAS) activity on both blood pressure and the vascular endothelium 
contribute to target organ damage and enhance cardiovascular risk. These effects include 
vasoconstriction and remodeling of the resistance vessels.9 Angiotensin II is considered 
a contributor to the development of hypercholesterolemia-induced atherosclerosis.10, 
11 It was found to be involved in inflammation, migration, proliferation and growth7, 12 by 
regulating adhesion molecule expression, as well as cytokine, chemokine and growth factor 
secretion.13 RAS activity is not only found in the circulation, but local RAS components have 
also been detected in several tissues, including cardiovascular tissues.14, 15 Furthermore, RAS 
activity was implicated in cholesterol synthesis, oxidation of low-density lipoprotein (LDL) 
molecules, production of reactive oxygen species and SMC proliferation, as well as monocyte 
activation and adhesion to the endothelium.8 Beneficial effects of RAS blockers, including 
angiotensin converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARBs) 
on atherosclerosis development have been observed in animal and human studies.16-18 The 
blockage of RAS appears to be an important factor in atherosclerotic plaque stabilization.7
RAS blockade by ACEi and ARBs may not be optimal due to the activation of feedback 
mechanisms that result in increased plasma renin activity (PRA).19, 20 Increased PRA has 
been associated with four to six times higher mortality rates as a result of myocardial 
infarctions and renal failure.19 Furthermore, a large longitudinal analysis recently revealed 
additional side effects in patients with ARB + ACEi therapy.21 Direct renin inhibitors (DRIs) 
have been suggested to be more effective than ACEi and ARBs in the prevention or reversal 
of target organ damage and cardiovascular events12 by blocking the RAS at the point of 
origin and at its rate-limiting step.9, 22 Furthermore, DRIs may exhibit less adverse effects 
compared to other RAS blockers.19, 23 Aliskiren is the first commercially available, orally 
active, non-peptide-like renin inhibitor approved for the treatment of hypertension. It 
inhibits the catalytic activity of renin by binding to the active site of renin. The blockade 
of renin with aliskiren may inhibit the feedback effects observed with ACEi and ARBs and 
thereby, provide a more effective blockage of the RAS.12 Clinical trials, including the ALLAY 










































Failure Treatment)25 and the AVOID (Aliskiren in the Evaluation of Proteinuria In Diabetes) 
studies,26 have shown beneficial effects of aliskiren on various markers of organ damage. A 
decrease in atherosclerosis development with aliskiren monotreatment has been observed 
in experimental studies.7, 15, 27 However, the effect of aliskiren on major clinical endpoints is 
not yet known.
To mimic the clinical situation, we have evaluated the effects of aliskiren alone or in 
combination with the 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase inhibitor, 
atorvastatin, as statins may be considered as standard treatment for cardiovascular disease 
(CVD). The purpose of this study is, therefore, to investigate the anti-atherosclerotic effects 
of the renin inhibitor aliskiren, alone and in combination with atorvastatin, as well as its 
effects on plaque composition in APOE*3Leiden.CETP transgenic mice. These mice have 
a human-like lipoprotein profile and develop atherosclerosis when fed a Western-type 
diet (WTD).28 They also respond to treatment with anti-atherosclerotic drugs in a similar 




Female heterozygous APOE*3Leiden.CETP transgenic mice, 8-12 weeks of age, from 
the specific pathogen free breeding stock at TNO-Biosciences (Leiden) were used. 
APOE*3Leiden mice, characterized by an enzyme-linked immunosorbent assay (ELISA) for 
human apoE, were crossbred with cholesteryl ester transfer protein (CETP) transgenic mice 
that express human CETP under control of its natural flanking regions.28 Animal experiments 
were approved by the Institutional Animal Care and Use Committee of The Netherlands 
Organization for Applied Research (TNO).
Experimental design and diets
Mice were fed on a regular chow until 8-12 weeks of age. During a 3-week run-in period, all 
mice received a semi-synthetic modified WTD, containing 0.25% cholesterol, 15% saturated 
fat and 40% sucrose (all w/w, final concentration). This resulted in moderately elevated 
plasma cholesterol levels of 16.2 ± 3.1 mmol/l. After matching into four groups of 14-17 
mice each based on age, body weight and plasma lipid levels, the mice received WTD alone 
(control group), or were treated with aliskiren (15 mg/kg/day), or with 0.0036% (w/w) 
atorvastatin (3.6 mg/kg/day), or with aliskiren (15 mg/kg/day) plus atorvastatin (3.6 mg/
kg/day) for a period of 14 weeks. Aliskiren (provided by Novartis Institutes for Biomedical 
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Alzet (model 2006 for first 6 weeks and thereafter model 1004 twice for 4 weeks) placed 
subcutaneously on the back of the animals. Mini-pumps loaded with PBS were placed in the 
control group and in the atorvastatin group. Atorvastatin was administered by admixture 
to the diet. The atorvastatin dosage was increased from 0.0018% w/w to 0.0036% w/w 
(3.6 mg/kg/day) after 3 weeks as a result of a non-significant reduction in total cholesterol 
levels (-10%, P=0.084). The animals received food and water ad libitum. Body weight and 
food intake were monitored throughout the study. The study was performed under blinded 
conditions.
Plasma total cholesterol levels, lipoprotein profile and markers of inflammation
After a 4-h fasting period, EDTA plasma was collected every 3-4 weeks (Sarstedt, Nümbrecht, 
Germany). Plasma total cholesterol levels (Roche Diagnostics, No-1489437) were measured 
by a standard enzymatic method. After 8 weeks of treatment, pooled lipoprotein profiles for 
total cholesterol and phospholipids were measured by fast protein liquid chromatography.34 
E-selectin levels and monocyte chemoattractant protein-1 (MCP-1) levels (R&D Systems 
Inc., USA) were determined by ELISA at sacrifice according to manufacturer’s instructions. 
Fibrinogen levels were determined by ELISA, using rabbit anti-rat fibrin monomer 
immunoglobulin G as capture antibody and peroxidase-conjugated goat anti-mouse 
fibrinogen immunoglobulin G (Nordic, Tilburg, The Netherlands) as detection antibody. 
Mouse plasma with gravimetrically determined fibrinogen content was used for calibration.
Systolic blood pressure
To evaluate the effect of aliskiren, the systolic blood pressure (SBP) was measured in all 
groups after 10 and 13 weeks of treatment by cuff-tail method using the Non-Invasive Blood 
Pressure Monitor (Columbus Instruments, OH, USA). For each mouse, the blood pressure 
was measured three times during one session.34 
Histological assessment of atherosclerosis
After the 14-week treatment period, all the mice were sacrificed and hearts were isolated, 
formalin fixed and embedded in paraffin. They were then sectioned perpendicular to the 
axis of the aorta, starting within the heart and working in the direction of the aortic arch. 
Once the aortic root was identified by the appearance of aortic valve leaflets, serial cross 
sections (5 µm thick with intervals of 50 µm) were mounted on 3-aminopropyl-triethoxy-
silane-coated slides.35 These sections were stained with hematoxylin-phloxine-saffron (HPS) 
for histological analysis. For each mouse, the lesion area was measured in four subsequent 
sections. Each section consisted of three segments. The average lesion area per cross section 










































For determination of atherosclerotic lesion size and severity, the lesions were classified 
into five categories according to the American Heart Association (AHA).36 I) early fatty 
streak: up to ten foam cells in the intima with no other changes, II) regular fatty streak: ten 
or more foam cells in the intima with no other changes, III) mild plaque: a fibrotic cap and 
the presence of foam cells in the media, IV) moderate plaque: progressed lesions with an 
affected media, but without loss of architecture in the media, V) severe plaque: the media is 
severely affected and broken elastic fibers, cholesterol clefts, calcification and necrosis are 
frequently observed.28, 37 Per mouse, the percentage of all lesions found in the respective 
categories was calculated. The total lesion area, number of lesions and undiseased segments 
were calculated per cross section. Lesion severity as a percentage of lesion area was also 
determined. Type I-III lesions were classified as mild lesions and type IV-V lesions were 
classified as severe lesions.
Mouse monocytes and T cells were immunostained with rabbit anti-mouse AIA31240 (1: 
1000; Accurate Chemical and Scientific, New York, USA) and rat anti-human CD3 (1: 500; AbD 
Serotec, Oxford, UK) which cross-reacts with mouse CD3, respectively. Macrophage area 
was measured after immunostaining with rat anti-mouse Mac-3 (1: 50; BD Pharmingen, the 
Netherlands). Collagen content in the plaque was quantified morphometrically after sirius 
red staining. Mouse SMCs were immunostained with mouse anti-human alpha actin (1: 800; 
DAKO, Glostrup, Denmark) which cross-reacts with mouse alpha actin. In each segment 
used for lesion quantification, the number of monocytes adhering to the endothelium and 
the number of T cells in the aortic root area were counted and the endothelium length 
and the total aortic root area were measured. The length of the endothelium did not differ 
between groups and there were no correlation between the number of T cells and the total 
aortic root area per group. We, therefore, calculated the average number of monocytes and 
T cells per cross section. Macrophage and collagen area were measured in the severe lesions 
(type IV-V) and calculated per cross section and as a percentage of lesion area.37 In addition, 
SMC area in the superficial part of the severe lesions,34 as well as necrotic area of the severe 
lesions (type IV-V) were determined per cross section and as a percentage of lesion area.
Statistical analysis
Significance of differences between the groups was calculated parametrically by analysis of 
variance (ANOVA) followed by post hoc analysis using the least significant difference (LSD) 
test. Variables with a non-Gaussian distribution were logarithmically transformed. Due to 
heterogeneity between groups, the variables, macrophage content (% of lesion area) and 
necrotic area (% of lesion area) were analyzed by ANOVA using Brown-Forsynthe for overall 
between groups test and the Dunnett’s T3 test for post hoc. Differences in lesion area were 
corrected for blood pressure by analysis of covariance (ANCOVA). The treatment group was 
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to the control group and the combination group was compared to the atorvastatin group. 
Values are presented as means ± standard deviations (SD). A P-value <0.05 was considered 
statistically significant. In figures: *P<0.05, **P<0.01, ***P<0.001 as compared to the 
control group and #P<0.05, ##P<0.01, ###P<0.001 as compared to the atorvastatin group.34
Results
Aliskiren reduced blood pressure and atorvastatin lowered plasma cholesterol in 
APOE*3Leiden.CETP mice
The APOE*3Leiden.CETP mice have SBP similar to wild-type control animals, thus 
atherosclerosis development is not driven by hypertension in this model. However, to 
verify the blood pressure-lowering effect of aliskiren, SBP was measured on two occasions 
during the study. Aliskiren treatment and the combination treatment reduced SBP by 
-19% (P<0.001) and by -15% (P<0.01), respectively, as compared to the control (103 ± 10 
mmHg). The combination treatment showed a -20% (P<0.001) reduction when compared 
to atorvastatin treatment alone (Table 1). To confirm the cholesterol-reducing effect of 
atorvastatin, plasma total cholesterol levels were measured and total cholesterol exposure 
(mmol/l * time in weeks) was calculated for each mouse. The control group had an average 
total cholesterol level of 15.5 ± 2.1 mmol/l, which was reduced by atorvastatin treatment 
alone and in combination with aliskiren treatment (both -24%, P<0.001). Similar reductions 
in total cholesterol exposure were seen in the respective groups. Lipoprotein profiling 
revealed that the reduction in total cholesterol was mainly confined to the very low-density 
lipoprotein (VLDL)/LDL fractions (data not shown). Aliskiren, in turn, did not affect plasma 
lipid levels when compared to the control group.
Table 1 The effect of aliskiren, atorvastatin and a combination of aliskiren and atorvastatin on plasma 
total cholesterol levels and systolic blood pressure (SBP) over a treatment period of 14 weeks.
Average total 
cholesterol (mmol/l)




Control 15.5 ± 2.1 263 ± 36 103 ± 10
Aliskiren 14.4 ± 4.1 248 ± 38 84 ± 10 ***
Atorvastatin 11.8 ± 3.0 *** 207 ± 35 *** 109 ± 12 
Aliskiren + atorvastatin 11.8 ± 2.1 *** 196 ± 28 *** 88 ± 12 **###
Values are means ± SD (n=14-17 per group). **P<0.01 and ***P<0.001 as compared to control, 










































Aliskiren, atorvastatin and the combination treatment reduced atherosclerosis 
development
After the 14-week treatment period, the mice were sacrificed to assess the effect of the 
treatments on atherosclerotic lesion development in the aortic root. Representative 
photomicrographs of atherosclerotic lesions are illustrated in Figure 1. First, the number 
of lesions was counted per cross section (4.0 ± 0.7 for the control) revealing no effect 
of treatment with aliskiren or atorvastatin alone, whereas the combination treatment 
decreased the number of lesions by -17% (P<0.05; Figure 2A). The total lesion area per cross 
section was 233 ± 136 *1000 µm2 in the control group (Figure 2B). In contrast to the number 
of lesions, total lesion area was reduced by aliskiren (-40%, P<0.01), atorvastatin (-61%, 
P<0.001) and the combination treatment (-69%, P<0.001), as compared to the control 
group. The combination treatment did not significantly differ from atorvastatin treatment 
alone. Lesion severity was also analyzed for each mouse, in which type I-III lesions represent 
mild lesions and type IV-V lesions represent severe lesions. This showed that approximately 
66% of the lesions in the control group were severe lesions in comparison to 50% in the 
aliskiren group (P<0.05), 46% in the atorvastatin group (P<0.01) and 56% in the combination 
group (N.S.; Figure 2C). Additionally, the percentage of undiseased segments was increased 
by atorvastatin (+331%, P<0.001) and the combination treatment (+426%, P<0.001), as 






Figure 1 Representative photomicrographs of atherosclerotic lesions in the cross section of the aortic 
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We further analyzed whether aliskiren had anti-atherosclerotic properties beyond its 
blood pressure-lowering qualities. We calculated, using an ANCOVA (with blood pressure 
as covariate), that after adjusting for blood pressure the reduction in lesion area remained 
significant for all groups (P<0.05; P<0.01; P<0.001, respectively; data not shown). This 
indicated that aliskiren had beneficial effects, other than blood pressure-lowering alone. 








Figure 2 The effect of aliskiren, atorvastatin and a combination of aliskiren and atorvastatin on 
atherosclerosis development in aortic root area. The number of lesions (A) and total lesion area per 
cross section (B), as well as the lesion severity as percentage of all lesions (C) and the percentage of 
undiseased segments (D) were determined after 14 weeks of treatment. Lesion severity was classified 
as mild (type I-III lesions) and severe (type IV-V lesions). 
Alisk, aliskiren; Atorva, atorvastatin; *P<0.05, **P<0.01 and ***P<0.001 as compared to control.
Aliskiren reduced functional markers of inflammation
As a result of the crucial role of inflammation in the development of atherosclerosis, fibrinogen 
levels, reflecting a general systemic inflammatory state, as well as the adhesion molecule, 
E-selectin and the pro-inflammatory chemokine, monocyte chemoattractant protein-1 










































affected by any of the treatments, indicating absence of changes in systemic inflammatory 
status. When compared to the control group (55 ± 11 ng/ml), the only significant difference 
in E-selectin levels was found in the combination group (-17%, P<0.05), revealing synergistic 
effects of aliskiren as this was a reduction of -18% (P<0.05) as compared to the atorvastatin 
group. MCP-1 levels were significantly reduced by -36% (P<0.01) in both the atorvastatin 
group and the combination group when compared to the control group (92 ± 21 pg/ml).
Table 2 The effect of aliskiren, atorvastatin and a combination of aliskiren and atorvastatin on plasma 
inflammation markers.
E-selectin (ng/ml) MCP-1 (pg/ml) Fibrinogen (mg/ml)
Control 55 ± 11 92 ± 21 2.1 ± 0.5
Aliskiren 62 ± 17 91 ± 44 2.0 ± 0.7
Atorvastatin 56 ± 13 59 ± 24 ** 2.3 ± 0.9 
Aliskiren + atorvastatin 46 ± 7 *# 59 ± 25 ** 2.1 ± 0.7 
The parameters were measured at the end of the study after 14 weeks of treatment. Values are means 
± SD (n=14-17 per group). *P<0.05 and **P<0.01 as compared to control, #P<0.05 as compared to 
atorvastatin.
As a functional measurement of vessel wall inflammation, monocyte adherence to the 
activated endothelium, as well as T cell abundance in the aortic root area were assessed. 
Figure 3 illustrates representative photomicrographs of the monocyte (Figure 3A) and T 
cell (Figure 3B) stainings, respectively. The average number of monocytes and T cells 
per cross section for the control group were 6.1 ± 3.6 and 14.9 ± 9.5, respectively (Table 
3). The atorvastatin and combination group showed a reduction in monocytes of -43% 
(P<0.05) and -51% (P<0.01), respectively, whereas aliskiren alone did not affect monocyte 
adherence. More interesting, aliskiren did affect the abundance of T cells in the aortic root 
area when administered alone and together with atorvastatin (-60%, P<0.01; -41%, P<0.05, 
respectively). Atorvastatin only tended to reduce the amount of T cells (P=0.084). Taken 
together, these data indicate anti-inflammatory effects of aliskiren via a reduction in T cell 
abundance and atorvastatin via a reduction in monocyte adherence. The anti-inflammatory 
effect may be enhanced by the combination treatment via a dampening of endothelial 

















































Figure 3 Representative photomicrographs of mouse monocytes and T cells after immunostaining with 
anti-mouse AIA31240 (A) and anti-human CD3 (B), respectively, as well as necrotic area (indicated by 
arrows) after hemotoxylin-phloxine-saffron (HPS) staining (C).
Table 3 The effect of aliskiren, atorvastatin and a combination of aliskiren and atorvastatin on 
functional markers of vessel wall inflammation.
Number of monocytes/ 
cross section
Number of T cells/ 
cross section
Control 6.1 ± 3.6 14.9 ± 9.5
Aliskiren 5.9 ± 3.7 6.0 ± 4.5 **
Atorvastatin 3.5 ± 2.3 * 7.6 ± 4.4 p=0.084
Aliskiren + atorvastatin 3.0 ± 2.5 ** 8.9 ± 6.7 *
The number of monocytes adhering to the vascular endothelium and T cells in the aortic root area 
were counted and calculated per cross section. Values are means ± SD (n=14-17 per group). *P<0.05 










































Aliskiren alone and in combination with atorvastatin improved plaque stability
The composition of all lesions measured was assessed to evaluate the effects of aliskiren, 
atorvastatin and the combination of aliskiren and atorvastatin on plaque stability. To this 
end, macrophage and necrotic area as destabilization components and SMC area in the 
cap, as well as collagen area as stabilization components were measured in the severe 
lesions (type IV-V) and calculated per cross section and as a percentage of the lesion area. 
Necrotic area was assessed after HPS staining (Figure 3C). Figure 4 illustrates representative 
photomicrographs of macrophage content and SMC content in the cap after immunostaining 
with anti-mouse Mac-3 and anti-human alpha actin, respectively and collagen content after 
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Figure 4 Representative photomicrographs of macrophage content and SMC content in the cap after 
immunostaining with anti-mouse Mac-3 and anti-human alpha actin, respectively, and collagen 
content after sirius red staining. 
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Figure 5 demonstrates the effect of treatment on the various components of lesion 
composition per cross section of the severe lesions (type IV-V). For the control group, the 
macrophage area and necrotic area in the severe lesions were 29.7 ± 20.3 *1000 µm2 and 
11.1 ± 7.9 *1000 µm2, respectively. Aliskiren, atorvastatin and the combination treatment 
reduced macrophage (-64%, P<0.001; -70%, P<0.001; -72%, P<0.001, respectively; Figure 
5A) and necrotic area (-52%, P=0.071; -68%, P<0.01; -84%, P<0.001, respectively; Figure 
5B). The combination treatment tended to reduce necrotic area to a greater extent than 
atorvastatin treatment alone (-50%, P=0.094). There were no significant differences in SMC 
area in the cap compared to the control (3.7 ± 2.6 *1000 µm2; Figure 5C).
After correcting for lesion size, aliskiren reduced macrophage content (-40%, P<0.01), 
the combination treatment reduced necrotic area (-54%, P<0.05) and atorvastatin and the 
combination treatment increased SMC content in the cap (+89%, P<0.01; +188%, P<0.001, 
respectively). A significant difference between the atorvastatin and the combination group 
(+52%, P<0.05) indicates a synergistic effect of the combination treatment on SMC content 
in the cap. No changes in collagen content were detected between groups (data not shown).
The stabilization/destabilization ratio of the severe lesions was calculated by dividing the 
sum of the SMC area in the cap and the collagen area by the sum of the macrophage and 
necrotic area (Figure 5D). All treatments increased the stability of the lesions (+62%, P<0.05; 
+75%, P<0.05; +109%, P<0.01, respectively). Similar increases in lesion stability were found 
after correcting for lesion size (data not shown). Therefore, aliskiren, atorvastatin and the 
combination treatment improved plaque stability. This effect of aliskiren was most potent 
when combined with atorvastatin as evidenced by a reduction in necrotic area, as well as by 














































 Figure 5 The atherosclerosis development was further analyzed by measuring the lesion composition 
of the severe lesions (type IV-V). A) Macrophage area per cross section. B) Necrotic area per cross 
section. C) SMC area in the cap per cross section. D) Lesion stability of the severe lesions (type IV-V) 
determined by the ratio of the stabilization factors (SMCs in the cap and collagen) to the destabilization 
factors (macrophages and necrotic area). 
Alisk, aliskiren; Atorva, atorvastatin; *P<0.05, **P<0.01 and ***P<0.001 as compared to control.
Discussion
In the present study, the anti-atherosclerotic effects of aliskiren alone and in combination 
with atorvastatin were evaluated in APOE*3Leiden.CETP mice. Aliskiren reduced SBP (~10-
20 mmHg) and atorvastatin reduced total cholesterol levels (~20-30%) in our study, which 
are both in accordance with findings from previous clinical trials.23, 38 We demonstrated that 
aliskiren reduced lesion size and severity and improved stability of the plaque, as illustrated 
by a reduction in macrophage content. The combination of aliskiren and atorvastatin was 
the most potent therapy in reducing the number and size of the lesions, as well as markers of 
inflammation and in improving plaque stability as evidenced by a reduction in macrophage 
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Hypertension is an important risk factor for the development of atherosclerosis. In 
accordance, numerous animal studies have found a decrease in atherosclerosis with or 
without a decrease in blood pressure after treatment with various RAS blockers, including 
ACEi and ARBs.6 Possible mechanisms by which RAS blockers may reduce atherosclerosis 
development described in animal and human studies include inhibition of oxidative stress, 
endothelial dysfunction and inflammation.13, 39 Nonetheless, changes in blood pressure as 
a result of RAS manipulation appear to have a consistent, direct effect on the size of the 
lesions.6 Aliskiren reduced blood pressure in our study, which may be a possible mechanism 
for the reduction in atherosclerosis development. However, it should be noted that the 
APOE*3Leiden.CETP mice used in this study did not have elevated blood pressure and that 
the atherosclerosis development is not driven by hypertension in this model. Moreover, the 
reduction in atherosclerosis development observed by aliskiren remained after correcting 
for blood pressure. We also demonstrated that other mechanisms besides blood pressure-
lowering, such as anti-inflammatory effects, were most likely involved in the reduction of 
atherosclerosis development observed after aliskiren treatment. In line with our study, 
aliskiren showed anti-atherosclerotic effects in Watanabe heritable hyperlipidemic (WHHL) 
rabbits and in ldlr-/- mice beyond its blood pressure-lowering effects,15, 27 confirming the 
involvement of other mechanisms. In these studies, aliskiren was administered in higher 
dosages compared to our study. In addition to monotreatment, we also administered 
aliskiren in combination with a statin, which is considered as a standard treatment in 
prevention of CVD and is, therefore, of clinical relevance. According to our data, aliskiren 
did not significantly enhance the inhibitory activity of atorvastatin on lesion size. However, a 
synergistic reduction in the number of lesions was found after the combination treatment. 
This suggests that the combination of aliskiren and atorvastatin was particularly effective in 
inhibiting early lesion formation, a process in which vascular inflammation plays an essential 
role.
Thus, to explore the mechanism behind the atherosclerosis protective effect of 
aliskiren in the current study, various inflammatory routes were assessed. The combination 
treatment showed a synergistic reduction in E-selectin, a marker of vascular inflammation. 
Aliskiren treatment alone had no effect on circulating MCP-1 levels, nor did it add to the 
reduction observed with atorvastatin treatment. The number of monocytes adhering to the 
endothelium, determined as a functional marker of vessel wall inflammation, confirmed 
these findings. Previously, reductions in vascular cellular adhesion molecule-1 (VCAM-1), 
intercellular adhesion molecule-1 (ICAM-1) and MCP-1 levels were described at substantially 
higher dosages of aliskiren and plasma cholesterol levels (21 mmol/l versus 15 mmol/l 
in the present study), leading to a more inflammatory-driven model.27 The lower dosage 
of aliskiren and a less inflammatory-driven animal model used in our study may provide 










































vascular inflammation. However, we found that aliskiren treatment alone and together with 
atorvastatin treatment reduced T cell abundance in the aortic root area. The participation 
of T cells in atherosclerotic lesion growth and destabilization has been extensively described 
in the literature, in which recent evidence also suggests that T cells may be involved in 
hypertension. The precise mechanism is still unknown.40 T cells have been shown to express 
angiotensin II receptors.41 It was also suggested, although not proven, that the presence of 
activated T cells in a perivascular distribution may cause a local effect of cytokines that may 
alter endothelial function.40 In our study, we assessed the total number of T cells using a 
general marker for T cells, namely CD3. We, therefore, determined the abundance of T cells 
in the aortic root area and not the number of activated T cells in the vessel wall.
The presence of inflammation in the lesions plays a crucial role in plaque instability. On 
the basis of postmortem examination, it is evident that an acute myocardial infarction is 
provoked by sudden rupture of vulnerable plaques followed by thrombosis.42 A vulnerable 
lesion is characterized by a thin, collagen-poor fibrous cap, decreased SMCs, increased 
macrophage infiltration and a large necrotic core.3 This type of lesion is referred to as a 
thin-cap fibroatheroma.43 Patients with unstable plaque have higher incidents of new 
coronary events. The therapeutic target has, therefore, shifted from enlargement of the 
lumen towards stabilization of the plaque.44 Therefore, additional to the lesion area, we also 
investigated the composition of the plaque by performing histological analyses.
All treatments reduced macrophage and necrotic area as evidenced by data from the 
current study. After correcting for lesion size, aliskiren treatment alone reduced macrophage 
content and when combined with atorvastatin, also increased SMC content in the cap of 
the more severe lesions. In addition, the combination treatment also reduced the necrotic 
area. The protective effects of aliskiren on plaque stability were further supported by an 
increase in the stabilization/destabilization ratio. Taken together, we demonstrated that 
aliskiren can enhance plaque stability and that the combination treatment enhanced the 
effects of atorvastatin alone, demonstrating beneficial effects of the combination treatment 
over both monotreatments. There seems to be some apparent inconsistency in the 
literature regarding the effects of aliskiren on lesion composition. Lu et al.15 found that renin 
inhibition by aliskiren reduced atherosclerotic lesion development in ldlr-/- mice without 
major alterations in cellular composition. In contrast, Nussberger et al.7 demonstrated that 
aliskiren can preferentially inhibit plaque vulnerability in a severe apoe-/- mouse model as 
illustrated by both an increase in SMC content, as well as a decrease in macrophage content. 
However, in the same publication, aliskiren had no effect on SMC content when SMCs 
already comprise a substantial portion of the atherosclerotic plaque in a second, less severe 
animal model.7 Our results further suggest that aliskiren in combination with atorvastatin is 
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In this study, we demonstrated the beneficial effects of aliskiren on atherosclerosis 
development and plaque stability alone and in combination with atorvastatin in a pre-
clinical model of CVD, possibly via a mechanism involving T cells. These results suggest a 
potential benefit of using aliskiren in a clinical setting, particularly in combination with statin 
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Objective Niacin potently lowers triglycerides, mildly decreases LDL-cholesterol, and largely 
increases HDL-cholesterol. Despite evidence for an atheroprotective effect of niacin from 
previous small clinical studies, the large outcome trials, AIM-HIGH and HPS2-THRIVE did 
not reveal additional beneficial effects of niacin (alone or in combination with laropiprant) 
on top of statin treatment. We aimed to address this apparent discrepancy by investigating 
the effects of niacin without and with simvastatin on atherosclerosis development and 
determine the underlying mechanisms, in APOE*3Leiden.CETP mice, a model for familial 
dysbetalipoproteinemia (FD).
Methods and Results Mice were fed a Western-type diet containing cholesterol without 
or with niacin (120 mg/kg/day), simvastatin (36 mg/kg/day) or their combination for 18 
weeks. Similarly as in FD patients, niacin reduced total cholesterol by -39% and triglycerides 
by -50%, (both P<0.001). Simvastatin and the combination reduced total cholesterol (-30%; 
-55%, P<0.001), whereas the combination revealed a greater reduction compared to 
simvastatin (-36%, P<0.001). Niacin decreased total cholesterol and triglycerides primarily 
by increasing VLDL clearance. Niacin increased HDL-cholesterol (+28%, P<0.01) and mildly 
increased reverse cholesterol transport. All treatments reduced monocyte adhesion to the 
endothelium (-46%; -47%, P<0.01; -53%, P<0.001), atherosclerotic lesion area (-78%; -49%, 
P<0.01; -87%, P<0.001) and severity. Compared to simvastatin, the combination increased 
plaque stability index [(SMC + collagen)/ macrophages] (3-fold, P<0.01). Niacin and the 
combination reduced T cells in the aortic root (-71%, P<0.01; -81%, P<0.001). Lesion area 
was strongly predicted by non-HDL-cholesterol (R2=0.69, P<0.001) and to a much lesser 
extent by HDL-cholesterol (R2=0.20, P<0.001).
Conclusion Niacin decreases atherosclerosis development mainly by reducing non-HDL-
cholesterol with modest HDL-cholesterol-raising and additional anti-inflammatory effects. 
The additive effect of niacin on top of simvastatin is mostly dependent on its non-HDL-
cholesterol-lowering capacities. These data suggest that clinical beneficial effects of niacin 
are largely dependent on its ability to lower LDL-cholesterol on top of concomitant lipid-
lowering therapy.













































The beneficial effects of niacin, also known as nicotinic acid or vitamin B3, on plasma 
lipids and lipoproteins were first described in the 1950s.1 According to a meta-analysis 
of 30 randomized controlled trials, niacin potently reduced triglycerides (TG) by ~15-
30% and increased HDL-cholesterol (HDL-C) by ~10-25%, while mildly reducing plasma 
total cholesterol (TC) by ~5-15% and LDL-cholesterol (LDL-C) by ~5-20%, suggesting an 
atheroprotective effect.2 Whereas previous small clinical studies supported this notion,3-6 
the recent large outcome trials, AIM-HIGH and HPS2-THRIVE failed to reveal additional 
beneficial effects of niacin on top of statin treatment.7, 8
In patients with atherosclerotic disease or those at risk for atherosclerotic disease due 
to dyslipidemia, the primary goal of lipid-modifying therapy is the lowering of LDL-C.9 To this 
end, statins are currently the standard treatment for cardiovascular disease (CVD) resulting 
in a 25-45% risk reduction for cardiovascular events.10 However, a substantial residual risk 
for adverse cardiovascular outcomes remains with statin therapy.3, 11 Moreover, despite 
maximally tolerated statin treatment, some patients cannot reach LDL-C goals. This high 
risk population together with statin intolerant patients verify the need for another LDL-
C-lowering agent to (further) reduce LDL-C levels.12 Treatment of low HDL-C is currently 
considered as a secondary lipid target in the reduction of cardiovascular risk,3 since low 
HDL-C is an independent risk factor for CVD.2, 13 Considering the current treatment options, 
the question remains whether to further reduce LDL-C or to increase HDL-C in addition 
to LDL-C-lowering.12 Therefore, due to both its non-HDL-C-lowering and HDL-C-raising 
properties, niacin was considered an attractive candidate for further cardiovascular risk 
reduction in addition to statin therapy.
Indeed, an initial small clinical study suggested that the addition of niacin to statin 
treatment may cause potentially clinical significant reductions in relative risk of cardiovascular 
events.6 Recently, a number of relatively small secondary prevention studies (ARBITER-2,4 
ARBITER-35 and ARBITER-6-HALTS3) have shown reduced progression and even regression of 
atherosclerosis with combination treatment of niacin and statins compared to statins alone, 
as measured by carotid artery intima-media thickness as a surrogate for clinical endpoints. 
Magnetic resonance imaging results from another study confirmed the reduction in carotid 
atherosclerosis with niacin in statin-treated patients.14 These clinical data were corroborated 
by recent observations that niacin reduced atherosclerosis development, independent of 
lipid-lowering or HDL-C-elevation, in hyperlipidemic LDL receptor knockout mice on a high 
fat diet containing 1.5% cholesterol.15 Despite these promising data, the large outcome trial, 
AIM-HIGH, addressing the effect of niacin on top of aggressive LDL-C-lowering treatment, 
has recently been prematurely terminated due to futility.8 In accordance, the much larger 










































extended-release (ER)-niacin/laropiprant in combination with statin treatment as compared 
to statin monotreatment.7 ER-niacin2 and ER-niacin/laropiprant combination treatment16 
are more tolerable formulations that have been developed due to a reluctance to use niacin 
for clinical treatment as a result of extreme flushing as a side effect.17
In the present study, we aimed to address the seeming discrepancy between the 
beneficial effects of niacin in initial clinical trials,3-6, 14 as well as in LDL receptor knockout 
mice, a model irresponsive to the lipid-modulating effects of niacin,15 and the lack of effect 
of niacin on top of statin treatment on reduction of cardiovascular events in the AIM-HIGH8 
and HPS2-THRIVE trials.7 Therefore, we evaluated the effects of niacin without and with 
simvastatin on atherosclerosis development and investigated the underlying mechanisms 
and contributing factors in APOE*3Leiden.CETP mice. This is a well-established mouse 
model for familial dysbetalipoproteinemia (FD) with human-like lipoprotein metabolism 
and atherosclerosis development. These mice respond to the lipid-lowering effects of both 
niacin18 and statins, e.g. atorvastatin,19 as well as the HDL-C-raising effect of niacin.18
Methods
Animals, diets and experimental design
Female APOE*3Leiden.CETP transgenic mice,20 expressing human cholesteryl ester transfer 
protein (CETP) under control of its natural flanking regions, were housed under standard 
conditions with a 12 h light-dark cycle and had free access to food and water during the 
experiment unless indicated otherwise. Body weight (BW) and food intake were monitored 
during the entire study. To increase plasma cholesterol levels up to ~12 mmol/L, 8-12 
week-old mice were fed a semi-synthetic cholesterol-rich diet, containing 15% (w/w) cacao 
butter and 0.1% cholesterol (Western-type diet; Hope Farms, Woerden, The Netherlands) 
for 3 weeks. After matching based on age, BW, TC, TG and HDL-C, mice (n=15 per group) 
received a control Western-type diet (WTD) without or with 0.1% (w/w) niacin (120 mg/kg/
day), 0.03% (w/w) simvastatin (36 mg/kg/day) or their combination for 18 weeks. During 
the treatment period, the effects of treatment on plasma lipids, lipoprotein profiles, CETP 
activity and CETP mass were assessed at the indicated time points.
The dose of simvastatin targeted a 30-35% reduction in TC and that of niacin a 20-
30% increase in HDL-C. While we achieved these targets, it should be noted that the dose 
of simvastatin was 3 times higher than the maximum dose used in the clinic taking into 
account a 10 times faster metabolism in mice. For niacin, the dose was comparable to that 
in patients, about 1 g/day. At the end of the experiment, all animals were sacrificed by CO2 
inhalation. Liver and white adipose tissue (WAT) were isolated to assess CETP expression 
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group). Separate additional experiments were performed to evaluate the effects of niacin 
on VLDL production and clearance, as well as reverse cholesterol transport (RCT). Animal 
experiments were approved by the Institutional Animal Care and Use Committee of The 
Netherlands Organization for Applied Research (TNO).
Plasma lipids and lipoprotein profiles
After a 4 h fast, blood was collected via tail vein bleeding and plasma was isolated. Plasma 
TC, HDL-C after precipitation of apoB-containing lipoproteins using MnCl2
21 and TG were 
determined individually using enzymatic kits, 1489437 and 1488872 (both from Roche 
diagnostics), according to the manufacturer’s protocols. After 4 and 18 weeks of treatment, 
pooled lipoprotein profiles for TC were measured by fast protein liquid chromatography 
(FPLC).20
VLDL production and clearance experiments
APOE*3Leiden.CETP mice (11-14 weeks of age) were fed a WTD containing 0.1% cholesterol 
for 3 weeks. Upon subsequent matching according to plasma TC and TG levels, mice received 
the cholesterol-containing WTD without or with 0.1% (w/w) niacin for an additional 3 
weeks18 and VLDL production and clearance were determined as described.22
Plasma was obtained via tail vein bleeding in heparin microvettes for randomization 
(Sarstedt, Germany) and in chilled paraoxon-coated capillary tubes to prevent ex vivo TG 
hydrolysis for VLDL production and clearance, and assayed for TG and TC using commercially 
available kits, 1488872 and 236691 (Roche Molecular Biochemicals, Indianapolis, IN, USA), 
respectively.
For the VLDL production experiment, 6 control and 6 niacin-treated mice were fasted for 
4 h. During the experiment, mice were sedated with 6.25 mg/kg acepromazine (Alfasan), 
6.25 mg/kg midazolam (Roche) and 0.31 mg/kg fentanyl (Janssen-Cilag). At t=0 min, 
blood was taken via tail bleeding and mice were injected intravenously with 100 µL PBS 
containing 100 µCi Trans35S label to measure de novo apoB synthesis. After 30 min, the mice 
received 500 mg of tyloxapol (Triton WR-1339, Sigma-Aldrich) per kg BW as a 10% (w/w) 
solution in sterile saline, to prevent systemic lipolysis of newly secreted hepatic VLDL-TG. 
Additional blood samples were taken 15, 30, 60, and 90 min after tyloxapol injection and 
used for determination of plasma TG concentration. After 120 min, the mice were sacrificed 
and blood was collected by orbital puncture for isolation of VLDL by density gradient 
ultracentrifugation. Incorporation of 35S-label was measured in the VLDL fraction as marker 
of de novo apoB synthesis.
For the VLDL clearance experiment, glycerol tri[3H]oleate (triolein, TO)- and [1α,2α(n)-
14C]cholesteryl oleate (CO)-double labeled VLDL-like emulsion particles (80 nm) were 










































µCi of [14C]CO to 100 mg of emulsion lipids before sonication (isotopes obtained from GE 
Healthcare, Little Chalfont, U.K.). APOE*3Leiden.CETP mice (5 control and 5 niacin-treated 
mice) were fasted for 4 h, sedated as described above, and injected intravenously with the 
radiolabeled emulsion particles (1.0 mg TG in 200 µL PBS). Blood was taken from the tail 
vein to determine the content of [3H]TO and [14C]CO in serum at 2, 5, 10 and 15 min after 
emulsion injection. Fifteen min after injection, plasma was collected by orbital puncture 
and mice were sacrificed by cervical dislocation. Organs were harvested and saponified to 
determine uptake of radioactivity derived from [3H]TO and [14C]CO by various organs.22
Endogenous CETP activity, CETP mass and CETP mRNA expression analysis
Plasma endogenous CETP activity was determined by a fluorescent method using donor 
liposomes enriched with nitrobenzoxadiazole-labeled cholesteryl esters (RB-CETP, Roar 
Biomedical, New York, NY) as described.19 CETP activity was calculated as nmol cholesteryl 
ester transfer/mL plasma/h. Plasma CETP mass was determined by using the DAIICHI 
CETP ELISA kit according to manufacturer’s instructions (Daiichi, Tokyo, Japan).18 Total 
RNA was extracted from liver and white adipose tissue (WAT) using an RNA isolation kit 
according to manufacturer’s specifications (Macherey-Nagel, Düren, Germany). Total RNA 
concentrations were measured with Nanodrop. One µg of RNA was reversed-transcribed 
to cDNA with iScriptcDNA Synthesis kit (Bio-Rad) and purified with Nucleospin Extract 
II kit (Macherey-Nagel, Düren, Germany). Real-time PCR (RT-PCR) was carried out on an 
iQ5 PCR detection system (Bio-Rad) using Sensimix SYBR Green RT-PCR mix (Quantace, 
London, UK). Hypoxanthine-guanine phosporibosyltransferase (HPRT) and acidic ribosomal 
phosphoprotein PO (36B4) were used as the standard housekeeping genes and expression 
levels were normalized to these housekeeping genes. Primer sequences are listed in Table 
S1.
Histological assessment of atherosclerosis
After isolation, hearts were fixed in formalin, embedded in paraffin and cross-sectioned 
(5 µm) throughout the aortic root area. For each mouse, four sections at intervals of 50 µm 
were used for quantitative and qualitative assessment of the atherosclerotic lesions after 
staining with hematoxylin-phloxine-saffron. For determination of severity of atherosclerosis, 
the lesions were classified into five categories: I) early fatty streak, II) regular fatty streak, III) 
mild plaque, IV) moderate plaque, and V) severe plaque according to the American Heart 
Association classification.19, 24 Lesion severity as a percentage of the number of lesions was 
calculated. To this end, type I-III lesions were classified as mild lesions and type IV-V lesions 
were classified as severe lesions. Total lesion area and number of lesions per cross section, 
as well as the percentage undiseased segments, were calculated. In each segment used 
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numbers of T cells in the total aortic root area were counted after immunostaining with AIA 
31240 (1:1000; Accurate Chemical and Scientific, New York, New York, USA) and CD3 (1:500; 
AbD Serotec, Oxford, UK), respectively. Macrophage content of the lesions was measured 
after immunostaining with Mac-3 (1:50; BD Pharmingen, the Netherlands). In addition, sirius 
red staining was used to quantify the collagen content in the plaque25 and the antibody 
alpha actin (1:800; DAKO, Glostrup, Denmark) was used to quantify the smooth muscle cell 
(SMC) content.26 Stained areas were measured using Cell D imaging software (Olympus Soft 
Imaging Solutions).
Reverse cholesterol transport experiment
16 recipient APOE*3Leiden.CETP mice (10-12 weeks of age) were fed a WTD containing 0.1% 
cholesterol for a run-in period of 3 weeks after which they were subdivided into 2 groups 
according to age, BW, TC, TG and HDL-C. After matching, mice (n=8 per group) received a 
control cholesterol-containing WTD without or with 0.1% (w/w) niacin (120 mg/kg/day) for 
3 weeks.
6 donor APOE*3Leiden.CETP mice (10-12 weeks of age) fed a WTD containing 
0.1% cholesterol for 3 weeks were injected intraperitoneally with 1 mL solution of 3% 
thioglycollate to induce an inflammatory response. Three days after the injection, mice were 
injected intraperitoneally with approximately 300 µCi [3H]-cholesterol together with 100 
µg/mL acetylated LDL. Mice were sacrificed 1 h later by CO2 inhalation. [
3H]-cholesterol-
labeled macrophages were collected from the 6 donor mice by peritoneal lavage. These 
macrophages were washed twice with cold PBS and injected intraperitoneally into the 16 
recipient APOE*3Leiden.CETP mice. Each recipient mouse received 2.8 x 106 [3H]-cholesterol-
labeled macrophages containing 7.8 x 106 dpm [3H]-cholesterol. Mice were individually caged 
for 48 h in order to collect feces and sacrificed by CO2 inhalation. 
3H-activity was determined 
in the plasma, liver and feces. The in vivo RCT experiment was based on methods previously 
described.27, 28
Statistical analysis
Significance of differences between the groups was calculated non-parametrically using 
a Kruskal-Wallis test followed by a Mann-Whitney U-test for independent samples. We 
performed a univariate analysis of variance (ANOVA) to investigate the role of TC, non-
HDL-C and HDL-C exposure as contributing factors in lesion development. A two-way 
analysis of covariance (ANCOVA) was performed to test for group differences in lesion area, 
monocyte adhesion, T cell abundance and macrophage area after correcting for HDL-C and 
non-HDL-C exposure. SPSS 17.0 for Windows (SPSS, Chicago, USA) was used for statistical 
analysis. All groups were compared to the control group and the combination group was 










































were considered statistically significant. In the figures, the symbol * is used to compare to 
the control group, and # to compare to the simvastatin group.
Results
Niacin, simvastatin and their combination reduce plasma total cholesterol and triglycerides 
and niacin increases HDL-C in APOE*3Leiden.CETP mice
To verify the lipid-lowering effect of niacin alone and in combination with simvastatin, we 
measured plasma TC (Figure 1A), TG (Figure 1B) and HDL-C (Figure 1C) levels during the 
study. The Western-type diet resulted in an average TC of 13.4 ± 1.7 mmol/L, TG of 4.3 ± 1.4 
mmol/L and HDL-C of 0.65 ± 0.13 mmol/L (control group). TC and TG levels were reduced 
by niacin (-39%, P<0.001; -50%, P<0.001), simvastatin (-30%, P<0.001; -19%, NS) and the 
combination (-55%, P<0.001; -52%, P<0.001). The combination reduced TC to a greater 
extent than simvastatin alone (-36%, P<0.001). Niacin increased HDL-C by +28% (P<0.01) as 
compared to the control, whereas the combination increased HDL-C by +14% (P<0.05) as 
compared to simvastatin monotreatment. Niacin alone resulted in higher HDL-C than the 
combination (P<0.001). The reductions in plasma TC induced by niacin, simvastatin and the 
combination were confined to apoB-containing lipoproteins as measured after lipoprotein 








































































































































































































































































































































































































































































Figure 1 Effect of niacin, simvastatin and their combination on plasma lipid levels. Plasma total 
cholesterol (A), triglycerides (B) and HDL-cholesterol levels were measured at various time points 
throughout the study. The average HDL-cholesterol levels were calculated for all the treatment groups 
(C). Lipoproteins were separated by FPLC and cholesterol was measured in the fractions after 18 weeks 
of treatment (D). 
Simva, simvastatin; values are means ± SD; n=15 per group; **P<0.01 and ***P<0.001 as compared to 
control; #P<0.05 and ###P<0.001 as compared to niacin + simvastatin.
Niacin reduces apoB-containing lipoprotein cholesterol by modestly increasing VLDL 
clearance without affecting VLDL production
To determine by which mechanism the level of apoB-containing lipoprotein cholesterol is 
decreased, first the VLDL-TG production was assessed after injection of Tran35S label and 
tyloxapol. VLDL-TG production did not differ between controls and niacin-treated mice 
(Figure 2A; control 6.1 ± 0.7 μmol/mL/h versus niacin 6.2 ± 0.8 μmol/mL/h; P=0.94). In 
addition, the apoB production rate, as measured by incorporation of 35S-activity in the VLDL 
fraction (Figure 2B; control 2.9 ± 0.5 μmol/mL/h versus niacin 2.9 ± 0.4 μmol/mL/h; P=0.94) 
and VLDL-apoB lipidation (control 1.3 ± 0.4 nmol/100 dpm versus niacin 1.4 ± 0.3 nmol/100 
dpm; P=0.69) did not differ between groups.
We then examined the clearance and uptake of [3H]TO and [14C]CO-labeled VLDL-like 










































was a trend towards a faster plasma clearance rate of [3H]TO (Figure 2C; control t1/2 = 6.4 ± 2.2 
min versus niacin t1/2 = 4.9 ± 0.9 min; P=0.19) and a significantly faster initial [
3H]TO clearance 
in the first 5 min after niacin treatment (P<0.05). Tissue-specific 3H-accumulation did not 
differ between groups, although there was a tendency (P=0.07) for a higher 3H-accumulation 
in the spleen from the niacin-treated mice (Figure 2D). This was accompanied by a non-
significant increase in the plasma clearance rate of [14C]CO (control t1/2 = 11.6 ± 5.5 min 
versus niacin t1/2 = 7.1 ± 1.7 min; P=0.12) with no differences in 
14C-accumulation in the 
various organs between groups (data not shown).
29 
 




Figure 2 Effect of niacin on VLDL production and clearance. To determine VLDL production, mice 
were injected with Trans35S label and tyloxapol and the accumulation of TG in plasma (A) and the 
production rate of VLDL-TG and apoB, as well as VLDL lipidation, defined as the ratio of VLDL-TG/apoB, 
were determined (B). To determine VLDL clearance, mice were injected with glycerol tri[3H]oleate- 
and [14C]cholesteryl oleate-labeled VLDL-like emulsion particles. Plasma 3H-activity was determined 
as percentage of the initial dose (C), and uptake of 3H-activity by various organs was determined as 
percentage of the injected dose per gram wet tissue (D). 
BAT, brown adipose tissue; gonWAT, gonadal white adipose tissue; subWAT, subcutaneous white 
adipose tissue; visWAT, visceral white adipose tissue; values are means ± SD; n=6 per group for VLDL 
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Niacin, simvastatin and their combination reduce plasma CETP activity, CETP mass and 
niacin alone and together with simvastatin reduces hepatic CETP gene expression
In a previous study, we showed that niacin increased HDL-C by decreasing hepatic CETP 
expression and plasma CETP concentration.18 To verify this, we measured plasma CETP 
activity and mass and hepatic CETP mRNA expression after 4 and/or 18 weeks of treatment 
(Table 1). Niacin, which most prominently increased HDL-C, reduced the average plasma 
CETP activity by -21% (P<0.01) and mass by -22% (P<0.01). Simvastatin reduced CETP activity 
and mass by -25% and -37%, respectively (both P<0.001) without affecting HDL-C levels. The 
combination reduced CETP activity (-34%; P<0.001) and mass (-48%; P<0.001) to an even 
higher extent. Previously, we demonstrated that this reduction was due to reduced CETP 
mRNA expression in the liver. In line with these results, we found that niacin alone and in 
combination with simvastatin tended to reduce hepatic CETP expression to -76% (P=0.072) 
and -58% (P=0.059), respectively. Besides the liver, WAT is considered as a major source of 
CETP and since WAT is a target of niacin,29 we also determined the effect of all treatments 
on CETP mRNA expression in WAT. Niacin did not decrease CETP expression in WAT (data not 
shown), which is consistent with a recent study in CETP transgenic mice.30 For the control 
group, a 125 times lower relative CETP expression was measured in WAT compared to the 
liver (data not shown). A mild correlation was found between hepatic CETP expression and 
plasma CETP mass (R2=0.25, P=0.006), whereas CETP expression in WAT did not correlate 
with plasma CETP mass (R2=0.02, P=0.45) (data not shown). Taken together, we concluded 
that the liver is the major determinant for circulating CETP levels in this model, which were 
affected by all the treatments.
Table 1 The effect of niacin, simvastatin and their combination on plasma CETP activity after 4 and 










Control 64.3 ± 11.4 21.3 ± 3.4 100 ± 30
Niacin 50.6 ± 6.6 ** 16.6 ± 3.5 ** 76 ± 23 P=0.072
Simva 48.1 ± 8.4 *** 13.4 ± 3.5 *** 76 ± 25
Niacin + Simva 42.6 ± 8.9 ***  P=0.081 11.0 ± 2.2 ***  P=0.050 58 ± 33 P=0.059
CETP, cholesteryl ester transfer protein; Simva, simvastatin. Values are means ± SD (n=15 per group 
for plasma CETP activity and mass and n=6-8 per group for hepatic CETP expression). **P<0.01 and 










































Niacin alone and in combination with simvastatin reduces atherosclerosis development to 
a greater extent than simvastatin treatment alone
After 18 weeks of treatment, we measured the effect of niacin, with and without simvastatin 
on atherosclerosis development in the aortic root. Figure 3 illustrates representative 
images of atherosclerotic lesions for each group. We determined the number of lesions 
per cross section (Figure 4A), the lesion severity as a percentage of all lesions (Figure 4B), 
the percentage undiseased segments (Figure 4C) and the total lesion area per cross section 
(Figure 4D). To determine lesion severity as a percentage of all lesions, type I-III lesions were 







Figure 3 Effect of niacin, simvastatin and their combination on plaque morphology. Representative 
images of hematoxylin-phloxine-saffron-stained atherosclerotic lesions in a cross section of the aortic 
root area for the control group (A), niacin group (B), simvastatin group (C) and the combination group 
































































































































































































































































































































































































































































































































Figure 4 Effect of niacin, simvastatin and their combination on atherosclerosis development in 
aortic root area. After 18 weeks of treatment, number of lesions (A), lesion severity (B), percentage 
undiseased segments (C) and tot l lesion area (D) were determined per cross section. Lesio  severity 
was classified as mild (type I-III) and severe (type IV-V) lesions. 
Simva, simvastatin; values are means ± SD; n=15 per group; **P<0.01 and ***P<0.001 as compared to 
control; ##P<0.01 as compared to niacin + simvastatin.
In the control group, a fair amount of atherosclerosis developed with 3.5 ± 0.9 lesions 
per cross section, of which 62 ± 16% were severe and only 17 ± 16% of the segments were 
undiseased. The total lesion area was 144 ± 63 x103 µm2 per cross section. When compared 
to the control, niacin reduced the number of lesions (-23%; P=0.056), attenuated lesion 
severity (P<0.001) and increased the percentage undiseased segments (+141%, P<0.001). 
Furthermore, niacin strongly decreased the total lesion area by -78% (P<0.001). Simvastatin 
alone was less effective as it only reduced lesion severity (P<0.01) and total lesion area 
(-49%, P<0.01). The combination had potent inhibiting effects on lesion development, as 
evidenced by reductions in lesion number (-48%, P<0.001), severity (P<0.001) and area 
(-87%, P<0.001), and by an increase in the percentage undiseased segments (+210%, 
P<0.001). Furthermore, the percentage undiseased segments, as well as the reduction in 
the lesion number and area was greater after the combination compared to simvastatin 
alone (-44%; +110%; -74%, all P<0.01). These results showed that niacin monotreatment 
was very potent in inhibiting atherosclerotic lesion development in APOE*3Leiden.CETP 










































Niacin improves lesion stability index and decreases functional markers of vascular 
inflammation
After investigation of lesion morphology, we analyzed the treatment effects on plaque 
composition. For all lesions, the macrophage area as destabilization factor (Figure 5A), as 
well as SMC (Figure 5B) and collagen area (data not shown) as stabilization factors were 
calculated per cross section. The macrophage, SMC and collagen area per cross section in 
the control group were 24.3 ± 8.6 x103 µm2, 4.6 ± 2.3 x103 µm2 and 64.2 ± 37.0 x103 µm2, 
respectively. All treatments reduced the macrophage (-73%, -52% and -90%; all P<0.001) 
and the SMC area (-66%, P<0.01; -50%, P<0.01; -79%, P<0.001). As a measure of the lesion 
stability index, the ratio of collagen and SMC area (i.e. stabilization factors) to macrophage 
area (i.e. destabilization factor) was determined for all lesions (data not shown). The lesion 
stability ratio for the control group was 2.7 ± 1.4. Combination treatment tended to increase 
this ratio by +201% (P=0.085).
After finding indications for more stable lesions, we specifically focused on the 
composition of the more severe lesions, which are considered to be the most vulnerable 
lesions. Additionally, we corrected for the lesion area. Thus, we measured the macrophage 
(Figure 5C), SMC (Figure 5D) and collagen content (data not shown) as a percentage of 
lesion area. The severe lesions in the control group consisted of 20% macrophages, 4% SMC 
and 45% collagen (latter data not shown). Niacin alone and in combination with simvastatin 
reduced the relative macrophage content by -18% (NS) and -54% (P<0.001), respectively and 
increased the relative SMC content by +97% (P<0.01) and +102% (P<0.05), respectively. The 
combination was superior to simvastatin monotreatment in stabilizing the plaque as seen by 
a reduction in macrophage content (-54%; P<0.05) and an increase in SMC content (+79%; 
P=0.057). There were no significant differences in collagen content between groups (data 
not shown). The lesion stability index was also calculated for the severe lesions based on 
the relative area (Figure 5E). Combination treatment increased this ratio by +371% (P<0.01) 
compared to the control (2.6 ± 1.0) and to a greater extent compared to simvastatin (P<0.05) 
alone.
As functional markers of vessel wall inflammation, the number of monocytes adhering 
to the activated endothelium (Figure 6A) and T cells in the aortic root area (Figure 6B) were 
counted and calculated per cross section. In the control group, 3.8 ± 1.2 adhering monocytes 
and 11.3 ± 8.3 T cells were present. A marked reduction of adhering monocytes of more 
than -45% (P<0.01; P<0.01 and P<0.001, respectively) was found in all treatment groups, 
whereas T cells abundance was reduced by niacin alone (-71%, P<0.01) and in combination 








































































































































































































































Figure 5 Effect of niacin, simvastatin and their combination on lesion composition. Macrophage area 
(A) and SMC area (B) were determined for all lesions and calculated per cross section. To correct 
for lesion size, macrophage content (C), SMC content (D), as well as plaque stability index (ratio of 
collagen and SMC content to macrophage content) (E) were also calculated as a percentage of lesion 
area, specifically in severe lesions (Type IV-V). 
Simva, simvastatin; SMC, smooth muscle cells; values are means ± SD; n=15 per group; *P<0.05, 









































































































Figure 6 Effect of niacin, simvastatin and their combination on monocyte adhesion and T cell number. 
The number of monocytes adhering to the endothelium (A) and the number of T cells in the aortic root 
area (B) were determined per cross section. 
Simva, simvastatin; values are means ± SD; n=15 per group; **P<0.01; ***P<0.001 as compared to 
control; ###P<0.001 as compared to niacin + simvastatin.
Niacin reduces atherosclerosis progression primarily by reducing non-HDL-cholesterol
In addition to inflammation, plasma cholesterol is certainly a strong determinant for 
atherosclerosis progression. We evaluated whether the anti-atherogenic effect of niacin 
and simvastatin could be explained by the reduction in plasma TC (Figure 7). Since 
atherosclerotic lesion area showed a quadratic dependence on plasma TC exposure, 
lesion area was transformed using a square root transformation. Lesion area was strongly 
predicted by plasma TC exposure (R2=0.70, P<0.001; Figure 7A), and non-HDL-C exposure 
(R2=0.69, P<0.001; Figure 7B) and to a much lesser extent by HDL-C exposure (R2=0.20, 
P<0.001; Figure 7C). Together, non-HDL-C and HDL-C exposure accounted for 71% of the 
variability in lesion area and predicted the lesion area independent of each other (P<0.001 
and P<0.05, respectively). Importantly, the effects of niacin and simvastatin on lesion 
area were lost after correcting for both HDL-C and non-HDL-C exposure (P=0.16; P=0.61, 
respectively). Furthermore, no effect of niacin and simvastatin on monocyte adhesion was 
found after correcting for non-HDL-C exposure (P=0.50; P=0.20, respectively). However, 
niacin decreased the square-root transformed macrophage area and T cell abundance even 
after correcting for non-HDL-C exposure (both P<0.01), whereas simvastatin did not (P=0.12; 
P=0.26, respectively).
Collectively, these data are compatible with a mechanism that niacin and simvastatin 
mainly decreased atherosclerotic lesion development via a reduction of non-HDL-C with an 
additional effect of HDL-C-elevation for niacin, while a direct effect on lesion macrophages 






































































































































































































































Figure 7 Correlation between plasma cholesterol exposure and lesion area. The square root of the 
lesion area was plotted against total cholesterol exposure (A), non-HDL-cholesterol exposure (B) and 
HDL-cholesterol exposure (C). Linear regression analyses were performed. 










































Niacin mildly increases reverse cholesterol transport
To investigate the possible mechanism by which the HDL-C-raising effect of niacin may 
contribute to its anti-atherogenic effect, we performed an in vivo RCT experiment. After 3 
weeks of treatment, mice were injected with [3H]-cholesterol-labeled macrophages. Forty 
eight hours after injection, plasma total 3H-activity tended to be decreased (-36%, P=0.065), 
whereas 3H-activity in the HDL fraction was increased after niacin treatment (+155%, P<0.01; 
Figure 8A). In addition, niacin increased 3H-activity in the liver (+33%; P<0.05) and tended to 












































































Figure 8 Effect of niacin on reverse cholesterol transport. [3H]-cholesterol-labeled macrophages were 
injected in control and niacin-treated mice and 3H activity was determined in plasma and HDL (A) and 
the liver 48 h after injection, as well as in feces collection between 0-48 h after injection (B). 
Values are means ± SD; n=8 per group; *P<0.05 and ** P<0.01 as compared to control.
Discussion
In this study, we aimed to address the discrepancy between the beneficial effects of niacin 
in initial clinical trials3-6, 14 and the lack of effect of niacin on top of statin treatment on 
reduction of cardiovascular events in the AIM-HIGH8 and HPS2-THRIVE7 trials by investigating 
the effects of niacin without and with simvastatin on atherosclerosis development and 
determining the underlying mechanisms in APOE*3Leiden.CETP mice, a mouse model 
for familial dysbetalipoproteinemia (FD). We demonstrated that niacin decreased 
atherosclerosis development mainly by reducing non-HDL-C with a modest HDL-C-raising 
and anti-inflammatory effect and that the additive effect of niacin on top of simvastatin was 
mostly dependent on its non-HDL-C-lowering capacities.
First, we showed that niacin and simvastatin both reduced plasma lipid levels. Niacin 
reduced (V)LDL-C and (V)LDL-TG and increased HDL-C, whereas simvastatin mainly reduced 
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effectively as compared to simvastatin alone. In our study, the reduction in plasma TC after 
niacin treatment alone and in combination with simvastatin was greater compared to recent 
clinical trials. The APOE*3Leiden mouse was initially developed as an animal model for FD 
or type III hyperlipoproteinemia, which is characterized by elevated levels of cholesterol and 
an increased ratio of cholesterol to TG in the VLDL and intermediate density lipoprotein (IDL) 
fractions, resulting in the appearance of β-VLDL particles.31, 32 Similarly as in FD patients, 
in APOE*3Leiden and APOE*3Leiden.CETP mice as a model for mixed dyslipoproteinemia, 
a major part of plasma cholesterol is contained in the VLDL and VLDL-remnant particles, 
leading to formation of β-VLDL particles, which further increases after cholesterol feeding. 
Whereas niacin reduces plasma TC by ~5-15%, LDL-C by ~5-20% and TG by ~15-30% in 
patients with hyperlipidemia,2 in two small studies in FD patients, niacin decreased TC by 
23-50% and TG by 43-62%33, 34 with -56% reduction of VLDL-C and -48% reduction of VLDL-
TG.34 Thus, the extent of lipid-lowering observed with niacin in APOE*3Leiden.CETP mice is 
comparable to that of FD patients.
Since plasma VLDL-TG and apoB levels are determined by the balance between VLDL 
production and clearance, we evaluated their individual contribution. VLDL production was 
not affected in niacin-treated mice, neither was apoB production nor lipidation of the VLDL 
particle. However, a modest effect of niacin on VLDL clearance was observed. The mechanism 
behind the lipid-lowering effect of niacin has been generally ascribed to a reduced hepatic 
VLDL production, as a result of decreased free fatty acid (FFA) flux from WAT after inhibition 
of hormone sensitive lipase. However, an initially decreased FFA flux is followed by a rebound 
effect with increased release of FFAs.1, 35 In humans, contradicting data describe that niacin 
decreased VLDL production without affecting VLDL clearance36-38 and on the other hand 
that niacin enhanced clearance of apoB without affecting production.39 The latter study is 
in line with our results, which implicate VLDL clearance rather than VLDL production as the 
possible mechanism by which niacin reduces apoB.
The niacin-induced increase in HDL-C in the present study may be attributed to a 
decrease in hepatic and plasma CETP leading to an inhibition of HDL delipidation as 
previously described.18 As similar effects on CETP levels and activity were observed after 
simvastatin treatment, without affecting HDL, different mechanisms are likely involved in 
either treatment. Interestingly, a decreased macrophage content accompanying decreased 
hepatic cholesterol accumulation as a result of niacin’s lipid-lowering effect was recently 
proposed as a mechanism by which niacin decreases hepatic CETP expression.30
An important observation from our study is that niacin decreases atherosclerosis 
progression and adds to the anti-atherogenic effect of simvastatin, in particular regarding 
its enhancing effect on plaque stability. Niacin decreased lesion number, severity and 
area, and increased the percentage undiseased segments. Moreover, niacin improved 










































Importantly, the combination treatment increased the plaque stability index, defined as the 
ratio of SMC and collagen to macrophage area, as compared to either niacin or simvastatin 
alone.
It is interesting to speculate on the mechanism(s) underlying the anti-atherogenic effect 
of niacin. In the APOE*3Leiden.CETP mouse model, statistical analyses revealed that the 
effects of niacin and simvastatin were largely explained by their reduction in non-HDL-C, as 
evidenced by a strong correlation between plasma non-HDL-C and lesion area. The fact that 
the combination treatment reduced non-HDL-C beyond the level reached by simvastatin 
alone can thus largely explain why niacin added to the anti-atherosclerotic effect of 
simvastatin. Though, HDL-C also appeared to predict lesion area independent of non-HDL-C, 
albeit that the predictive value of HDL-C was much smaller than that of non-HDL-C. The 
HDL-C-raising effect of niacin may, therefore, have contributed to some extent to the anti-
atherosclerotic activity of niacin.
To explore the contribution of the niacin-induced increase in HDL-C to the reduction of 
atherosclerosis, we investigated the functionality of HDL by performing an RCT experiment. 
From this experiment, we conclude that the effect of niacin on RCT may partially contribute 
to, but is not the driving force behind its anti-atherogenic effects. This is in accordance with 
our statistical correlations, which showed non-HDL-C to be a much stronger contributor 
to atherogenesis. Although HDL-C contributed to some extent, we observed that niacin’s 
attenuating effect on atherosclerosis development in APOE*3Leiden.CETP mice, fed a 
Western-type diet with 0.1% cholesterol, is largely explained by its lipid-lowering effect. 
At first sight, this seems to contradict a recent report showing that niacin reduced 
atherosclerosis development in LDL receptor-deficient mice under conditions that left plasma 
cholesterol levels unaffected.15 In that mouse model, the atheroprotective effects of niacin 
were mainly explained by impaired homing macrophage recruitment to atherosclerotic 
plaques and by promoting cholesterol efflux from macrophages by upregulation of ABCG1. 
However, it should be noted that those mice were fed a high fat diet containing as much 
as 1.5% cholesterol. A previous study from our laboratory showed that dietary cholesterol 
induced dose-dependent marked inflammation in mice,40 where the liver switches to an 
inflammatory, pro-atherosclerotic state as reflected by a strong increase in serum amyloid 
A levels at dietary cholesterol levels exceeding 0.5%. Previously, Lukasova et al.15 evaluated 
the anti-atherogenic effect of niacin under highly inflammatory conditions, at which the anti-
inflammatory properties of niacin may become dominant and may not necessarily reflect 
the mode of action for niacin under mild cholesterol intake as used in the present study.
It should be noted that we also obtained evidence that niacin exerted anti-inflammatory 
effects in our mouse model under milder dietary conditions. Firstly, niacin reduced 
monocyte adhesion and macrophage area of the atherosclerotic lesions. In fact, niacin 
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data not only corroborate the findings in LDL receptor-deficient mice,15 but also the recent 
observations that niacin reduced collar-inflicted vascular inflammation and inhibited intima-
media neutrophil recruitment in New Zealand White rabbits independent of changes in 
plasma lipids.41 Secondly, we observed that niacin, but not simvastatin, strongly reduced 
the number of T cells in the aortic root area, which are involved in the progression of 
atherosclerosis.42 The reduction was independent of non-HDL-C exposure, suggesting the 
anti-inflammatory effect observed was brought about by niacin, instead of HDL-derived. This 
is in accordance with a study where niacin inhibited monocyte chemotactic protein 1 (MCP-
1), RANTES and fractalkine in adipocytes. These chemokines contribute to the recruitment 
of T cells and macrophages. WAT is known to express the GPR109A receptor and has the 
ability to contribute to both systemic and local (perivascular) inflammation associated with 
atherosclerosis.29, 43
Although initial clinical studies showed that niacin reduced atherosclerosis development 
in combination with statins3-5 and reduced the relative risk of cardiovascular events,6 
results from the large outcome trials, AIM-HIGH and HPS2-THRIVE did not confirm earlier 
findings.8, 44, 45 In order to test the HDL hypothesis, the AIM-HIGH investigators minimized the 
differences in LDL levels between the groups. Patients enrolled in the trial were subjected to 
aggressive LDL-C-lowering treatment, aimed at LDL-C of 40-80 mg/dL (1.03-2.07 mmol/L), 
reaching mean baseline LDL-C of 71 mg/dL (1.84 mmol/L) and HDL-C of 35 mg/dL (0.91 
mmol/L).46 A modest increase in HDL-C was observed in the placebo group, resulting in a 
4-5 mg/dL (0.10-0.13 mmol/L) difference in HDL-C between groups. This, together with the 
aggressive LDL-C-lowering may have given rise to insufficient power to detect a reduction 
in events.45 Unexpectedly, the much larger outcome trial, HPS2-THRIVE failed to reveal 
further cardiovascular risk reduction when adding ER-niacin/laropiprant to vigorous statin 
treatment, plus if required ezetimibe, as compared to statin/(ezetimibe) monotreatment.7 
Furthermore, there was a significant increase in non-fatal serious adverse events and drop-
out rate in the ER-niacin/laropiprant-treated patients. The lack of inclusion criteria for HDL-C 
resulted in a baseline HDL-C of >40 mg/dL (1.14 mmol/L) with a low baseline LDL-C level of 
<70 mg/dL (1.64 mmol/L). Patient stratification revealed that baseline HDL-C levels did not 
predict efficacy of niacin and that indeed, only in patients with high LDL-C, niacin reduced 
major cardiovascular events.
In conclusion, our results show that niacin decreases atherosclerosis development 
mainly by reducing non-HDL-C with modest HDL-C-raising and additional anti-inflammatory 
effects. The additive effect of niacin on top of simvastatin is mostly dependent on its non-
HDL-C-lowering capacities. These data suggest that clinical beneficial effects of niacin are 
largely dependent on its ability to lower LDL-C on top of concomitant lipid-lowering therapy 
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Table S1 RT-PCR primer sequences




HPRT, hypoxanthine-guanine phosporibosyltransferase; 36B4, acidic ribosomal phosphoprotein PO; 
CETP, cholesteryl ester transfer protein.
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Objective The residual risk that remains after statin treatment supports the addition of 
other LDL-C-lowering agents and has stimulated the search for secondary treatment targets. 
Epidemiological studies propose HDL-C as a possible candidate. Cholesteryl ester transfer 
protein (CETP) transfers cholesteryl esters from atheroprotective HDL to atherogenic (V)
LDL. The CETP inhibitor anacetrapib decreases (V)LDL-C by ~15-40% and increases HDL-C by 
~40-140% in clinical trials. We evaluated the effects of a broad dose range of anacetrapib 
on atherosclerosis and HDL function, and examined possible additive/synergistic effects of 
anacetrapib on top of atorvastatin in APOE*3Leiden.CETP mice.
Methods and Results Mice were fed a diet without or with ascending dosages of 
anacetrapib (0.03; 0.3; 3; 30 mg/kg/d), atorvastatin (2.4 mg/kg/d) alone or in combination 
with anacetrapib (0.3 mg/kg/d) for 21 weeks. Anacetrapib dose-dependently reduced CETP 
activity (-59% to -100%, P<0.001), thereby decreasing non-HDL-C (-24% to -45%, P<0.001) 
and increasing HDL-C (+30% to +86%, P<0.001). Anacetrapib dose-dependently reduced 
atherosclerotic lesion area (-41% to -92%, P<0.01) and severity, increased plaque stability 
index and added to the effects of atorvastatin by further decreasing lesion size (-95%, 
P<0.001) and severity. Analysis of covariance showed that both anacetrapib (P<0.05) and 
non-HDL-C (P<0.001), but not HDL-C (P=0.76), independently determined lesion size.
Conclusion Anacetrapib dose-dependently reduces atherosclerosis, and adds to the anti-
atherogenic effects of atorvastatin, which is mainly ascribed to a reduction in non-HDL-C. In 
addition, anacetrapib improves lesion stability. 
Keywords cholesteryl ester transfer protein, non-HDL-cholesterol, HDL-cholesterol, HDL 












































Intervention trials provide ample evidence that lowering of low-density lipoprotein-
cholesterol (LDL-C) contributes to a reduction in cardiovascular (CV) risk.1-3 However, the 
residual risk that remains after statin treatment, as well as failure for some patients to 
reach recommended LDL-C targets despite statin treatment, support the addition of other 
LDL-C-lowering agents and also stimulate the search for secondary treatment targets.3, 4 
Prospective epidemiological studies propose high-density lipoprotein (HDL)-C as a potential 
target.5 Cholesteryl ester transfer protein (CETP) plays an important role in lipid metabolism 
by facilitating the transfer of cholesteryl esters from atheroprotective HDL to atherogenic 
(V)LDL in exchange for triglycerides (TG), and inhibition of CETP activity has been proposed 
as a therapeutic way to increase HDL-C levels.6-11
In mouse models for atherosclerosis, CETP expression aggravated atherosclerosis 
development.12, 13 Most but not all studies in rabbits and mice showed that CETP inhibition 
reduced atherosclerosis development.14-19 However, torcetrapib failed to enhance the anti-
atherogenic effects of atorvastatin and induced a pro-inflammatory, vulnerable plaque 
phenotype in APOE*3Leiden.CETP mice.19 In the large clinical outcome trial (ILLUMINATE), 
torcetrapib increased the risk of major CV events and mortality despite a 72% increase in 
HDL-C and a 25% reduction in LDL-C.20 The unexpected detrimental effects were ascribed to 
either an off-target blood pressure effect or the possible generation of dysfunctional HDL 
particles.20 The much less potent CETP inhibitor dalcetrapib increased HDL-C by 31% to 40% 
with a minimal reduction in LDL-C, but did not translate into clinical benefit and resulted 
in premature termination of the dal-OUTCOMES trial.21 Nonetheless, other CETP inhibitors 
are currently in clinical development. Amongst these, anacetrapib and evacetrapib have 
remarkable lipid-modulating abilities without the unwanted blood pressure effect as 
observed with torcetrapib.22 In phase II trials, anacetrapib (10 to 300 mg) decreased LDL-C 
by ~15% to 40% and increased HDL-C by ~40% to 140% and evacetrapib (30 to 500 mg) 
decreased LDL-C by ~15% to 35% and increased HDL-C by ~50% to 130%.23, 24
To elucidate whether pharmacological CETP inhibition is anti-atherogenic and to what 
extent this is due to its LDL-C-lowering and HDL-C-raising abilities, we evaluated the 
effects of partial to full inhibition of CETP activity with a broad dose range of anacetrapib 
monotreatment on lipid modulation, atherosclerosis development and HDL functionality in 
APOE*3Leiden.CETP mice. Secondly, to mimic clinical intervention trials where dyslipidemic 
patients also receive statin treatment, we examined the possible additive/synergistic 
effects of anacetrapib on top of atorvastatin treatment in this well-established model for 
lipoprotein metabolism and atherosclerosis. These mice respond in a human-like manner to 












































Female APOE*3-Leiden.CETP transgenic mice13 (n=105) were housed under standard 
conditions with a 12 h light-dark cycle and had free access to food and water. Body weight 
and food intake were monitored during the study. At the age of 9 to 16 weeks, mice were 
fed a semi-synthetic cholesterol-rich diet, containing 15% cacao butter, 1% corn oil, 40.5% 
sucrose, 20% acid casein, 10% corn starch, 6.2% cellulose (Western-type diet, WTD; AB-
Diets, Woerden, the Netherlands) and 0.1% cholesterol (SigmaAldrich, Zwijndrecht, the 
Netherlands) for a run-in period of 5 weeks. Animals were matched based on body weight, 
total cholesterol (TC), TG, HDL-C and age (n=15 per group) and received a control Western-
type diet (WTD) without or with incremental dosages of anacetrapib (0.03; 0.3; 3 and 30 
mg/kg/d; Dalton Chemical Laboratories Inc., Canada), atorvastatin (2.4 mg/kg/d) or a 
combination of atorvastatin (2.4 mg/kg/d) and anacetrapib (0.3 mg/kg/d) for a treatment 
period of 21 weeks. All animals were sacrificed by CO2 inhalation and hearts were isolated to 
assess atherosclerosis development. Animal experiments were approved by the Institutional 
Animal Care and Use Committee of The Netherlands Organization for Applied Research 
(TNO).
Plasma lipids, lipoprotein profile, endogenous cholesteryl ester transfer protein activity, 
cholesteryl ester transfer protein concentration and serum amyloid A 
After 4 h fasting, blood was collected in ethylenediaminetetraacetic acid (EDTA)-coated 
cups via tail vein bleeding and plasma was isolated every 2 to 4 weeks. To measure HDL-C, 
apoB-containing particles were precipitated from diluted plasma (15 µL previously frozen 
plasma + 15 µl PBS) by adding 5 µL of 20% polyethylene glycol (PEG) in 200 mM glycine 
buffer (pH10). This mixture was incubated for 5 min at 25˚C and centrifuged at 6000 rpm 
for 5 min at 25˚C. Thirty µL of supernatant was mixed with 20 µl of 20% PEG in 200 mM 
glycine buffer and incubated for 5 min at 25˚C and centrifuged at 6000 rpm for 20 min 
at 25˚C. TC was measured in the supernatant to determine plasma HDL-C levels. Plasma 
TC and TG were determined individually using enzymatic kits (cat. no. 1458216 and cat. 
no. 1488872, Roche Diagnostics) according to manufacturer’s protocol, and average plasma 
TC, TG, non-HDL-C and HDL-C levels were calculated. The distribution of cholesterol over 
plasma lipoproteins was determined by fast-performance liquid chromatography (FPLC) as 
previously described.13
Plasma endogenous CETP activity and CETP concentration were determined as previously 
described.28 Endogenous CETP activity was determined by a fluorescent method using donor 
liposomes enriched with nitrobenzoxadiazole-labeled cholesteryl esters (Roar Biomedical, 
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cholesteryl ester transfer/mL plasma/h. Plasma CETP concentration (ALPCO Diagnostics, 
Salem, USA) and serum amyloid A (SAA; Tridelta development Ltd, Maynooth, Ireland) were 
measured by ELISA according to manufacturer’s instructions.
 
Atherosclerosis quantification
After sacrifice, hearts were isolated and fixed in formalin, embedded in paraffin and cross-
sectioned (5 µm) throughout the entire aortic root area. Cross sections were stained with 
hematoxylin-phloxine-saffron for histological analysis. Each cross section consisted of three 
segments separated by aortic valve leaflets and for each mouse four cross sections were 
used to assess atherosclerotic lesion area and severity. The lesions were classified into five 
categories according to the American Heart Association classification: I) Early fatty streaks: 
Up to ten foam cells in the intima with no other changes; II) Regular fatty streaks: Ten or 
more foam cells in the intima with no other changes; III) Mild plaque: A fibrotic cap and the 
presence of foam cells in the media; IV) Moderate plaque: More progressed lesions with 
an affected media, but without loss of architecture of the media; V) Severe plaque: The 
media is severely affected. Broken elastic fibers, cholesterol clefts, calcification and necrosis 
are frequently observed. Total lesion area, the number of lesions per cross section, as well 
as the percentage undiseased segments were determined as previously described.28, 29 To 
determine lesion severity, the type I-III lesions were classified as mild lesions and the type 
IV-V lesions were classified as severe lesions. Images were taken with the Olympus BX51 
microscope and lesion areas were measured using Cell D imaging software (Olympus Soft 
Imaging Solutions).
The severe lesions (type IV-V) were further analyzed to assess lesion composition 
after immunostaining with mouse anti-human alpha actin (1:800; Monosan, Uden, The 
Netherlands) for smooth muscle cells (SMCs), and rat anti-mouse Mac-3 (1:50; BD Pharmingen, 
the Netherlands) for macrophages followed by sirius red staining for collagen. Necrotic 
area and cholesterol clefts, monocyte adhesion to the endothelium, and the calculation of 
plaque stability index (defined as the ratio of collagen and SMC area as stabilization factors 
to macrophage and necrotic area as destabilization factors) were determined as previously 
described.28, 29 All parameters of lesion composition were calculated per cross section and 
as a percentage of lesion area. Images of the lesions were taken with the Olympus BX40 
microscope with Nuance 2 multispectral imaging system, and stained areas were quantified 













































HDL from control and treated mice was isolated by sequential ultracentrifugation (d = 
1.063–1.21 g/mL) according to the method of Havel et al.30 using solid potassium bromide 
(Merck) for density adjustment as described previously.31 
Vascular cell adhesion molecule detection by cell western
Human arterial endothelial cells (HAECs) (P7) were incubated with isolated HDL for 12 hours 
and treated with TNF-alpha (R&D Systems) for 4 hours. Cells were fixed in 3.7% formaldehyde, 
washed, blocked and incubated overnight with vascular cell adhesion molecule (VCAM-1) 
antibody (R&D Systems). Cells were washed and secondary antibody anti-goat (Odyssey 
Licor) with Draq-5 for normalization (680CW) was added. After incubation, cells were 
washed and fluorescence was measured.32 
Apoptotic cell death inhibition in a cellular system
HAECs (P7) were treated with an apoptosis-inducing agent in the presence and absence of 
isolated HDL. Cells were lysed and apoptosis was detected using a DNA fragmentation assay 
(Cell Death Detection ELISAPLUS) according to the supplier’s protocol (Roche Applied Science, 
11 774 425 001). In short, supernatant was placed into a streptavidin-coated microplate and 
incubated with a mixture of anti-histone-biotin and anti-DNA-peroxidase (POD) antibodies. 
Plates were washed to remove unbound components. The amount of nucleosome retained 
in the immunocomplex was quantitatively photometrically determined with ABTS as 
peroxidase substrate.
Statistical Analysis
Significance of differences between the groups was calculated non-parametrically using 
a Kruskal-Wallis test for independent samples, followed by a Mann-Whitney U-test for 
independent samples. An analysis of covariance (ANCOVA) was performed to test for group 
differences in lesion area with HDL-C and non-HDL-C exposure as covariates. To test whether 
collinearity was present between the explanatory variables, we calculated the variance 
inflation factor (VIF) and the condition index (CI). Values of VIF > 5 and values of CI > 10 were 
used as a cutoff for collinearity.33, 34
SPSS 17.0 for Windows was used for statistical analysis. All groups were compared with 
the control group and the combination group was compared with the atorvastatin group. 
Bonferroni-Holm’s method was used to determine the level of significance in the case of 













































Anacetrapib, atorvastatin and their combination decrease cholesteryl ester transfer 
protein activity despite an increase in cholesteryl ester transfer protein concentration
To assess the extent to which an ascending dose range of anacetrapib inhibits CETP, we 
measured CETP activity after 8 weeks of treatment and CETP concentration after 21 weeks 
of treatment (Table 1). Anacetrapib monotreatment (0.03; 0.3; 3 and 30 mg/kg/d) reduced 
CETP activity by -59% to -100% (P<0.001) and increased plasma CETP concentration by +11% 
(NS) to +29% (P<0.001). Both CETP activity and concentration were decreased by atorvastatin 
alone (-29% and -24%, P<0.001) and in combination with 0.3 mg/kg/d anacetrapib (-84% 
and -23%, P<0.001). Thus, adding anacetrapib to atorvastatin further reduced CETP activity 
(-78%, P<0.001) without affecting CETP concentration when compared with atorvastatin.
Table 1 Effect of anacetrapib, atorvastatin and their combination on the cholesteryl ester transfer 
protein activity after 8 weeks of treatment and cholesteryl ester transfer protein concentration after 





Control 66.8 ± 10.1 15.7 ± 1.2
0.03 mg/kg/d anacetrapib 27.1 ± 7.1 *** (-59%) 17.4 ± 3.1 (+11%)
0.3 mg/kg/d anacetrapib 6.3 ± 4.8 *** (-91%) 19.9 ± 2.4 *** (+27%)
3 mg/kg/d anacetrapib 0.7 ± 3.3 *** (-99%) 20.2 ± 3.1 *** (+29%)
30 mg/kg/d anacetrapib 0.0 ± 2.3 *** (-100%) 18.5 ± 4.1 (+18%)
Atorvastatin 47.5 ± 8.2 *** (-29%) 11.9 ± 2.3 *** (-24%)
Atorvastatin + 
0.3 mg/kg/d anacetrapib
10.5 ± 8.3 *** ### (-84%) 12.1 ± 2.1 *** (-23%)
***P<0.001 when compared with control; ###P<0.001 when compared with atorvastatin. Data are 
presented as means ± SD (% inhibition or increase when compared with the control); n=15 per group.
Anacetrapib alone and in combination with atorvastatin reduces plasma non-HDL-
cholesterol and increases HDL-cholesterol
During the study, plasma lipids were measured every 2 to 4 weeks and average plasma TC 
(Figure 1A), TG (Figure 1B), non-HDL-C (Figure 1C) and HDL-C (Figure 1D) were calculated. 
In the control group, the Western-type diet resulted in an average plasma TC of 10.8 ± 
1.1 mmol/L, TG of 1.8 ± 0.5 mmol/L, non-HDL-C of 9.5 ± 1.1 mmol/L and HDL-C of 1.2 ± 
0.2 mmol/L. When compared with the control, anacetrapib monotreatment (0.03; 0.3; 
3 and 30 mg/kg/d) decreased TC (-19%; -25%; -27% and -31%, P<0.001 for all) mainly by 
decreasing non-HDL-C (-24%; -36%; -42% and -45%, P<0.001 for all). In addition, anacetrapib 
monotreatment increased HDL-C (+30%; +60%; +86% and +86%, P<0.001 for all) and 















































Figure 1. Effect of anacetrapib, atorvastatin and their combination on total cholesterol, triglycerides, 
non-HDL-cholesterol and HDL-cholesterol levels. Plasma total cholesterol (A), triglycerides (B) non-
HDL-cholesterol (C) and HDL-cholesterol (D) were measured throughout the study and average levels 
were calculated. Lipoprotein profiles for cholesterol were assessed by FPLC lipoprotein separation 
to study effects of anacetrapib alone (E) and in combination with atorvastatin (F) after 18 weeks of 
treatment.
**P<0.01, ***P<0.001 when compared with control; ###P<0.001 when compared with atorvastatin. 
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Atorvastatin decreased TC (-33%, P<0.001) by decreasing non-HDL-C (-37%, P<0.001) and 
with no effect on HDL-C and TG. The combination treatment decreased TC (-48%, P<0.001), 
non-HDL-C (-60%, P<0.001) and TG (-33%, P<0.01) and increased HDL-C (+56%, P<0.001). 
Anacetrapib enhanced the lipid-modifying effects of atorvastatin with greater reductions 
in TC (-22%, P<0.001), non-HDL-C (-36%, P<0.001) and TG (-32%, P<0.001) and a greater 
increase in HDL-C (+72%, P<0.001) when comparing the combination treatment with 
atorvastatin monotreatment. Lipoprotein profiles confirmed the lipid-modifying effects of 
anacetrapib and revealed the formation of larger HDL particles, as observed previously19 
after treatment with higher dosages of anacetrapib (3 and 30 mg/kg/d; Figure 1E and 1F).
Atorvastatin in combination with anacetrapib reduces atherosclerosis progression to a 
greater extent than atorvastatin alone
After 21 weeks of treatment, the effects of anacetrapib, atorvastatin and their combination 
on the progression of atherosclerosis were assessed in the aortic root area as illustrated by 
representative images in Figure 2. The number of lesions (Figure 3A), lesion area (Figure 
3B), undiseased segments (Figure 3C) and lesion severity (Figure 3D) were assessed as 
previously described.28, 29
For the control group, 4.1 ± 0.6 lesions per cross section developed with a total lesion 
area of 169 ± 51 *103 µm2. Approximately 71% of these lesions were severe lesions (type 
IV-V) and only 5% of the segments were undiseased. Anacetrapib monotreatment (0.03; 
0.3; 3 and 30 mg/kg/d) dose-dependently reduced lesion area (-41%, P<0.01; -72%; -86% 
and -92%, P<0.001 for all) and the number of lesions and improved lesion severity as 
indicated by less severe lesions (down to 15%, P<0.001) and more undiseased segments (up 
to 46%, P<0.001). Atorvastatin monotreatment reduced total lesion area (-63%, P<0.001) 
and improved lesion severity without affecting the number of lesions and undiseased 
segments. When compared with the control, the combination treatment further decreased 
total lesion area (-95%, P<0.001), the number of lesions (-41%, P<0.01), and lesion severity 
and increased the percentage undiseased segments. When compared with atorvastatin 
monotreatment, the combination treatment decreased total lesion area (-87%, P<0.001), 
the number of lesions (-34%, P=0.06) and severity and increased the percentage undiseased 















































Figure 2. Effect of anacetrapib, atorvastatin and their combination on plaque morphology. 
Representative images of hematoxylin-phloxine-saffron-stained atherosclerotic lesions in a cross 
section of the aortic root area for the control group (A), 0.03 mg/kg/d anacetrapib (B), 0.3 mg/kg/d 
anacetrapib (C), 3 mg/kg/d anacetrapib (D), 30 mg/kg/d anacetrapib (E), atorvastatin group (F) and 
















































Figure 3. Effect of anacetrapib, atorvastatin and their combination on atherosclerosis development in 
the aortic root area. The number of lesions per cross section (A), total lesion area per cross section 
(B), the percentage undiseased segments (C) and lesion severity as a percentage of all lesions (D) were 
determined after 21 weeks of treatment. Lesion severity was classified as mild (type I-III) and severe 
(type IV-V) lesions.
**P<0.01, ***P<0.001 when compared with control; #P<0.05, ###P<0.001 when compared with 
atorvastatin. Data are presented as means ± SD (n=15 per group).
Anacetrapib, atorvastatin and their combination improve lesion stability 
In addition to atherosclerotic lesion size and severity, we assessed the number of monocytes 
adhering to the endothelium as a functional marker for vascular inflammation (Figure 4A). 
Adhering monocytes per cross section in the control group (i.e. 4.1 ± 2.6) were reduced 
by the higher dosages of anacetrapib (-60%, P<0.01 and -61%, P<0.01), as well as by 
atorvastatin alone and in combination with anacetrapib (-48%, P<0.05 and -78%, P<0.001). 
When compared with atorvastatin, the combination treatment reduced the number of 
monocytes to a greater extent (-57%, P<0.01). In addition, we analyzed the composition of 
the severe lesions (type IV-V), since these lesions are considered to be most vulnerable and 
prone to rupture. All parameters of lesion composition were calculated per cross section 










































4B) and SMC content in the cap (Figure 4C) were considered as stabilization factors and 
macrophage content (Figure 4D) and necrotic content (Figure 4E) were considered as 
destabilization factors. The severe lesions in the control group consisted of approximately 
54% collagen, 6% SMCs in the cap, 10% macrophages and 4% necrosis. The lesion stability 
index for the control group presented as the ratio of stabilization to destabilization factors 
was 4.9 ± 2.0 (Figure 4F).
When corrected for lesion area, the two higher dosages of anacetrapib (3 and 30 mg/kg/d) 
revealed a more stable plaque phenotype by increasing collagen content (+21%, P<0.001 
and +28%, P<0.001) and SMC content in the cap (+120%, P<0.01 and +119%, P<0.05) and by 
decreasing macrophage (-53%, P=0.06 and -60%, P=0.05) and necrotic (-73%, P<0.001 and 
-46%, P<0.05) content. This is reflected by an increase in lesion stability index in these two 
treatment groups (+427%, P<0.001 and +366%, P<0.01). Atorvastatin in combination with 
anacetrapib tended to increase the SMC content in the cap (+194%, P=0.07) and decreased 
necrotic content (-96%, P<0.05) with no effect on lesion stability index. However, it should 
be noted that there were almost no lesions in the combination group and only two mice 
that received the combination treatment of anacetrapib and atorvastatin developed severe 
lesions.
Anacetrapib does not affect HDL function
To explore the contribution of the anacetrapib-induced increase in HDL-C to the reduction 
of atherosclerosis, we investigated the endothelial-vasoprotective properties of HDL, 
in particular with respect to anti-inflammatory and anti-apoptotic properties in cultured 
arterial endothelial cells. HDL isolated from anacetrapib-treated mice had no effect on pro-
















































   
Figure 4. Effect of anacetrapib, atorvastatin and their combination on lesion composition. The number 
of monocytes adhering to the vascular endothelium per cross section (A) was calculated. In the 
severe lesions (type IV and V), collagen content (B) and SMC content in the cap (C) were determined 
as stabilization factors and macrophage content (D) and necrotic content (E) were determined as 
destabilization factors, all as a percentage of lesion area. The plaque stability index was calculated as 
the ratio of the stabilization factors to the destabilization factors (F).
*P<0.05, **P<0.01, ***P<0.001 when compared with control; ##P<0.01 when compared with 













































  Figure 5. Effect of anacetrapib, atorvastatin and their combination on endothelial-vasoprotective 
properties of HDL, in particular pro-inflammatory cytokine-induced VCAM-1 expression (A) and 
apoptotic cell death (B).
Data are presented as means ± SD.
Anacetrapib reduces atherosclerosis progression primarily by reducing non-HDL-
cholesterol exposure
We evaluated whether the effects of anacetrapib and atorvastatin on atherosclerosis 
development could be explained by either an increase in HDL-C or a decrease in non-
HDL-C or both. Lesion area was normalized by cubic root transformation (lesion area (1/3)). 
Univariate regression analysis showed that lesion area was predicted by TC (Figure 6A), 
mainly non-HDL-C (Figure 6B) and to a lesser extent by HDL-C (Figure 6C). Analysis of 
covariance (ANCOVA) showed that both anacetrapib treatment, at the dosages of 3 and 
30 mg/kg/d (P<0.05) and non-HDL-C (P<0.001), but not HDL-C (P=0.76), independently 
determined lesion size. Importantly, the variance inflation factors of HDL-C and non-HDL-C 
(VIF = 4.42 and 3.18 respectively) and the condition index (CI = 4.43) did not exceed the 
threshold for collinearity between the explanatory variables. Collectively, these data are 
compatible with a mechanism that anacetrapib mainly decreases atherosclerotic lesion 
development via a reduction of non-HDL-C with an additional effect by the compound itself 














































   
Figure 6. Correlation between plasma cholesterol exposure and lesion area. Linear regression analyses 
were performed on the cubic root of lesion area plotted against total cholesterol exposure (A), non-











































Figure 7  
Figure 7. Hypothetical scheme of factors contributing to the effect of anacetrapib on atherosclerotic 
lesion area as suggested by statistical analyses. An analysis of covariance (ANCOVA) was performed to 
test for group differences in lesion area with HDL-C and non-HDL-C exposure as covariates. HDL-C was 
not an independent predictor of lesion area when non-HDL-C was included as covariate, suggesting 
that the effect of anacetrapib on atherosclerosis development was mainly mediated through the 
reduction of non-HDL-C. The higher dosages of anacetrapib (3 and 30 mg/kg/d) also revealed an 
effect on atherosclerosis that was independent of non-HDL-C, but this effect was not explained by the 
increase in HDL-C.
Anacetrapib slightly increased serum amyloid A as a marker of inflammation
To assess the effect of anacetrapib on general inflammatory status, we measured plasma 
SAA levels, a systemic inflammatory marker after 16 weeks of treatment (Figure 8). Plasma 
SAA levels in the control group were 1.6 ± 0.5 µg/mL. When compared with the control, 
0.3 mg/kg/d anacetrapib tended to increase SAA levels (+37%, P=0.07). No effects on body 




   
Figure 8. The effects of anacetrapib, atorvastatin and their combination on plasma SAA levels were 
measured after 16 weeks of treatment.












































The present study is the first intervention study in a mouse model for atherosclerosis designed 
to investigate the effects of the CETP inhibitor, anacetrapib alone and in combination 
with atorvastatin on the progression of atherosclerosis, lesion stability and HDL function. 
In clinical trials, the effectiveness of novel treatment regimes in CVD is only being tested 
in patients on a statin background which makes this study unique in also evaluating the 
effects of anacetrapib monotreatment. In APOE*3Leiden.CETP mice, a broad dose range 
of anacetrapib dose-dependently reduced atherosclerosis development. This effect was 
mainly ascribed to the reduction in non-HDL-C despite a remarkable increase in HDL-C and 
without affecting HDL functionality. Anacetrapib improved lesion stability when given at a 
higher dose (3 and 30 mg/kg/d). In addition, a moderate dose of anacetrapib (0.3 mg/kg/d) 
added to the anti-atherogenic effects of atorvastatin.
In our study, incremental dosages of 0.03 to 30 mg/kg/d anacetrapib dose-dependently 
decreased CETP activity by > 60%, decreased non-HDL-C by 24% to 45% and increased 
HDL-C by 30% to 86%. These lipid-altering effects are comparable to findings from phase I, II 
and III clinical trials. In phase I trials, an anacetrapib-induced reduction in CETP activity of > 
60% was accompanied by dose-dependent LDL-C-lowering and HDL-C-raising effects both in 
healthy subjects35 and in patients with dyslipidemia.36 In line with our results, these studies 
also report an increase in CETP concentration possibly due to the formation of an inactive 
complex between CETP and HDL.37 In a phase II trial, 8 weeks of treatment with ascending 
dosages of anacetrapib monotreatment (10 to 300 mg/d) reduced LDL-C by 16% to 39% 
and increased HDL-C by 44% to 139%. Similar to our study, the addition of anacetrapib to 
atorvastatin produced incremental LDL-C reductions.23
The present study in APOE*3Leiden.CETP mice demonstrates that total blockage of 
CETP does not reveal adverse effects on the clinical endpoint when compared with partial 
blockage: anacetrapib dose-dependently reduced the progression of atherosclerosis 
and increased plaque stability whereas the anti-atherogenic effects of atorvastatin were 
enhanced in combination with a moderate dose of anacetrapib.
Inconsistent data have been reported on the effect of other CETP inhibitors on 
atherosclerosis development in animals expressing CETP. In rabbits, dalcetrapib reduced 
atherosclerosis in one study with no effect in another study.15, 17 In contrast to the human 
situation,21 the reduction in atherosclerosis after dalcetrapib treatment was accompanied 
by a 40% to 50% decrease in non-HDL-C together with an increase in HDL-C.15 In mice, 
torcetrapib monotreatment decreased atherosclerosis.19 However, unlike the present study, 
these effects were not enhanced in combination with atorvastatin in the same mouse 
model.19 In rabbits, torcetrapib treatment decreased atherosclerosis where aortic lesion 










































of increased HDL-C or other pleiotropic effects of HDL. However, in the APOE*3Leiden.CETP 
mouse model, statistical analyses revealed that HDL-C was not an independent predictor 
of lesion area when non-HDL-C was included as covariate, suggesting that the effect of 
anacetrapib on atherosclerosis development was mainly mediated through the reduction of 
non-HDL-C. The higher dosages of anacetrapib (3 and 30 mg/kg/d) also revealed an effect 
on atherosclerosis that was independent of non-HDL-C, but this effect was not explained 
by the increase in HDL-C and could point to other hitherto unknown (off target) effects of 
anacetrapib.
Besides atherosclerotic lesion size, lesion composition should also be taken into 
consideration given that in the human situation, a vulnerable lesion consisting of more 
macrophages, a large necrotic core and a thin, collagen-poor, fibrous cap is more prone 
to rupture.38 Previously, our group showed that torcetrapib produced a pro-inflammatory, 
unstable plaque phenotype as seen by increased monocyte adherence to the vascular 
endothelium and consequently increased macrophage content of the lesions.19 In the present 
study, anacetrapib decreased monocyte adherence and improved lesion composition as 
shown by an increase in stabilization factors (collagen and SMC content) and a decrease 
in destabilization factors (macrophage and necrotic content). The inconsistencies can be 
ascribed to the off-target activation of the renin-angiotensin-aldosterone system (RAAS) 
and blood pressure effect of torcetrapib.39 Indeed, in our mouse model for atherosclerosis, 
torcetrapib also increased aldosterone levels in plasma.19
The large phase III DEFINE trial was designed to further assess the efficacy and 
tolerability of anacetrapib in statin-treated patients with or at risk for coronary heart 
disease.40 Anacetrapib (100 mg/d) decreased LDL-C by 40% and increased HDL-C by 138% 
with an acceptable safety profile and no indication for an increase in CV events. In fact, post 
hoc analyses suggested a reduction in CV endpoints. These initial data provided a rationale 
for conducting a larger clinical endpoint trial of pharmacological CETP inhibition despite 
the conflicting outcomes of genetic CETP deficiency and the ILLUMINATE trial.20 In view of 
the detrimental effects of torcetrapib in the ILLUMINATE trial, anacetrapib was thoroughly 
screened and revealed minimal side effects without any indication for an off-target pressure 
effect.23, 35, 36
Despite the absence of reported side effects of anacetrapib, there are some concerns 
about target-related side effects due to formation of large buoyant cholesterol-rich HDL-
2 particles after CETP inhibition,41, 42 which may be dysfunctional with regard to their 
endothelial-vasoprotective effects and consequently their atheroprotective properties10, 
37, 43, 44 and that this may have contributed to the failure of torcetrapib.20 In the present 
study, we investigated the effects of HDL isolated from control and anacetrapib-treated 
mice on parameters of vascular inflammation and function. HDL from anacetrapib-treated 
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endothelial cells. This is in line with results from recent studies where no differences were 
observed in the effect of HDL from control or anacetrapib-treated hamsters and humans 
on inflammatory markers (adhesion molecule expression, monocyte chemotactic protein-1 
secretion, monocyte adhesion, NFkB activation and cytokine mRNAs) in endothelial cells45 
and macrophages.46 Importantly, although anacetrapib treatment did not improve the 
anti-inflammatory and anti-apoptotic effects of HDL, it also did not adversely affect these 
functions of HDL. In addition, we found no effect of anacetrapib on serum paraoxonase 
1 (PON-1) activity and the aortic content of reactive oxygen species (ROS) (data not 
shown). Formation of large cholesterol-rich HDL-2 particles in CETP-deficiency or after 
CETP inhibition has also been suggested to affect the cholesterol efflux capacity of these 
particles.41, 42 Although we did not address this in the present study, data from literature 
consistently indicate that the cholesterol efflux capacity is not impaired but improved. 
HDL from CETP-deficient patients displayed enhanced ability to promote cholesterol efflux 
from macrophages in an ABCG1-dependent manner.41 In humans, anacetrapib-treated HDL 
showed increased ABCA1- and ABCG1-mediated cholesterol efflux capacity.46 Collectively, 
these data indicate that CETP inhibition does not result in formation of dysfunctional HDL 
with regard to its atheroprotective properties as assessed by ex vivo (cell) assays.
It should be noted that in the DEFINE trial, a non-significant 18% increase in C-reactive 
protein, a marker of inflammation, after anacetrapib treatment was found.40 In the present 
study, the inflammatory marker, SAA was slightly elevated after anacetrapib treatment, but 
this effect was alleviated when anacetrapib was given in combination with atorvastatin.
The effects of two other CETP inhibitors, DRL-17822 and TA-8995 (DEZ-001), as well as 
a vaccine against CETP, ATH03, are being tested in phase I/II clinical development. In large 
phase III clinical trials, the effects of 100 mg anacetrapib (REVEAL) and 130 mg evacetrapib 
(ACCELERATE) in patients on standard statin treatment on CV outcomes are currently being 
investigated and results are expected in 2016/17.44 The outcome of these trials will resolve 
the unanswered questions regarding possible beneficial effects of pharmacological CETP 
inhibition and may give additional insight into the HDL-hypothesis and the contribution of 
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Objectives Recently, we showed in APOE*3-Leiden.CETP mice that anacetrapib attenuated 
atherosclerosis development by reducing (V)LDL-C rather than by raising HDL-C. Here, we 
investigated the mechanism by which anacetrapib reduces (V)LDL-C and whether this effect 
was dependent on the inhibition of CETP.
Approach and Results APOE*3-Leiden.CETP mice were fed a Western type diet alone or 
supplemented with anacetrapib (30 mg/kg bw/d). Microarray analyses of livers revealed 
down regulation of the cholesterol biosynthesis pathway (P<0.001) and predicted down 
regulation of sterol regulatory element-binding protein-1 and -2 controlled pathways 
(z-score -2.56 and z-score -2.90, respectively; both P<0.001). These data suggest increased 
supply of cholesterol to the liver. We found that hepatic proprotein convertase subtilisin/
kexin type 9 (Pcsk9) expression was decreased (-28%, P<0.01) accompanied by decreased 
plasma PCSK9 levels (-47%, P<0.001), and increased hepatic LDL receptor protein content 
(+64%, P<0.01). Consistent with this, anacetrapib increased the clearance and hepatic uptake 
(+25%, P<0.001) of [14C]cholesteryl oleate-labeled VLDL-mimicking emulsion particles. In 
APOE*3-Leiden mice that do not express CETP, anacetrapib still decreased (V)LDL-C and 
plasma PCSK9 levels, indicating that these effects were independent of CETP inhibition.
Conclusions Anacetrapib reduces (V)LDL-C by two mechanisms: 1) inhibition of CETP activity, 
resulting in remodelled VLDL particles that are more susceptible to hepatic uptake and 2) a 
CETP-independent reduction of plasma PCSK9 levels that has the potential to increase LDL 
receptor-mediated hepatic remnant clearance.
Keywords CETP, Cholesterol/Metabolism, Drug therapy/Hypolipidemic drugs, LDL/












































High plasma levels of (very) low-density lipoprotein [(V)LDL]-cholesterol (C) and triglycerides 
(TG), as well as low levels of high-density lipoprotein (HDL)-C are important risk factors for 
cardiovascular diseases. The standard treatment for the reduction of cardiovascular disease 
risk is statin therapy aiming to reduce plasma (V)LDL-C. However, a substantial residual risk 
remains despite of statin treatment. This has prompted the search for secondary treatment 
targets.1, 2 Prospective epidemiological studies indicate HDL-C as a potential target.3 The ratio 
of plasma (V)LDL-C to HDL-C is to a great extent affected by cholesteryl ester transfer protein 
(CETP). CETP facilitates the transfer of cholesteryl esters from HDL to (V)LDL in exchange for 
TG.4 In several mouse models, including C57Bl/6, Ldlr-/- and APOE*3-Leiden (E3L) transgenic 
mice, CETP expression aggravates the development of atherosclerosis.5-7 Although human 
studies have shown conflicting results with regard to the association between CETP-
deficiency and decreased cardiovascular disease risk,8, 9 CETP inhibition is actively pursued as 
a potential strategy to reduce this risk.10 This has led to the development of pharmacological 
CETP inhibitors, such as torcetrapib, dalcetrapib, anacetrapib and evacetrapib.
In clinical trials, torcetrapib, anacetrapib and evacetrapib have been shown to increase 
HDL-C (up to +72%11;+139%12; +129%,13 respectively) and to reduce LDL-C (down to -25%11; 
-40%12; -36%,13 respectively); whereas dalcetrapib only increased HDL-C (up to +40%).14 
Although torcetrapib showed favourable effects on the lipoprotein profile, it failed in phase 
III clinical development due to increased risk of major cardiovascular events and mortality. 
These adverse effects were ascribed to an off-target effect11 and pro-inflammatory lesions.15 
A large phase III clinical trial with dalcetrapib was prematurely terminated, due to a lack of 
clinical benefit.14 Nonetheless, the effects of anacetrapib and evacetrapib on cardiovascular 
outcomes are currently being evaluated in phase III clinical trials.16 Neither compound shows 
increased blood pressure as observed with torcetrapib12, 13 and both compounds are more 
potent in increasing HDL-C and reducing LDL-C as compared to torcetrapib and dalcetrapib.
Recently, we have shown that anacetrapib treatment increased HDL-C and reduced (V)
LDL-C and TG, and dose-dependently reduced atherosclerotic lesion size and severity in 
APOE*3-Leiden.CETP (E3L.CETP) mice, a well-established mouse model for hyperlipidemia 
and atherosclerosis with a human-like lipoprotein metabolism.17-19 Analysis of covariance 
showed that the effect on lesion size was mainly explained by a reduction in (V)LDL-C.20 
However, the mechanism by which anacetrapib reduces plasma (V)LDL-C and TG is not 
fully understood. To elucidate this, we performed microarrays on the livers from this latter 
study, identifying pathways affected by anacetrapib. To confirm physiological consequences 
of these identified pathways, we performed a VLDL production experiment and studied 
the clearance of VLDL-mimicking emulsion particles. By using E3L mice with or without 












































RNA isolation, microarray and qPCR validation
Liver pieces were obtained from a previous experiment performed by Kühnast and Van der 
Tuin et al.,20 investigating the effects of anacetrapib on atherosclerosis in female E3L.CETP 
mice. In this study, mice were treated with a semi-synthetic cholesterol-rich diet, containing 
15% (w/w) cacao butter, 1% corn oil and 0.1% cholesterol (Western-type diet; AB-Diets, 
Woerden, the Netherlands) with or without anacetrapib (30 mg/kg bw/d) for 21 weeks. 
Total RNA was extracted from these liver pieces using the Nucleospin RNAII kit (Macherey-
Nagel) according to manufacturer’s protocol. The microarray, including quality control, RNA 
labelling, hybridization and data extraction was performed by ServiceXS B.V. (Leiden, The 
Netherlands). 
To perform real time quantitative PCR (qPCR) for validation, RNA quality was verified by 
the lab-on-a-chip method using ExperionTM RNA StdSens analyses kit (Bio-Rad). Total RNA 
was reverse-transcribed with iScript cDNA synthesis kit (Bio-Rad) and qPCR was performed 
using a CFX96TM Touch Real-Time PCR Detection System (Bio-Rad). Gene expression was 
normalized to Beta-2 microglobulin and hypoxanthine-guanine phosphoribosyltransferase. 
Relative expression was calculated as compared to the control group using Bio-Rad CFX 
ManagerTM software 3.0 (Bio-Rad).
Microarray data analyses
The probe-level background subtracted expression values were used as input for lumi 
package21 of the R/Bioconductor (http://www.bioconductor.org; http://www.r-project.
org) to perform quality control and a quantile normalization. Unexpressed probes (p>0.01 
in all experiments) were removed from further analyses. Differentially expressed probes 
were identified using the limma package of R/Bioconductor.22 The calculated P-values 
<0.05 were used as a threshold for pathway analyses using Ingenuity Pathway Analysis suite 
(www.ingenuity.com, accessed 2013). Upstream regulator analysis was performed using 
the Ingenuity Pathway Analysis software. This analysis determines the activation state of 
transcription factors based on the observed differential gene expression and results in an 
overlap p-value and activation z-score for each transcription factor in the Ingenuity Pathway 
Analysis knowledgebase. The overlap p-value indicates the significance of the overlap 
between the known target genes of a transcription factor and the differentially expressed 
genes measured in an experiment. The activation z-score indicates activation (positive 
z-score) or inhibition (negative z-score) of a particular transcription factor. An activation 












































To investigate the effects of anacetrapib on VLDL production and clearance, female E3L23 
and E3L.CETP7 transgenic mice, 8-10 weeks of age, were fed a Western-type diet for a run-
in period of 3-4 weeks. They were then matched based on plasma total cholesterol (TC), 
HDL-C, TG, body weight and age into two groups receiving either no treatment (control) or 
anacetrapib (30 mg/kg bw/d) for four weeks after which VLDL production (E3L.CETP only) 
or clearance (E3L and E3L.CETP) was determined. After both experiments the mice were 
sacrificed by CO2 asphyxiation. The mice were housed under standard conditions with a 12 
hour light-dark cycle and had free access to food and water during the experiment. Body 
weight and food intake were monitored during the study. The Institutional Ethics Committee 
for Animal Procedures from the Leiden University Medical Center, Leiden, The Netherlands, 
approved the protocol.
Plasma lipid measurements
Blood was collected after a 4 hour fasting period in heparin-coated capillaries via tail vein 
bleeding and plasma was isolated. TC and TG were determined using enzymatic kits (Roche) 
according to manufacturer’s protocol. To measure HDL-C, apoB-containing particles were 
precipitated from plasma with 20% polyethylene glycol 6000 (Sigma Aldrich) in 200 mM 
glycine buffer (pH 10) and HDL-C was measured in the supernatant.20
Hepatic LDLr protein and plasma PCSK9 measurements
Snap-frozen mouse livers were lysed in ice-cold lysis buffer containing 50 mM Hepes (pH 
7.6), 50 mM NaF, 50 mM KCl, 5 mM NaPPi, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 5 mM 
β-glycerophosphate, 1 mM sodium vanadate, 1% NP40 and protease inhibitors cocktail 
(Roche). Thereafter, protein level was determined using the BCA Protein Assay Kit (Pierce) 
according to manufacturer’s instructions. Laemmli buffer (Sigma-Aldrich) was added to 
samples containing equal amounts of protein. Samples were separated on a 10% sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis, and blotted to polyvinylidene difluoride. 
Blots were incubated with goat-anti-mouse-LDL receptor (1:1000, AF2255, R&D Systems) 
and mouse-anti-α-Tubulin (1:1000, T5168, Sigma-Aldrich) and subsequently incubated with 
the appropriate secondary antibody. Bands were visualized by enhanced chemiluminescence 
with Pierce ECL 2 substrate following manufacturer’s protocol and quantified using Image 
J software as previously described.24 Plasma proprotein convertase subtilisin/kexin type 9 











































Hepatic VLDL-TG and VLDL-apoB production analyses
Mice (n= 8/9 per group) were anesthetized with 6.25 mg/kg Acepromazine (Alfasan), 6.25 
mg/kg Midazolam (Roche) and 0.31 mg/kg Fentanyl (Janssen-Cilag) after a 4-hour fast. A 
basal blood sample was taken from the tail and the mice received an intravenous injection 
of 100 µl PBS containing 100 µCi Tran35S label (MP Biomedicals) via the tail vein. After 30 
min, animals received an intravenous injection of Tyloxapol (Triton WR-1339, Sigma-Aldrich; 
500 mg/kg body weight), as a 10% (w/w) solution in sterile saline, to prevent systemic 
lipolysis of newly secreted hepatic VLDL-TG.25 At indicated time points up to 90 min after 
Tyloxapol injection, blood was taken and plasma TG concentration was determined. After 
120 min, mice were sacrificed and blood was collected for isolation of the VLDL fraction by 
density gradient ultracentrifugation.26 Tran35S-activity was measured in the VLDL fraction 
and VLDL-apoB production rate was calculated as dpm/h.27
Clearance analysis of VLDL-mimicking emulsion particles
Glycerol tri(9,10(n)[3H]oleate ([3H]TO) and [1α,2α (n)-14C]cholesteryl oleate ([14C]CO) double-
radiolabeled VLDL-mimicking emulsion particles (mean diameter 80 nm) were prepared 
as previously described.28 After a 4 hour fast, particles were injected via the tail vein in 
conscious mice (n= 8/9 per group). At 2, 5, 10, and 15 min post-injection, blood was taken 
to determine the plasma decay of [3H]TO and [14C]CO. Plasma volumes were calculated 
as 0.04706 x body weight (g) as described.29 Mice were sacrificed after 15 min, perfused 
with ice-cold PBS with 0.1% heparin (v/v), and organs were harvested to determine tissue 
specific [3H]TO and [14C]CO uptake. Subsequently, organs were dissolved overnight at 56°C 
in Tissue Solubilizer (Amersham Biosciences), and quantified for 3H and 14C activity. Uptake 
of [3H]TO- and [14C]CO-derived radioactivity by the organs was calculated as dose per organ 
after correction for organ weight.
Statistical analysis
Significance of differences between the groups was calculated non-parametrically using a 
Mann-Whitney U test. All reported p-values are two-tailed, and p-values of less than 0.05 












































Pathway analyses predict down regulation of sterol regulatory element-binding protein-1 
and -2 controlled pathways by anacetrapib.
To determine the effects of anacetrapib treatment on hepatic gene expression in E3L.CETP 
mice,20 microarray analyses were performed. A total of 95 genes (FDR P<0.05; Supplemental 
Table I) were differentially expressed between control and anacetrapib-treated female 
mice of which 46 genes were up regulated and 49 genes were down regulated. To gain 
insight into affected biological processes, a gene-set enrichment analysis was performed 
using the Ingenuity Pathway Analysis suite (as described in material and methods). This 
analysis showed that the cholesterol biosynthesis pathway was significantly affected (Table 
1). In silico prediction of transcription factor activity (Table 2), based on the differentially 
expressed genes, predicted inhibition of genes regulated by sterol regulatory element-
binding protein (SREBP) 1 (P<0.001; z-score -2.90) and SREBP-2 (P<0.001; z-score -2.56), 
which are key regulators of cholesterol synthesis. Furthermore, anacetrapib activated 
genes regulated by nuclear receptor subfamily 1, group I, member 2 (P<0.001; z-score 
+2.75) and member 3 (P<0.001; z-score +2.94). Both nuclear receptors function as sensors 
of endobiotic and xenobiotic substances. These data indicate that anacetrapib reduces 
cholesterol biosynthesis and activates a xenobiotic response.
Table 1: Significantly regulated pathways.
Ingenuity Canonical Pathways -log(p-value) Ratio
Superpathway of Cholesterol Biosynthesis 10.50 0.24
PXR/RXR Activation 6.32 0.09
Superpathway of Geranylgeranyldiphosphate Biosynthesis I
(via Mevalonate)
6.00 0.22
Bupropion Degradation 5.39 0.16
LPS/IL-1 Mediated Inhibition of RXR Function 5.28 0.04
Cholesterol Biosynthesis I 4.65 0.23
Cholesterol Biosynthesis II (via 24,25-dihydrolanosterol) 4.65 0.23
Cholesterol Biosynthesis III (via Desmosterol) 4.65 0.23
Isoleucine Degradation I 4.54 0.21
Mevalonate Pathway I 4.54 0.21
Female E3L.CETP mice were fed a Western-type diet with or without anacetrapib (30 mg/kg bw/d) 
for 22 weeks. RNA was isolated from liver tissue and a microarray analysis was performed. Selected 
differentially expressed genes (95 genes, see Table I) were used as input for pathway analysis through 
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Anacetrapib decreases hepatic and circulating PCSK9, and increases hepatic LDLr protein 
in E3L.CETP mice
In addition to effects on cholesterol biosynthesis and xenobiotic metabolism, microarray 
analyses showed a decrease in the expression of Pcsk9 mRNA, a downstream target of the 
SREBP-2 pathway (Supplemental Figure I),30 in the liver of anacetrapib-treated E3L.CETP 
mice (-78%, P<0.05; Supplemental Table I), which was confirmed by qPCR (-27%, P<0.01; 
Figure 1A). In accordance, anacetrapib reduced plasma PCSK9 levels (-47%, P<0.01; Figure 
1B). Since PCSK9 plays an important role in the degradation of intracellular LDL receptor 
(LDLr),31-33 hepatic LDLr mRNA expression and protein levels were measured. Anacetrapib 
did not affect the hepatic Ldlr expression (Figure 1C), but did increase hepatic LDLr protein 
levels (+64%, P<0.05; Figure 1D). The decrease in plasma PCSK9 levels and increase in LDLr 
suggest an increased capability of the liver to take up lipoprotein remnants.
 21 




Figure 1. Anacetrapib decreases PCSK9 mRNA expression and plasma levels and increases hepatic 
LDLr protein levels in E3L.CETP mice.
Female E3L.CETP mice were fed a WTD with or without anacetrapib (30 mg/kg bw/d) for 21 weeks, 
blood was collected for plasma PCSK9 levels and livers for mRNA expression. Hepatic PCSK9 mRNA 
expression (A) and plasma levels (B). Hepatic LDLr mRNA (C) and protein (D) levels.
Data are presented as means ± SD (n= 14/15 per group). * P<0.05, ** P<0.01, ***P<0.001 when 










































Anacetrapib does not affect triglyceride metabolism, but increases lipoprotein remnant 
clearance by the liver in E3L.CETP mice
To further investigate the effects of anacetrapib on lipoprotein metabolism, we performed 
a new experiment with female E3L.CETP mice fed a Western-type diet with or without 
anacetrapib for 4 weeks. Plasma lipid and lipoprotein levels were decreased to the same 
extent as shown in Figure 2A (data not shown). Anacetrapib treatment did not affect the 
VLDL-TG production rate (Figure 2B), the VLDL-35S-apoB production rate (Figure 2C) nor the 
ratio of VLDL-TG to VLDL-apoB production rate (Figure 2D), indicating no changes in number 
or composition of newly synthesized VLDL particles.
Figure 2. Anacetrapib does not affect hepatic VLDL-TG production in E3L.CETP mice.
Female E3L.CETP mice were fed a WTD with or without anacetrapib (30 mg/kg bw/d) for 4 weeks, 
blood was collected by tail bleeding after 4h fasting, and plasma TC, TG, (V)LDL-C and HDL-C were 
determined (A). After treatment, hepatic VLDL production was assessed (B). 35S-apoB production was 
determined by scintillation counting of the isolated VLDL fraction (C) and the VLDL-TG production rate 
to VLDL-apoB production rate ratio was calculated (D).
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The effect of anacetrapib on VLDL clearance was assessed by an intravenous injection of 
glycerol tri(9,10(n)[3H]oleate ([3H]TO) and [1α,2α (n)-14C]cholesteryl oleate ([14C]CO) double-
radiolabeled VLDL-mimicking emulsion particles. At indicated time points, blood was taken 
to determine clearance from plasma. After 15 min, mice were sacrificed and organs were 
harvested to determine tissue specific uptake of radioactivity-derived from [3H]TO and [14C]
CO. We observed no effects on the plasma clearance (Figure 3A) or the tissue specific uptake 
of [3H]TO-derived activity (Figure 3B). However, anacetrapib increased the plasma clearance 
of the [14C]CO label of the VLDL-mimicking emulsion particles (Figure 3C), decreased plasma 
half-life of [14C]CO (-56%, P<0.001; Figure 3C inlay) and increased the uptake of [14C]CO by 
the liver (+25%, P<0.001; Figure 3D). Since these particles reflect the behaviour of VLDL,34 






Figure 3. Anacetrapib increases lipoprotein remnant clearance by the liver in E3L.CETP mice.
Female E3L.CETP mice were fed a WTD with or without anacetrapib (30 mg/kg bw/d) for 4 weeks. 
Mice received an injection with glycerol tri[3H]oleate- and [14C]cholesteryl oleate-double labelled 
VLDL-mimicking emulsion particles. Blood was drawn at the indicated time points and 3H and 14C 
plasma decay (A and C) and tissue specific activity (B and D) were determined. The inlay in figure A 
and C show plasma half-life.










































Anacetrapib decreases (V)LDL-C and PCSK9 levels in E3L mice
To determine whether the effects of anacetrapib on (V)LDL metabolism were dependent 
on CETP inhibition, similar experiments were performed in female E3L mice that do not 
express CETP. Notably, anacetrapib reduced TC (-17%, P<0.05) and (V)LDL-C (-20%, P<0.05; 
Figure 4A) levels in E3L mice without CETP, concomitantly with a decrease in hepatic Pcsk9 
expression and plasma PCSK9 levels (-37%, P<0.05; Figure 4B). These data clearly show that 
anacetrapib has a CETP-independent lipid-lowering effect. Comparing E3L with E3L.CETP 
mice, anacetrapib increased the particle clearance in E3L.CETP mice to the similar level 
as observed in E3L mice without anacetrapib (Figure 3C and 4C). Anacetrapib showed no 
additional effects on the plasma clearance of [3H]TO and [14C]CO (Figure 4C and 4E) labels of 
the VLDL-mimicking emulsion particles, nor the tissue specific uptake of [3H]TO and [14C]CO 
















































Figure 4. Anacetrapib decreases (V)LDL-C and plasma PCSK9 levels, without affecting lipoprotein 
remnant clearance in E3L mice.
Female E3L mice were fed a WTD with or without anacetrapib (30 mg/kg bw/d) for 4 weeks, blood was 
collected by tail bleeding after 4h fasting, and plasma TC, TG, (V)LDL-C, HDL-C (A) and plasma PCSK9 
levels (B) were determined. After treatment mice received an injection with glycerol tri[3H]oleate- and 
[14C]cholesteryl oleate-double labelled VLDL-mimicking emulsion particles. Blood was drawn at the 
indicated time points and 3H and 14C plasma decay (C and E) and tissue specific activity (D and F) were 
determined. The inlay in figure A and E show plasma half-life.











































In this study, we investigated the mechanism by which anacetrapib reduces plasma (V)
LDL-C and whether these effects are dependent on CETP. In E3L.CETP mice, anacetrapib 
decreased gene expression of cholesterol biosynthesis pathways in the liver, most probably 
via inhibition of Srebp-1 and/or Srebp-2 signalling. In addition, we identified two important 
processes by which anacetrapib increases cholesterol clearance. First, anacetrapib increased 
cholesterol clearance by the liver, without affecting VLDL-TG production rate and clearance 
in E3L.CETP mice. Secondly, in a CETP-independent manner, anacetrapib decreased hepatic 
Pcsk9 expression and plasma PCSK9 levels. In E3L mice that do not express CETP, anacetrapib 
decreased (V)LDL-C and plasma PCSK9 levels. However, no effects on cholesterol or VLDL-TG 
clearance were detected. These results indicate that CETP inhibition results in remodelled 
particles that are more susceptible for hepatic clearance.
The observed reduction in plasma PCSK9 levels after anacetrapib treatment is in 
accordance with recent findings in rhesus macaques.35 Here, we demonstrate that this 
effect is independent of CETP inhibition as this was also observed in E3L mice without CETP. 
A recent study in C57Bl/6 mice also confirmed a CETP-independent decrease in plasma 
PCSK9 levels by anacetrapib.36 Pathway analyses of the gene expression data predicted that 
anacetrapib decreases liver cholesterol synthesis by reducing SREBP-2 regulated pathways. 
It is known that SREBP-2 is the principal nuclear transcription factor for the regulation of 
hepatic Pcsk9 expression.30 Therefore, the reduction of plasma PCSK9 levels by anacetrapib 
may be attributed to the reduction of SREBP-2 pathway.
Accumulating evidence shows that inhibiting PCSK9 is an effective strategy to reduce 
LDL-C both in preclinical and clinical studies.37, 38 This effect is attributed to a reduction of 
hepatic LDLr degradation and a subsequent increase of LDL remnant clearance. Our results 
showed an increase in hepatic LDLr protein levels in E3L.CETP mice after 21 weeks of 
anacetrapib in parallel with a decrease in plasma PCSK9 levels. Partially in contrast, we found 
that after 4 weeks of anacetrapib treatment in E3L mice with or without CETP expression, 
anacetrapib did not change hepatic LDLr protein levels (data not shown) despite a clear 
reduction of plasma PCSK9 levels (Figure 4B). This discrepancy of anacetrapib affecting 
plasma PCSK9 levels but not hepatic LDLr protein levels might be due to the duration of the 
treatment i.e. 4 weeks versus 21 weeks of treatment. Indeed, in the study in C57Bl/6 mice 
receiving anacetrapib for 1 week, anacetrapib reduced both plasma PCSK9 and hepatic LDLr 
protein levels,36 suggesting a treatment time-dependent effect of anacetrapib on PCSK9 and 
LDLr. Although the effects of anacetrapib in E3L.CETP mice closely resemble the effects in 
humans,12, 20 the effects of anacetrapib on plasma PCSK9 and hepatic LDLr protein levels in 
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The comparison of the clearance rates of VLDL remnants in E3L mice with and without 
CETP (Figures 3C and 4C) indicates that the presence of CETP results in a decreased remnant 
particle clearance. This implies that inhibiting the activity of CETP alone is sufficient 
to increase lipoprotein remnant clearance in E3L.CETP mice. The main activity of CETP 
is to transfer cholesteryl esters from HDL to (V)LDL in exchange for TG. Apparently, this 
lipoprotein remodelling activity of CETP renders the (V)LDL less susceptible to clearance. 
In E3L.CETP mice, anacetrapib treatment results in an increase of plasma apolipoprotein 
E levels (+59%, P<0.001, data not shown), which is indicative for lipoprotein remodelling. 
Interestingly, anacetrapib treatment in humans has also been shown to increase plasma 
apolipoprotein E levels.12
Although the direct effects of CETP inhibition on lipoprotein remnant clearance in humans 
have not been described, treatment with the CETP-inhibitor torcetrapib has been shown to 
increase the fractional catabolic rate of both VLDL-apoE39 and VLDL-apoB100.40 However, 
the potentially increased catabolism of (V)LDL and thus anti-atherogenic properties were 
clearly not sufficient to offset or overrule the adverse side effects of torcetrapib.
Microarray analyses also revealed that anacetrapib activates genes regulated by the 
nuclear receptor subfamily 1, group I (NR1I), members 2 and 3. These transcription factors 
function as sensors of both toxic and xenobiotic exogenous compounds and toxic products 
derived from endogenous metabolism, and activate pathways to eliminate these products.41 
In our study, activation of these receptors indicated that anacetrapib was recognized as a 
xenobiotic product by the liver. It is not yet known whether this has consequences beyond 
activation of elimination pathways and whether this will have clinical implications. Phase I/
II clinical studies evaluating the effects of anacetrapib reported an acceptable side-effect 
profile.12, 42-44 However, it should be noted that a non-significant increase in C-reactive protein 
was found after anacetrapib treatment.42 We also found elevated SAA levels in anacetrapib-
treated E3L.CETP mice.20
In the present study, we present evidence that anacetrapib reduces (V)LDL-C by two 
mechanisms: 1) inhibition of CETP activity, resulting in remodelled lipoproteins that are 
more susceptible to clearance and 2) a CETP-independent reduction of plasma PCSK9 levels 
that has the potential to increase LDLr-mediated clearance. This reduction in (V)LDL-C is 
the crucial factor mediating the atheroprotective effects of anacetrapib in E3L.CETP mice.20 
Whether the additional beneficial effects of anacetrapib on top of a statin translate into 
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Supplemental Figure I. Regulation of sterol regulatory element-binding protein gene 
(Srebf) -1 and Srebf-2-related genes by anacetrapib. 
Molecular network  showing Srebf-1 and -2-related gene regulation of anacetrapib. The 
molecular network consists of genes that are differentially expressed after anacetrapib 
treatment (cut off: P<0.01) and are coloured red if upregulated or green if downregulated 
(cut off: FDR<0.05). An in silico prediction based on the differentially expressed target genes 
was performed to indicate Srebf-1 and -2 activation state. Predicted regulation of genes is 
indicated by orange if they are predicted to be upregulated and blue if predicted to be 
downregulated.
Supplemental Figure I. Regulation of sterol regulatory element-binding protein gene (Srebf) -1 and 
Srebf-2-related genes by anacetrapib.
Molecular network showing Srebf-1 and -2-related gene regulation of anacetrapib. The molecular 
network consists of genes that are differentially expressed after anacetrapib treatment (cut off: 
P<0.01) and are coloured red if upregulated or green if downregulated (cut off: FDR<0.05). An in silico 
prediction based on the differentially expressed target genes was performed to indicate Srebf-1 and 
-2 activation state. Predicted regulation of genes is indicated by orange if they are predicted to be 
upregulated and blue if predicted to be downregulated.
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Objective Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition is a potential novel 
strategy for treatment of CVD. Alirocumab is a fully human PCSK9 monoclonal antibody in 
phase III clinical development. We evaluated the anti-atherogenic potential of alirocumab 
in APOE*3Leiden.CETP mice.
Methods Mice received a Western-type diet and were treated with alirocumab (3 or 10 mg/
kg, weekly subcutaneous dosing) alone and in combination with atorvastatin (3.6 mg/kg/d) 
for 18 weeks.
Results Alirocumab alone dose-dependently decreased total cholesterol (-37%; -46%, 
P<0.001) and triglycerides (-36%; -39%, P<0.001) and further decreased cholesterol in 
combination with atorvastatin (-48%; -58%, P<0.001). Alirocumab increased hepatic LDL 
receptor protein levels, but did not affect hepatic cholesterol and triglyceride content. Fecal 
output of bile acids and neutral sterols was not changed. Alirocumab dose-dependently 
decreased atherosclerotic lesion size (-71%; -88%, P<0.001) and severity and enhanced these 
effects when added to atorvastatin (-89%; -98%, P<0.001). Alirocumab reduced monocyte 
recruitment and improved the lesion composition by increasing the smooth muscle cell and 
collagen content and decreasing the macrophage and necrotic core content.
Conclusion Alirocumab dose-dependently decreases plasma lipids and, as a result, 
atherosclerosis development, and enhances the beneficial effects of atorvastatin in 
APOE*3Leiden.CETP mice. In addition, alirocumab improves plaque morphology.












































Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease involved in LDL 
metabolism.1 PCSK9, previously known as neutral apoptosis regulated convertase, is mainly 
expressed in the liver, kidney, and intestines.2, 3
Besides familial hypercholesterolemia (FH) caused by ldlr mutations and familial defective 
apolipoprotein B100 caused by apob mutations,1 autosomal dominant hypercholesterolemia 
can be caused by gain-of-function mutations of the pcsk9 gene, now commonly referred to 
as FH3.3, 4 Conversely, loss-of-function mutations of the pcsk9 gene were associated with 
a reduction in LDL-cholesterol (LDL-C) and protection against coronary heart disease.5, 6 In 
addition, familial hypobetalipoproteinemia related to loss-of-function mutations of pcsk9 
resulted in very low plasma levels of LDL-C, attributed to an increased clearance rate of LDL.7
Several studies have confirmed that PCSK9 is responsible for targeting the LDL receptor 
(LDLR) for lysosomal degradation in the liver by preventing recycling of the receptor to the 
cell membrane after internalization of the LDL-bound LDLR.4 PCSK9 interacts with the LDLR on 
the cell membrane, after which the LDLR-PCSK9 complex is internalized and travels through 
the endosome to the lysosome for degradation.8 In a study in mice, adenovirus-mediated 
expression of PCSK9 increased plasma LDL-C levels, which was associated with decreased 
hepatic LDLR protein, although LDLR mRNA levels were unaffected.9 On the contrary, mice 
lacking PCSK9 have decreased plasma LDL-C as a result of increased hepatic LDLR levels.10 A 
recent study in wild-type, APOE-/-, and LDLR-/- mice with or without expression of PCSK9 
revealed a direct relationship between PCSK9 and atherosclerosis development, mainly 
mediated via the LDLR, and suggests that PCSK9 inhibition will be beneficial in reducing 
atherosclerosis.11
Although statins remain the most effective treatment option for CVD, there remains a 
substantial persistent cardiovascular risk and, despite statin treatment, some patients cannot 
reach the recommended LDL-C target.12, 13 Recent outcome studies and post hoc analyses 
indicate that therapeutic regimens that further lower LDL-C lead to further reductions in 
cardiovascular events14-16 and, consequently, cholesterol management guidelines have 
evolved to more rigorous goals.17-19 The upregulation of the LDLR after statin treatment is 
accompanied by an upregulation of PCSK9, which in turn promotes LDLR degradation.20-22 In 
humans, the ~35% to 50% decrease in LDL-C after atorvastatin treatment (10 to 40 mg) was 
accompanied by a ~7% to 35% increase in circulating PCSK9 levels.21, 22 Inhibition of PCSK9 is, 
therefore, a potential novel strategy for treatment of CVD, specifically in combination with 
statin treatment. Several approaches to inhibit PCSK9, including monoclonal antibodies, 
gene silencing, and mimetic peptides, are currently being investigated.4 The anti-PCSK9 
monoclonal antibody, alirocumab is a lead compound in this class and is currently being 










































Alirocumab, also known as SAR236553/REGN727, is a fully human, monoclonal antibody 
that lowers plasma LDL-C in normocholesterolemic volunteers23 and hypercholesterolemic 
patients on stable statin dose.24, 25 In patients with hypercholesterolemia, alirocumab in 
combination with low- and high-dose atorvastatin decreased LDL-C to a greater extent 
than titration to high-dose atorvastatin, and considerably more patients who received 
the combination treatments reached LDL-C goals of <100 mg/dL or <70 mg/dL compared 
with patients who received atorvastatin treatment alone.26 Phase II trials demonstrated 
reductions in LDL-C of 40% to 72% across a dose range of 50 to 150 mg administered every 2 
weeks, and of 32% to 48% with doses 200 to 300 mg administered every 4 weeks.23-25
The aim of this study was to investigate the effects of two dosages of alirocumab alone 
and in combination with atorvastatin on plasma lipids, atherosclerosis development and 
lesion composition in APOE*3Leiden.CETP mice.27 This is a well-established model for 
hyperlipidemia and atherosclerosis with all features of familial dysbetalipoproteinemia 
(FD) in humans, which is characterized by accumulation of remnant lipoproteins and an 
increased VLDL-cholesterol to LDL-C ratio.28 APOE*3Leiden mice have an impaired clearance 
of (V)LDL and increased triglycerides (TG) levels and are thereby mimicking the slow 
clearance observed in humans, in contrast to normal wild-type mice which have a very 
rapid clearance of apoB-containing lipoproteins.29 The lipoprotein profile in APOE*3Leiden.
CETP mice reflects that of FD patients with a similar response to lipid-modifying therapies,30 
including statins,31 fibrates,32 niacin,33 and cholesteryl ester transfer protein inhibitors.34 This 
is illustrated by a comparable reduction in cholesterol in all apoB-containing lipoprotein 
subfractions with statin treatment.35 We hypothesized that alirocumab alone could reduce 
progression of atherosclerosis and add to the atheroprotective effects of atorvastatin. 




Ninety female APOE*3Leiden.CETP transgenic mice (9 to 13 weeks of age),27 expressing 
human cholesteryl ester transfer protein (CETP) under control of its natural flanking regions, 
were used. During the study, mice were housed under standard conditions with a 12 h light-
dark cycle and had free access to food and water. Animal experiments were approved by the 













































Mice received a semi-synthetic cholesterol-rich diet, containing 15% (w/w) cacao butter and 
0.15% cholesterol (Western-type diet [WTD]; Hope Farms, Woerden, The Netherlands) for a 
run-in period of 3 weeks to increase plasma total cholesterol (TC) levels up to ~15 mmol/l. 
Body weight and food intake were monitored regularly during the study. After matching 
based on body weight, plasma TC, TG and age, mice (n=15 per group) received a WTD alone 
or were treated with two dosages of alirocumab (3 or 10 mg/kg) alone or in combination 
with atorvastatin (3.6 mg/kg/d) for 18 weeks, and an arm with atorvastatin alone was added. 
Alirocumab (provided by Regeneron) was administered via weekly subcutaneous injections 
and atorvastatin was added to the diet. We aimed for a reduction in TC of about 20% to 30% 
with the dose of atorvastatin. At the end of the treatment period all animals were sacrificed 
by CO2 inhalation. Livers and hearts were isolated to assess hepatic LDLR protein levels, lipid 
content, atherosclerosis development, and plaque composition.
Plasma lipids, lipoprotein analysis and measurement of alirocumab levels
Plasma was isolated from blood collected in EDTA-coated cups via tail vein bleeding after a 4-h 
fast every 2 to 4 weeks. Plasma TC and TG were determined using enzymatic kits according to 
the manufacturer’s protocols (cat. no. 1458216 and cat. no. 1488872, respectively; Roche/
Hitachi) and average plasma TC and TG levels were calculated by total exposure over number 
of weeks. Lipoprotein profiles for TC were measured after lipoprotein separation by fast 
protein liquid chromatography (FPLC) after 4, 12, and 18 weeks of treatment.27 Alirocumab 
levels were measured by a human Fc enzyme-linked immunosorbent assay.
Hepatic LDLR protein levels
Liver tissues were homogenized in lysis buffer (50 mM Tris-HCL [pH=7.4], 150 mM 
NaCl, 0.25% deoxycholic acid, 1% NP-40 [Igepal], 1mM EDTA, protease inhibitor cocktail 
[complete, Roche], 1 mM PMSF, 1 mM Na3VO4) and then centrifuged at 6500 rpm at 4˚C 
for 30 min. Protein concentration in cell lysates was determined by bicinchonic acid protein 
assay (Thermo Scientific) according to manufacturer’s instructions. 50 µg of protein lysates 
were separated by SDS-PAGE and then transferred to polyvinylidene fluoride membranes 
(Millipore). Blots were subjected to goat anti-mouse LDLR from R&D Systems and rabbit 
anti-goat horseradish peroxidase (HRP) from AbD Serotec or mouse anti-α-Tubulin from 
Sigma and horse anti-mouse HRP from Cell Signaling Technologies (according to the 
manufacturer’s instructions); blots were developed with West Femto Super Signal ECL 
(Thermo Scientific) and subjected to the Chemi-Doc-it imaging system. Intensities of protein 










































Hepatic lipid analysis and fecal excretion of bile acids and neutral sterols
Liver tissue samples were homogenized in phosphate-buffered saline, and the protein 
content was measured. Lipids were extracted, separated by high-performance thin-layer 
chromatography on silica gel plates, and analyzed with TINA2.09 software (Raytest Isotopen 
Messgeräte Straubenhardt, Germany), as previously described.37
Mice were housed at five mice per cage, and feces were collected during two 
consecutive periods of 72 h and 48 h, respectively. Aliquots of lyophilized feces were used 
for determination of neutral and acidic sterol content by gas-liquid-chromatography, as 
previously described.38
Histological assessment of atherosclerosis
Hearts were isolated, fixed in formalin, and embedded in paraffin. They were then sectioned 
perpendicular to the axis of the aorta, starting within the heart and working in the direction 
of the aortic arch. Once the aortic root was identified by the appearance of aortic valve 
leaflets and smooth muscle cells (SMCs) instead of collagen-rich tissue, serial cross sections 
(5 µm thick with intervals of 50 µm) were taken and mounted on aminopropyl-triethoxy-
silane (APES)-coated slides. These sections were stained with hematoxylin-phloxine-saffron 
(HPS) for histological analysis. For each mouse, atherosclerosis was measured in four 
subsequent cross sections. Each section consisted of three segments. The average total 
lesion area per cross section was then calculated.36, 39 For determination of lesion severity 
the lesions were classified into five categories according to the American Heart Association 
classification40: 0) no lesion I) early fatty streak, II) regular fatty streak, III) mild plaque, IV) 
moderate plaque, and V) severe plaque. The percentage of each lesion type was calculated, 
and type I-III lesions were classified as mild lesions and type IV-V lesions were classified as 
severe lesions.36, 39 To determine the total plaque load in the thoracic aorta, perfusion-fixed 
aortas (from the aortic origin to the diaphragm) were cleaned of extravascular fat, opened 
longitudinally, pinned en face, and stained for lipids with oil red O as described previously.41 
Data were normalized for analyzed surface area and expressed as a percentage of the stained 
area. Photos/images were taken with the Olympus BX51 microscope and lesion areas were 
measured using Cell D imaging software (Olympus Soft Imaging Solutions). 
In the aortic root, lesion composition was determined for the severe lesions (type IV-
V) as a percentage of lesion area after immunostaining with anti-human α-actin (1:800; 
Monosan, Uden, The Netherlands) for SMCs, and anti-mouse Mac-3 (1:25; BD Pharmingen, 
the Netherlands) for macrophages followed by sirius red staining for collagen. Necrotic 
area and cholesterol clefts were measured in macrophage/collagen staining.36, 39, 42 In 
each segment used for lesion quantification, the number of monocytes adhering to the 
endothelium and the number of T cells in the total aortic root area were counted after 
immunostaining with AIA 31240 antibody (1:1000; Accurate Chemical and Scientific, New 
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mouse CD54 antibody, GTX76543 (GeneTex, Inc., San Antonio, TX, USA) was used for 
immunostaining of intercellular adhesion molecule 1 (ICAM-1).43 Photos/images of the 
lesions were taken with the Olympus BX40 microscope with Nuance 2 multispectral imaging 
system, and stained areas were quantified using Image J software. 
Flow cytometric analysis 
After 8 weeks of treatment, peripheral blood mononuclear cells (PBMCs) were isolated 
from fresh blood samples and were sorted into GR-1+ (neutrophils/granulocytes), GR-
1- (lymphocytes/monocytes), CD3+ (T cells), CD19+ (B cells) and CD11b+/Ly6Clow and 
CD11b+/Ly6Chi (monocytes) cells using flow cytometric analysis. The following conjugated 
monoclonal antibodies were used from Becton Dickinson: GR-1 FITC, CD3 PerCpCy5-5, CD19 
V450, CD11b APC and Ly6C PE-Cy7.
Statistical analysis
Significance of differences between the groups was calculated non-parametrically using 
a Kruskal-Wallis test for independent samples, followed by a Mann-Whitney U-test for 
independent samples. Linear regression analyses were used to assess correlations between 
variables. Since the atherosclerotic lesion area showed a quadratic dependence on plasma 
cholesterol exposure, it was transformed using square root transformation. 
IBM SPSS Statistics 20 for Windows (SPSS, Chicago, USA) was used for statistical analysis. 
All groups were compared with the control group and with the atorvastatin group, and 
3 mg/kg alirocumab was compared with 10 mg/kg alirocumab either with or without 
atorvastatin. Values are presented as means ± SD. Bonferroni-Holm’s method was used to 
determine the level of significance in the case of multiple comparisons. P-values <0.05 were 
considered statistically significant. In figures, significant effects after correction for multiple 
comparisons are indicated by * to compare with the control group, † to compare with the 
atorvastatin group and ‡ to compare 3 mg/kg alirocumab with 10 mg/kg alirocumab. 
Results
Alirocumab and atorvastatin monotreatment and their combination decrease plasma TC 
and TG in APOE*3Leiden.CETP mice
Alirocumab binds both human and mouse PCSK9 with high affinity (Kd=0.58nM and 2.6nM, 
respectively, at pH 7.4 and 25°C) as determined by surface plasmon resonance. Circulating 
alirocumab levels were detected in all groups administered alirocumab and ranged between 
5 to 12 µg/ml (3 mg/kg dose) and 12 to 30 µg/ml (10 mg/kg dose) during the study. No 
immune response was observed as evidenced by stable efficacy throughout the study. After 










































(control group) reached average plasma TC and TG levels of 16.2 ± 1.8 mmol/l and 2.9 ± 0.6 
mmol/l, respectively (Figure 1A and 1B). Compared with the control, alirocumab decreased 
average plasma TC (-37%, P<0.001; -46%, P<0.001) and TG (-36%, P<0.001; -39%, P<0.001) 
and further decreased TC in combination with atorvastatin (-48%, P<0.001; -58%, P<0.001). 
Compared with atorvastatin, both combination treatments decreased TC (-36%, P<0.001; 
-48%, P<0.001) and TG (-39%, P<0.001; -50%, P<0.001) to a greater extent than atorvastatin 
alone. The (higher) reductions in TC (at the higher dose) after alirocumab alone (-14%, 
P<0.01; 3 mg/kg alirocumab vs. 10 mg/kg alirocumab) and in combination with atorvastatin 
(-19%, P<0.001; 3 mg/kg alirocumab + atorvastatin vs. 10 mg/kg alirocumab + atorvastatin) 
were dose-dependent and sustained during the study. TC reductions after alirocumab 







Figure 1 Effect of alirocumab, atorvastatin, and their combination on average plasma TC (A) and 
TG (B) levels as measured throughout the 18-week study. Lipoprotein profiles for cholesterol were 
assessed by FPLC lipoprotein separation to study effects of alirocumab alone (C) and in combination 
with atorvastatin (D). 
*P<0.05, ***P<0.001 as compared with control; †††P<0.001 as compared with atorvastatin; ‡P<0.05, 
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Alirocumab without and with atorvastatin decreases plasma lipids by reducing LDLR 
degradation
Hepatic LDLR protein levels were measured to verify whether PCSK9 inhibition by alirocumab 
decreases plasma lipids by rescuing LDLR degradation (Figure 2). Hepatic LDLR protein 
levels were increased after alirocumab treatment alone (+80%, P<0.05; +133%, P<0.01) 
and together with atorvastatin (+98%, P<0.01; +178%, P<0.05). Compared with atorvastatin 
alone, both the combination treatments increased LDLR protein levels to a greater extent 
(+71%, P<0.01; +140%, P<0.05). An inverse correlation between LDLR protein levels and 








Figure 2 Effect of alirocumab, atorvastatin, and their combination on hepatic LDLR protein levels. 
*P<0.05, **P<0.01 as compared with control; †P<0.05, ††P<0.01 as compared with atorvastatin (n=8 
per group).
Alirocumab does not affect hepatic lipids and fecal bile acid and neutral sterol excretion
To evaluate the consequences of alirocumab-induced alterations in lipoprotein metabolism 
on hepatic lipid metabolism and excretion into feces, we determined liver lipids and fecal 
excretion of bile acids and neutral sterols. Alirocumab did not affect the hepatic content of 
cholesterol and TG, whereas atorvastatin and the combination treatments led to significant 
reductions in hepatic cholesteryl esters (-48%, P<0.05; -41%, P<0.05 and -44%, P=0.28, 
respectively) as compared with the control group, without a change in hepatic TG (Table 
1). Fecal output of bile acids and neutral sterols was not changed by the treatments (Table 
2). These data indicate that despite the greater influx of cholesterol from the plasma 











































Table 1 Effect of alirocumab, atorvastatin and their combination on liver lipids.
Liver lipids (µg/mg protein)
FC CE TG
Control 11.6 ± 1.6 50.6 ± 14.0 119.2 ± 33.3
3 mg alirocumab 11.2 ± 1.4 48.2 ± 8.2 † 117.7 ± 21.6
10 mg alirocumab 11.4 ± 2.0 53.9 ± 10.4 ††† 142.1 ± 43.0
Atorvastatin 9.5 ± 0.9 26.2 ± 4.8 * 90.6 ± 28.5
3 mg alirocumab + atorvastatin 10.4 ± 1.8 29.6 ± 5.8 * 103.5 ± 36.8
10 mg alirocumab + atorvastatin 10.7 ± 1.2 28.3 ± 9.0 109.8 ± 28.8
FC, free cholesterol; CE, cholesterol esters. *P<0.05 as compared with control; †P<0.05, †††P<0.001 
as compared with atorvastatin






Control 25.8 ± 5.5 13.5 ± 3.3
3 mg alirocumab 20.4 ± 6.2 14.3 ± 2.7
10 mg alirocumab 21.6 ± 5.6 12.4 ± 3.2
Atorvastatin 30.3 ± 6.5 10.7 ± 2.4
3 mg alirocumab + atorvastatin 28.6 ± 6.0 11.4 ± 2.2
10 mg alirocumab + atorvastatin 27.5 ± 4.4 12.7 ± 1.6
Alirocumab dose-dependently reduces atherosclerosis development and enhances the 
atheroprotective effects of atorvastatin
Effects of alirocumab on atherosclerosis development in the absence and presence of 
atorvastatin were assessed in the aortic root and arch after 18 weeks of treatment. 
Representative images of atherosclerotic lesions as illustrated in Figure 3 show that 
alirocumab, atorvastatin, and their combination reduced lesion progression. To confirm 
a reduction in atherosclerosis development, we determined lesion area per cross section 
(Figure 4A), and calculated lesion severity (Figure 4C). For the control group, total lesion 
area was 278 ± 89 x 103 µm2 per cross section. Alirocumab dose-dependently decreased 
atherosclerotic lesion size (-71%, P<0.001; -88%, P<0.001) and dose-dependently enhanced 
the effects of atorvastatin (-89%, P<0.001; -98%, P<0.001) as compared with the control. 
Mice treated with alirocumab alone and in combination with atorvastatin had more lesion-
free sections and fewer severe (type IV-V) lesions compared with the control. Atorvastatin 
alone decreased lesion size (-35%, P<0.05) and reduced severity to a lesser extent with 
no effect on the percentage undiseased segments. When compared with atorvastatin 
monotreatment, the combinations further decreased lesion size (-82%, P<0.001; -97%, 
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To evaluate the effect of alirocumab treatment on lesion development at another spot 
along the aorta prone to development of atherosclerosis, plaque surface in the aortic arch 
was measured (Figure 4B). At this site, lesion development is delayed as compared with 
the aortic root.41 In line with the effects on atherogenesis in the aortic origin, both doses 








Figure 3 Effect of alirocumab, atorvastatin, and their combination on plaque morphology. 
Representative images of HPS-stained atherosclerotic lesions in a cross section of the aortic root 
area for the control (A), 3 mg/kg alirocumab (B), 10 mg/kg alirocumab (C), atorvastatin (D), 3 mg/kg 

















































Figure 4 Effect of alirocumab, atorvastatin, and their combination on atherosclerosis development in 
aortic root and arch. After 18 weeks of treatment, the total lesion area per cross section was assessed 
(A). The total plaque load in the aortic arch was analyzed after oil red O-staining (B). Lesion severity 
was assessed and categorized as no lesions, mild (type I-III) lesions and severe (type IV-V) lesions (C). 
Data are expressed as percentage of the stained area. 
*P<0.05, ***P<0.001 as compared with control; †P<0.05, ††P<0.01, †††P<0.001 as compared with 
atorvastatin; ‡P<0.05, ‡‡P<0.01 for 3 mg/kg alirocumab compared with 10 mg/kg alirocumab (n=15 
per group in the root area and n=6-7 in the arch).
We evaluated whether the anti-atherogenic effect of alirocumab and atorvastatin could 
be explained by the reduction in plasma TC. A strong correlation between plasma TC levels 
and atherosclerotic lesion area in the aortic root was observed (R2=0.84, P<0.001; Figure 5), 

















































Figure 5 Correlation between average plasma TC and atherosclerotic lesion area. The square root of 
the lesion area was plotted against average TC. Linear regression analysis was performed.
Alirocumab improves plaque morphology
After investigating lesion morphology, we analyzed treatment effects on plaque composition 
in the severe lesions (type IV-V), as shown by representative images in Figure 6. To illustrate 
that a pro-inflammatory plaque phenotype is not always dependent on the size of the 
lesions, we included representative images of similar size lesions for the control group and 
the alirocumab group. Lesion macrophage area plus lesion necrotic core area (including 
cholesterol clefts), were quantified as pro-inflammatory factors (Figure 7A), whereas SMCs 
in the fibrotic cap and collagen area were quantified as fortifying factors (Figure 7B). All 
were expressed as a percentage of total lesion area. Lesions in the control group consisted 
of 10.3% macrophages, 4.8% necrotic core and cholesterol clefts, 3.1% SMCs in the cap and 
48.4% collagen. Alirocumab (10 mg/kg) alone and in combination with atorvastatin reduced 
the pro-inflammatory factors as compared with control (-37% P<0.001; -73% P<0.001) and 
with atorvastatin treatment (-35% P<0.001; -72% P<0.001). Fortifying factors were increased 
by 10 mg/kg alirocumab + atorvastatin as compared with control (+29% P<0.001) and dose-
















































Figure 6 Effect of alirocumab, atorvastatin, and their combination on lesion composition. Representative 
images of immunostaining with Mac-3 for macrophages followed by sirius red staining for collagen 


















































Figure 7 Effect of alirocumab, atorvastatin, and their combination on lesion composition. Macrophage 
and necrotic content, including cholesterol clefts as pro-inflammatory factors (A), and SMC and 
collagen content as fortifying factors (B), were determined in the severe (type IV-V) lesions after 
correcting for lesion size. 
**P<0.01, ***P<0.001 as compared with control; †P<0.05, ††P<0.01, †††P<0.001 as compared with 
atorvastatin (n=15 per group).
Alirocumab reduces monocyte and T cell recruitment
As a functional marker of vessel wall inflammation, the number of monocytes adhering to the 
activated endothelium (Figure 8A) and the number of T cells in the aortic root area (Figure 
8B) were counted and calculated per cross section. In the control group, 5.7 ± 4.2 adhering 
monocytes and 16.7 ± 7.7 T cells were present. When administered alone and together with 
atorvastatin, the higher dose of alirocumab (10 mg/kg) decreased the adhering monocytes 
(-57%, P<0.05; -82%, P<0.001) and the abundance of T cells (-37%, P<0.05; -62%, P<0.001). 
To further underline the mechanism by which alirocumab reduced monocyte adherence, 










































control, 39% of the endothelium was positive for ICAM-1 compared with 19% (P<0.001) 
after 10 mg/kg alirocumab monotreatment and 16% (P<0.001) when given in combination 
with atorvastatin. The reduction in monocyte adherence was, therefore, corroborated by a 
reduction in adhesion molecule expression in endothelial cells after alirocumab treatment 
















Figure 8 Effect of alirocumab, atorvastatin, and their combination on markers of vascular inflammation. 
The number of monocytes adhering to the endothelium (A) and the number of T cells in the aortic root 
area (B) were determined per cross section. In addition, ICAM-1 was determined as percentage of the 
stained area (C). Representative images are included. 
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Alirocumab reduces circulating monocytes
The effects of alirocumab alone and in combination with atorvastatin on white blood 
cell count was assessed by flow cytometry (Table 3). Interestingly, alirocumab alone and 
together with atorvastatin reduced granulocytes/neutrophils (-20%, P<0.05; -34%, P<0.01) 
and monocytes (-28%, P<0.05; -39%, P<0.01) when expressed as a percentage of the PBMC 
population. More specifically, alirocumab alone and in combination with atorvastatin 
tended to decrease pro-inflammatory Ly6Chi (-8%, N.S.; -19%, P<0.001) and increase anti-
inflammatory Ly6Clow (+12%, N.S.; +35%, P<0.001) monocytes. Therefore, the effect of 
alirocumab on vascular recruitment and adhesion of monocytes may be augmented by a 
reduction in circulating monocytes.
Table 3 Effect of alirocumab, atorvastatin, and their combination on white blood cell count as assessed 
by flow cytometric analysis after 8 weeks of treatment.





(% of PBMC population) 8.9 ± 2.4 7.1 ± 2.0 * † 5.1 ± 1.6 *** 5.9 ± 2.0 **
Lymphocytes/monocytes 
(% of PBMC population) 91.1 ± 2.4 92.9 ± 2.0 * † 94.9 ± 1.6 *** 94.1 ± 2.0 **
	 T cells 
(% of PBMC population) 22.9 ± 4.6 21.4 ± 5.0 † 17.0 ± 4.8 ** 18.5 ± 4.5 P=0.054
	 B cells 
(% of PBMC population) 63.9 ± 8.5 66.3 ± 15.0 69.5 ± 17.4 ** 66.9 ± 2.0 **
	 Monocytes 
(% of PBMC population) 12.3 ± 5.0 8.9 ± 2.5 * ††† 5.3 ± 2.4 *** 7.5 ± 2.8 ** †
	 CD11b+ Ly6Chi
(% of monocytes) 62.2 ± 8.5 57.5 ± 8.4 51.2 ± 6.4 ** 50.2 ± 4.1 ***
	 CD11b+ Ly6Clow
(% of monocytes) 35.6 ± 7.7 40.0 ± 8.0 † 47.8 ± 6.3 *** 48.0 ± 3.5 ***
PBMC, peripheral blood mononuclear cells. *P<0.05, **P<0.01, ***P<0.001 as compared with control; 
†P<0.05, †††P<0.001 as compared with atorvastatin (n=15 per group)
Safety aspects of alirocumab
No effects on body weight (gain) and food intake were noted in any treatment group as 
compared with the control group (data not shown). The 10 mg/kg dose of alirocumab on 
top of atorvastatin treatment led to a reduction in liver weight as compared with the control 
group after 18 weeks of treatment ( -20%, P<0.05, respectively), whereas monotreatment did 
not have an effect on liver weight. Plasma aspartate transaminase and alanine transaminase 


















































Control 91.6 ± 75.6 223.0 ± 189.6 1.23 ± 0.25
3 mg alirocumab 67.1 ± 42.7 189.4 ± 108.7 1.18 ± 0.25
10 mg alirocumab 153.0 ± 122.6 426.3 ± 309.2 * 1.38 ± 0.43
Atorvastatin 59.8 ± 24.3 217.0 ± 76.5 1.05 ± 0.12
3 mg alirocumab + atorvastatin 54.5 ± 25.6 171.7 ± 66.1 1.02 ± 0.17
10 mg alirocumab + atorvastatin 51.0 ± 23.7 157.6 ± 29.2 † 0.99 ± 0.10 *
ALT, alanine transaminase; AST, aspartate transaminase. *P<0.05, as compared with control, †P<0.05 
as compared with atorvastatin
Discussion
The PCSK9 monoclonal antibody alirocumab has been shown to strongly lower LDL C and non-
HDL-cholesterol (HDL-C) alone and on top of statin treatment,23-26 and is currently in phase 
III clinical development, which includes a large CVD outcome trial in hypercholesterolemic 
patients with relatively recent acute coronary syndrome treated with high-dose statins.44 
It should be realized that the effectiveness of alirocumab on cardiovascular endpoints will 
only be assessed in patients who also receive statins. Therefore, the present study was 
designed to investigate the effects of alirocumab on atherosclerosis development, alone 
and in combination with atorvastatin. Taken together, we have shown that alirocumab dose-
dependently decreases plasma cholesterol and reduces progression of atherosclerosis. 
Moreover, alirocumab improves lesion morphology and composition, and enhances the 
beneficial effects of atorvastatin in APOE*3Leiden.CETP mice. This is the first study to show 
that a monoclonal antibody to PCSK9 reduces atherosclerosis development.
Rescue of LDLR from intracellular degradation was verified by an increase in hepatic 
LDLR protein levels after alirocumab treatment. Consequently, alirocumab decreased TC 
(-37% to -46%) and TG (-36% to -39%) by a reduction in non-HDLs. The dose-dependent 
reduction in TC after alirocumab treatment was enhanced in combination with atorvastatin 
(-48% to -58%). These results support an improvement in cholesterol management by 
adding alirocumab to statin treatment. The dose-dependent cholesterol-lowering effects 
in our study are in accordance with results from phase I and phase II clinical trials.23-26 In 
phase I trials, alirocumab administered as a single ascending dose (50 to 250 mg) in healthy 
subjects, and as multiple doses (50 to 150 mg) in statin-treated FH patients, decreased LDL-C 
by 33% to 46% and by 39% to 61%, respectively.23 Results from the latter study indicate an 
additive effect of alirocumab on statin treatment, since similar reductions were observed 
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In a phase II trial in patients with hypercholesterolemia, addition of 50 to 150 mg 
alirocumab every 2 weeks to 10 to 40 mg/d atorvastatin decreased LDL-C by 40% to 72% and 
TC by 23% to 45%.25 In a phase II trial in patients with FH, addition of 150 mg of alirocumab 
every 2 weeks to a stable dose of statin, with or without ezetimibe, decreased LDL-C by 
68% and TC by 44%.24 A multicenter phase II trial confirmed these findings with a 66% 
to 73% reduction in LDL-C and a 41% to 47% reduction in TC when adding alirocumab to 
either 10 or 80 mg/d atorvastatin in hypercholesterolemic patients.26 In the present study, a 
similar additive cholesterol-lowering effect on top of atorvastatin treatment (-36% to -48% 
reductions in TC as compared with atorvastatin alone) was found. The clinical trials also 
provide evidence for additional modest reductions in TGs and modest increases in HDL-C. 
However, baseline TG levels were low in the latter studies, which may explain the larger 
effect on TG found in our study.
A higher (V)LDL clearance increases liver cholesterol exposure and may result in changes 
in hepatic cholesterol content and/or fecal excretion of cholesterol or, after its conversion, 
bile acids. However, alirocumab did not lead to hepatic lipid accumulation, whereas 
atorvastatin and the combination treatments significantly reduced cholesteryl ester content 
without changes in hepatic TG. Intriguingly, fecal output of bile acids and neutral sterols 
remained unchanged by the treatments. In line with our data, full absence of PCSK9 was 
recently reported not to be associated with hepatic lipid accumulation or fecal excretion of 
cholesterol.45 However, contrasting data in PCSK9 -/- mice demonstrated increased LDL-C 
excretion via the transintestinal cholesterol excretion pathway and subsequently mildly 
increased fecal neutral sterol loss, with unfortunately no data on fecal bile acid loss.46 As 
opposed to PCSK9 inhibition by alirocumab in the present study, lack of PCSK9 was reported 
to increase fecal bile acid output.45 These data indicate that, despite the greater influx of 
cholesterol from the plasma compartment into the liver, hepatic cholesterol homeostasis is 
maintained, although the precise mechanism remains to be established.
The lipid-modifying effects of PCSK9 inhibition provide indications for an atheroprotective 
effect. This notion is supported by data from a study where mice expressing high levels of 
PCSK9 had significantly more aortic cholesterol ester accumulation, and developed severe 
aortic lesions, compared with wild-type and PCSK9 knockout mice when fed an atherogenic 
diet.11 In the same study, no differences were found in LDLR-deficient mice expressing no, 
normal, or high PCSK9 levels, suggesting that PCSK9 modulates atherosclerosis mainly via 
the LDLR. However, to date, the atheroprotective effect of pharmacological PCSK9 inhibition 
has not been investigated. Our study demonstrates for the first time that inhibition of serum 
PCSK9 with the monoclonal antibody, alirocumab decreases plasma lipid levels and as a 
result reduces atherosclerosis development, as evidenced by a reduction in atherosclerotic 
lesion size and severity in the aortic root area and arch. This dose-dependent inhibitory 










































where a considerable number of animals did not develop any severe lesions. Although 
pleiotropic effects of statin treatment may contribute to the reduction in CVD risk,47 results 
from our study emphasize the importance of cholesterol-lowering per se in treatment of 
CVD. In our study, the effects of alirocumab alone and in combination with atorvastatin on 
lesion area were mainly predicted by the reduction in plasma TC levels as illustrated by the 
strong association (R2 = 0.84) between TC levels and the lesion area.
In the present study, alirocumab, atorvastatin, and their combination reduced the 
circulating granulocytes/neutrophils and monocytes, in particular pro-inflammatory 
Ly6Chi monocytes. Ly6Chi monocytes are proposed to be precursors of pro-inflammatory 
M1 macrophages48 and studies in mice have shown that hypercholesterolemia induces 
Ly6Chi monocytosis.49 In addition, alirocumab decreased endothelial expression of 
ICAM-1 and consequently reduced monocyte adhesion to the vascular endothelium. In 
hypercholesterolemia, modified lipoproteins induce endothelium activation, thereby 
mediating the arrest and transmigration of circulating monocytes into the subendothelial 
space where they differentiate into macrophages.48
In addition to monocyte adhesion, alirocumab reduced other markers of vascular 
inflammation, including T cell abundance in the aortic root area, as well as macrophage 
and necrotic content and cholesterol clefts of the lesions. Cholesterol crystals have been 
shown to be particularly pro-inflammatory and to trigger local and systemic inflammatory 
responses.50, 51 Moreover, increased macrophage content and a large necrotic core, as well 
as a thin, collagen-poor fibrous cap and decreased SMCs, are important characteristics of 
a vulnerable lesion that is prone to rupture.47 Alirocumab alone and in combination with 
atorvastatin reduced vascular inflammation and strongly improved the plaque morphology.
The present study is a progression/prevention study which may pose as a potential 
limitation with respect to translation to the clinic where patients with existing lesions are 
often treated. Nonetheless, data from this study may also suggest beneficial effects on 
markers of atherosclerosis by reducing TC with alirocumab in the human situation where 
new lesions are formed alongside existing plaques.
PCSK9 has received a considerable amount of attention in the last decade as a possible 
target for treatment of CVD, and several approaches to inhibit the protein are currently 
being investigated.4 Efficacy and safety of alirocumab will be further investigated in large 
phase III clinical outcome trials, in patients with FH and in high cardiovascular risk patients 
with hypercholesterolemia on lipid-modifying therapy within the ODYSSEY program.44 These 
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Introduction Cholesterol contained in LDL particles is well recognized as a primary causal 
risk factor for cardiovascular disease. However, despite consistent epidemiological evidence 
for an inverse association between HDL-C and coronary heart disease, clinical trials aimed 
at raising HDL-C (AIM-HIGH, HPS2-THRIVE, dal-OUTCOMES) failed to meet their primary 
goals. This systematic review and meta-analysis investigated the effects of established and 
novel treatment strategies, specifically targeting HDL, on inhibition of atherosclerosis in 
cholesteryl ester transfer protein-expressing animals, and the prevention of clinical events 
in randomized controlled trials. 
Methods and Results Linear regression analyses using data from preclinical studies revealed 
associations for TC and non-HDL-C and lesion area (R2=0.258, P=0.045; R2=0.760, P<0.001), 
but not for HDL-C (R2=0.030, P=0.556). In clinical trials, non-fatal myocardial infarction risk 
was significantly less in the treatment group with pooled odd ratios of 0.87 [0.81; 0.94] for 
all trials and 0.85 [0.78; 0.93] after excluding some trials due to off-target adverse events, 
whereas all-cause mortality was not affected (OR 1.05 [0.99-1.10]). Meta-regression analyses 
revealed a trend towards an association between between-group differences in absolute 
change from baseline in LDL-C and non-fatal myocardial infarction (P=0.066), whereas no 
correlation was found for HDL-C (P=0.955). 
Discussion We conclude that the protective role of lowering LDL-C and non-HDL-C is well-
established. The contribution of raising HDL-C on inhibition of atherosclerosis and the 
prevention of cardiovascular disease remains undefined and may be dependent on the mode 
of action of HDL-C-modification. Nonetheless, treatment strategies aimed at improving HDL 
function and raising apolipoprotein A-I may be worth exploring. 
Keywords HDL-C-raising pharmaceutical interventions; preclinical studies; randomized 
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In 1913, Nikolai N. Anitschkow first described the involvement of cholesterol in atherosclerosis 
development when rabbits fed a high-cholesterol diet developed human-like arterial 
lesions.1 The recent 100th year anniversary of this discovery is worth commemorating 
given that serum cholesterol contained in low-density lipoprotein (LDL) particles is now 
well recognized as a primary causal risk factor for cardiovascular disease as evidenced by 
experimental, epidemiological and genetic studies.2 Indeed, intervention trials with statin 
therapy confirmed a reduced incidence of coronary heart disease as a consequence of 
cholesterol-lowering3, 4 and recent trials indicated that intensive lipid-lowering with statins 
may be more beneficial in risk reduction than less intensive (or standard) therapy.5 According 
to results from the latter meta-analysis, every 1 mmol/L (40 mg/dL) reduction in LDL-C was 
associated with a 22% reduction in the risk of major vascular events suggesting that a 2-3 
mmol/L reduction in LDL-cholesterol (LDL-C) would correspond with a 40-50% reduction 
in events. However, treatment of cardiovascular disease remains suboptimal due to (i) the 
residual risk that persists after statin treatment,6 (ii) failure for some patients to reach LDL-C 
targets despite statin treatment,7 and (iii) lack of adherence as a result of statin intolerance.8 
Therefore, the search for secondary treatment targets is warranted.
In the 1970s, Miller & Miller hypothesized that a reduction in plasma high-density 
lipoprotein (HDL) concentration may accelerate the development of atherosclerosis and 
ischemic heart disease by impairing cholesterol clearance from the arterial wall.9 Besides 
its major role in reverse cholesterol transport, HDL has also been described to have anti-
inflammatory, anti-oxidant, anti-platelet and vasodilatory properties.10 Although the original 
hypothesis referred to HDL particle concentration which could not be measured at the time,10 
epidemiological studies consistently reported an inverse association between coronary 
heart disease risk and HDL-C.11-13 Results from 4 prospective epidemiologic studies indicated 
that an increase of 1 mg/dL (0.03 mM) in HDL-C was associated with a 2-3% reduction in 
coronary heart disease risk.14
Several therapeutic approaches aimed at raising HDL-C levels have since been investigated. 
However, undisputed proof for causality of low HDL-C in cardiovascular disease is lacking 
and clinical trials aimed at raising HDL-C to prevent disease (AIM-HIGH, HPS2-THRIVE, dal-
OUTCOMES) have failed to meet their primary goals.15-17 In addition, data from Mendelian 
randomization studies showed that genetic variants related to altered plasma HDL-C per 
se were not associated with risk of myocardial infarction,18, 19 and that despite an inverse 
correlation, HDL-C and myocardial infarction risk are not causally related. Nonetheless, 
numerous therapeutic strategies aimed at raising HDL-C or improving HDL function are still 










































This systematic review investigated the effects of established and novel treatment 
strategies, specifically targeting HDL, on inhibition of atherosclerosis development in 
cholesteryl ester transfer protein (CETP)-expressing animals, since CETP is a crucial gene 
involved in HDL metabolism and implicated in the mechanisms by which most therapies 
modulate HDL.20 In addition, we conducted a meta-analysis to evaluate the potential effects 
of these treatment strategies on the prevention of clinical events in randomized controlled 
trials, focusing specifically on the contribution of non-HDL-C/LDL-C-lowering versus HDL-C-
raising.
2. Methods
The study was performed in accordance with the Preferred Reporting Items for Systematic 
Reviews and Meta-Analysis guidelines using a PRISMA checklist.21
2.1 Preclinical studies
2.1.1 Literature search strategy
To identify relevant preclinical studies, we performed a computerized search of PUBMED 
and EMBASE. The search was restricted to studies published in the English-language from 
January 1975 to current. The following treatment strategies, specifically targeting HDL were 
included in the search: niacin; peroxisome proliferator-activated receptor (PPAR)-α agonists 
(fibrates); PPAR-γ agonist (glitazones); PPAR-α/γ agonists (glitazars); PPAR-δ agonists; CETP 
inhibitors; liver X receptor (LXR) agonists; micro RNAs; reconstituted HDL and apolipoprotein 
A-I-based compounds. We focused on preclinical studies evaluating the effects of these 
treatment strategies on atherosclerosis development in CETP-expressing animals. Statins 
were not included in the search criteria since the effects of statins on HDL/apolipoprotein 
A-I in relation to clinical outcomes were recently extensively reviewed.22 Additional studies 
were identified by searching bibliographies from relevant studies and additional review 
articles. 
2.1.2 Study selection
To investigate the role of HDL-C-raising treatment strategies on atherosclerosis development, 
we included preclinical studies that reported an increase in HDL-C. The effect of reconstituted 
HDL and apolipoprotein A-I-based compounds were described regardless of an effect on 
lipids, since several studies revealed protection against atherosclerosis with no change in 
plasma lipids. Studies were excluded if the relevant compound was used in a control group. 
All studies were screened to eliminate irrelevant studies by title and abstract. Remaining 
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2.1.3 Quality assessment and data extraction
The following data were extracted from relevant preclinical studies: study design 
(compound, animal model, sex, diet, run-in phase, group size, dose and treatment phase), 
baseline and on-treatment serum/plasma total cholesterol (TC) and HDL-C levels, as well 
as atherosclerotic lesion area. The data were extracted by one author (SK) and thoroughly 
checked by another author (JWAvdH). Disagreements between authors were resolved by 
consensus. 
2.1.4 Data presentation and analysis
To evaluate the effects of lipid-modifying treatment strategies on atherosclerosis, the 
percentage difference in atherosclerotic lesion area (gain) between the control and the 
treatment group was reported for all preclinical studies. Plasma/serum TC and HDL-C levels 
were retrieved for all time points reported in these studies. If not reported, non-HDL-C 
levels were calculated (TC – HDL-C). TC, non-HDL-C and HDL-C levels were standardized 
by converting mmol/L to mg/dL by multiplying by 38.67. Where possible, the percentage 
difference in TC, non-HDL-C and HDL-C exposure (duration of intervention in weeks x 
cholesterol levels) between the control and the treatment groups were calculated from 
the retrieved data and correlated with the between-group percentage difference in 
atherosclerotic lesion area. Reconstituted HDL and apolipoprotein A-I-based treatment 
strategies were not included in the correlations, but described in the discussion section due 
to different mechanisms of action. 
2.1.5 Statistical analysis
Linear regression analyses were used to assess the association between the percentage 
difference in TC, non-HDL-C and HDL-C exposure and atherosclerotic lesion area between 
the control and the treatment groups.
2.2 Randomized controlled clinical trials
2.2.1 Literature search strategy
To find relevant randomized controlled clinical trials, we performed a search of PUBMED 
including studies from clinicaltrials.gov, a clinical trial registry and results database, 
and EMBASE. We included the same restrictions and treatment strategies as previously 
described for preclinical studies (see 2.1.1). The search involved clinical trials reporting major 
cardiovascular events and we searched for phase II, III and IV clinical trials, multicenter, 
randomized controlled trials and meta-analyses. Additional studies were identified by 
searching bibliographies from relevant trials, as well as meta-analyses and review articles. 










































2.2.2 Study selection 
Inclusion criteria used for the selection of clinical trials for pooled meta-analyses were as 
follows:
•	 A randomized placebo-controlled trial design
•	 Patients with type 2 diabetes or cardiovascular disease or patients at risk of 
developing cardiovascular disease
•	 A trial sample size of ≥ 200 participants in each study arm
•	 A mean follow up duration of ≥ 1 year
•	 Pharmaceutical HDL-C-raising agents
•	 At least two of the following clinical outcomes: all-cause mortality, coronary heart 
disease mortality, non-fatal myocardial infarction and stroke
After discarding irrelevant records based on title and abstract, relevant articles were selected 
based on full text screening.
2.2.3 Quality assessment and data extraction
Study design (compound, study population, follow up duration and sample size), baseline 
characteristics (age, sex, BMI, history of cardiovascular disease, diabetes, hypertension, 
smoking, myocardial infarction, stroke, angina, revascularization, heart failure, peripheral 
vascular disease and previous statin use), baseline and on-treatment TC, HDL-C, LDL-C and 
non-HDL-C levels, as well as the occurrence of clinical events (all-cause mortality, coronary 
heart disease mortality, non-fatal myocardial infarction and stroke) were obtained from 
selected clinical trials. The data were extracted by one author (SK) and thoroughly checked 
by another author (JWAvdH). Disagreements between authors were resolved by consensus.
2.2.4 Data presentation and analysis
We performed 4 separate meta-analyses to analyze the effects of treatment on the 
prevention of all-cause mortality, coronary heart disease mortality, non-fatal myocardial 
infarction and stroke in randomized controlled trials. These 4 meta-analyses were repeated 
after excluding a number of trials using compounds with serious off-target cardiovascular 
adverse events. These include trials with torcetrapib and aleglitazar of which clinical 
development was stopped due to adverse effects, as well as pioglitazone which was shown 
to increase heart failure.23-28 Other primary endpoint data were not included in this meta-
analysis, because of different composite endpoints for the various trials. In addition, we 
performed 2 meta-analyses to assess the effects of treatment on the prevention of non-
fatal myocardial infarction in patients with low versus high baseline LDL-C by dividing the 
remaining trials into 2 subgroups using LDL-C levels of 100 mg/dL as the cut-off. In fact, the 
trials with lower baseline LDL-C levels concern patients on statin treatment (60%-100% of 
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mg/dL, and 60% of these patients received statin treatment at trial entry. We, therefore, 
included this study in the subgroup analysis of patients with low baseline LDL-C.29
Baseline and on-treatment TC, LDL-C, non-HDL-C and HDL-C levels were standardized by 
converting mmol/L to mg/dL by multiplying by 38.67. When lipid data were presented for 
multiple time points, we reported results from the longest follow up period. To determine 
the between-group differences in lipid changes, we calculated the difference between the 
absolute and the percentage change from baseline in the control group and the treatment 
group. Meta-regression analyses were performed to assess the potential association 
between the between-group differences in absolute and percentage change from baseline 
in LDL-C, as well as HDL-C and the occurrence of non-fatal myocardial infarction.
2.2.5 Statistical analysis 
A random effects model was employed to pool clinical trial-specific odds ratios in order 
to estimate an overall odds ratio and its associated confidence intervals. Inverse variance 
method which gives more weight to larger trials was used to pool outcomes for different 
trials. The overall effects corresponding to a fixed and random effects model are reported 
together in the same forest plot along with their confidence intervals. The sizes of the square 
boxes on the forest plots are proportional to the total number of patients in the selected 
trials. An overall test on heterogeneity between studies was performed for each separate 
meta-analysis (value I-squared in figures). To estimate the between-study variance, which is 
represented as ‘tau’ in the forest plots, DerSimonian-Laird’s method has been employed.30 
The log-transformed odd ratios for myocardial infarction was modeled as a linear function of 
the between-group differences in absolute and percentage change from baseline in LDL-C, 
as well as HDL-C by employing meta-regression. All statistical analyses were performed 




The computerized search identified 967 records of which 119 duplicates were removed. 
The remaining 848 records were screened based on title and abstract and an additional 
729 records were excluded. After reviewing 119 full text articles, 92 irrelevant records were 
removed and the results of 29 preclinical studies, including 2 studies that were not identified 














































Figure 1 An outline of the systematic search conducted to identify relevant preclinical studies for the 
systematic review.
3.1.2 Study design and baseline lipid levels
The study design and baseline lipid levels for the selected preclinical studies are summarized 
in Table 1. In these studies, the effects of niacin,31, 32 PPAR-α agonists,33, 34 PPAR α/γ 
agonist,35 CETP antisense,36 CETP vaccines,37-40 CETP inhibitors,41-45 SR-BI inhibitor,46 ABCA1 
degradation inhibitors,47 purified or reconstituted HDL,48-51 apolipoprotein A-I Milano52-57 and 
apolipoprotein A-I mimetic peptide58, 59 on atherosclerosis development were investigated in 
APOE*3Leiden.CETP and ldlr+/-.CETP mice, New Zealand White (NZW), Japanese White (JW) 
and Watanabe heritable hyperlipidemic (WHHL) rabbits, as well as F1B hamsters. Whereas 
several studies were designed to detect a reduction in the progression of atherosclerosis, 
a number of lipid-modifying treatment studies33-35 and most purified and reconstituted 
HDL and apolipoprotein A-I-based studies investigated the effects of treatment on existing 
atherosclerosis in a regression set-up. All animals received a cholesterol-containing diet 
except for WHHL rabbits, which spontaneously develop atherosclerosis. In a number 
of studies, atherosclerosis was induced by collar placement, electric and balloon 
injury/denudation.33, 51-57 The effects of PPAR-δ agonists60 and miR-33 antagonism61 on 
atherosclerosis development were investigated in animals that do not express CETP and 
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lipoprotein metabolism. Studies of LXR and FXR agonists in CETP-expressing animals were 
not included in this review, since no increase in HDL-C was observed except for the study 
by Srivastava et al. evaluating the anti-atherosclerotic activities of PPAR-α, PPAR-γ and LXR 
agonist (T0901317) in F1B hamsters.34 
3.1.3 Effect of lipid-modifying treatment strategies on atherosclerosis development
All lipid-modifying treatment strategies decreased atherosclerotic lesion area, except 






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3.1.4 The association between TC/non-HDL-C/HDL-C and atherosclerotic lesion area 
To further explore the atheroprotective role of non-HDL-C and HDL-C, a linear regression 
model was employed to study the association between the between-group percentage 
difference in TC, non-HDL-C and HDL-C exposure and atherosclerotic lesion area (Figure 2). 
Whereas TC and non-HDL-C associated with lesion area (R2=0.258, P=0.045 and R2=0.760, 
P<0.001, respectively), no correlation was found for HDL-C (R2=0.030, P=0.556). After 
excluding an extreme data point (400% increase in HDL-C), both TC and non-HDL-C strongly 
correlated with lesion area (R2=0.695, P<0.001 and R2=0.818, P<0.001, respectively), but the 



















Figure 2 The correlation between percentage differences in plasma TC (A and B), non-HDL-C (C and D), 
as well as HDL-C (E and F) exposure and atherosclerotic lesion area between the control and treatment 
groups for all preclinical studies (A, C, E) and after excluding an extreme data point (400% increase in 
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3.2 Randomized controlled clinical trials 
3.2.1 Reference screening
The titles and abstracts of 629 records excluding 147 duplicates that were identified in the 
computerized search were reviewed and 287 records were removed. After retrieving 195 
full text articles, 181 records were removed due to failure to meet the inclusion criteria. 
Together with an additional 8 articles that were identified from the bibliographies of relevant 
trials, meta-analysis and review articles, a total number of 22 randomized controlled trials 






Figure 3 An outline of the systematic search conducted to identify relevant randomized controlled 
clinical trials for the meta-analysis.
3.2.2 Trial design and baseline characteristics
The trial design and baseline characteristics for the 22 randomized controlled trials that 
met the inclusion criteria are reviewed in Table 2. These trials evaluated the effects of 
PPAR-α agonists,29, 62-72 niacin,15, 16, 72 CETP inhibitors,17, 23-26, 73 as well as PPAR-γ27 and PPAR-α/γ 
agonists28 on clinical outcomes. The 22 trials enrolled a total number of 121 666 patients: 
61 093 in the control group and 60 573 in the treatment group. The mean duration of follow 
up was 3.8 years. The CDP trial investigated the effects of both clofibrate and niacin in two 















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3.2.3 Effect of lipid-modifying treatment strategies on clinical outcomes
All 22 trials were included in the analysis of all-cause mortality. Trials that did not report 
coronary heart disease mortality, non-fatal myocardial infarction and stroke were excluded 
from the analyses. The occurrence of all-cause mortality tended to be more frequent after 
lipid-modifying treatment as compared to the control with pooled odds ratios obtained by 
employing a random effects model of 1.05 [0.99; 1.10] for all studies and 1.04 [0.99; 1.10] 
after excluding a number of trials due to serious off-target adverse events (data not shown). 
The risk of non-fatal myocardial infarction was significantly less in the treatment group for an 
analysis of all trials (Figure 4) and after excluding a number of trials due to off-target adverse 
events (data not shown). A significant heterogeneity was observed for non-fatal myocardial 
infarction (I2=40.8%, P=0.025). However, the pooled odds ratio obtained by employing a 
random effects model was 0.87 [0.81; 0.94] for all trials and 0.85 [0.78; 0.93] after excluding 
trials with off-target effects. No significant differences were observed in the occurrence of 







Figure 4 Forest plot for the effects of lipid-modifying treatment strategies, specifically targeting HDL-C, 
other than statins (PPAR-α agonists, niacin, CETP inhibitors, PPAR-γ and PPAR-α/γ agonists) on the 









































Innovative Pharmaceutical Interventions in Cardiovascular Disease
161
7
3.2.4 Effect of treatment on the prevention of non-fatal myocardial infarction in patient 
populations with low versus high baseline LDL-C
To assess the effects of lipid-modifying treatment on the prevention of non-fatal myocardial 
infarction in patients with high baseline LDL-C62, 63, 65-69 versus low baseline LDL-C,15-17, 29, 73 we 
performed 2 separate meta-analyses by dividing the remaining trials into 2 subgroups using 
LDL-C levels of 100 mg/dL as the cut-off. In patients with high baseline LDL-C, the occurrence 
of non-fatal myocardial infarction was significantly lower after lipid-modifying treatment 
as compared to patients in the control group (0.77 [0.68; 0.86]; Figure 5A). However, lipid-
modifying treatment strategies failed to prevent the occurrence of non-fatal myocardial 






Figure 5 Forest plots for the effects of lipid-modifying treatment strategies, specifically targeting 
HDL-C, other than statins (PPAR-α agonists, niacin and CETP inhibitors) on the occurrence of non-fatal 
myocardial infarction in patient populations with baseline LDL-C > 100 mg/dL (A) and baseline LDL-C 











































3.2.5 The association between LDL-C/HDL-C and non-fatal myocardial infarction
Meta-regression analyses revealed a trend towards an association between between-group 
differences in absolute change from baseline in LDL-C and non-fatal myocardial infarction 





Figure 6 The association between absolute between-group differences in LDL-C and HDL-C change 
from baseline (mg/dL) and non-fatal myocardial infarction (log[OR]) in randomized controlled trials 
involving lipid-modifying treatment strategies, specifically targeting HDL-C, other than statins (PPAR-α 
agonists, niacin and CETP inhibitors), demonstrating a trend toward a positive correlation for LDL-C 
(P=0.066) and no correlation for HDL-C (P=0.955).
4. Discussion
The current systematic review and meta-analysis confirm the importance of cholesterol-
lowering in the treatment of atherosclerosis and cardiovascular disease. However, based on 
data from preclinical studies and clinical trials, the protective effect of raising HDL-C is less 
defined and may be dependent on the mode of action of HDL-C-modification.
4.1 Treatment strategies aimed at raising HDL-C and atherosclerosis: preclinical studies
This systematic review investigated the effects of established and novel treatment strategies 
other than statins, specifically targeting HDL, on inhibition of atherosclerosis in animals 
expressing CETP. Most rodent models for atherosclerosis, for example apoe-/- and ldlr-/- mice, 
lack this crucial gene involved in HDL metabolism.74 APOE*3Leiden.CETP mice express human 
CETP under control of its natural flanking regions.75 These mice have impaired clearance 
of apolipoprotein B-containing lipoproteins and mimic the slow clearance observed in 
humans, particularly in patients with familial dysbetalipoproteinemia.76 The APOE*3Leiden.
CETP mice develop diet-induced atherosclerosis and respond to lipid-lowering and HDL-C-
raising drugs in a human-like manner.32, 44, 45, 77-82 Rabbits and hamsters naturally express CETP 
and develop diet-induced atherosclerosis. Nonetheless, it should be noted that cholesterol-
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advanced lesions as observed in humans.58 WHHL rabbits, a LDL receptor-deficient model 
for familial hypercholesterolemia spontaneously develop severe atherosclerotic lesions that 
are morphologically more similar to human lesions.83 Hamsters are not a widely used as a 
model for atherosclerosis since it takes considerable time to develop atherosclerosis, and 
the lesions have a spotty-like appearance covering the whole aorta.
Using data from relevant animal studies that studied the effects of lipid-modifying 
treatment on atherosclerosis development as described below, we found significant 
correlations between both TC and non-HDL-C exposure and atherosclerosis (between-group 
percentage difference), however, there was no significant association between HDL-C and 
atherosclerosis. 
4.1.1 Niacin
The benefits of niacin on plasma lipids was first described in 1955 and led to the development 
of niacin for therapeutic purposes.84 Several mechanisms have been proposed for the 
beneficial effects of niacin on lipid metabolism. These include decreased free fatty acid 
flux from adipose tissue to the liver, decreased TG synthesis, increased apolipoprotein A-I 
lipidation and decreased apolipoprotein A-I removal, as well as inhibition of CETP.20, 80, 85 In 
addition, niacin also exerts anti-inflammatory and anti-oxidant effects independent of lipid-
lowering.85 
In NZW rabbits, the increase in HDL-C/LDL-C ratio after treatment with different nicotinic 
acid derivatives resulted in a reduction in aortic surface area.31 In APOE*3Leiden.CETP mice, 
the reduction in atherosclerotic lesion area was mostly accounted for by a decrease in non-
HDL-C, although to some extent HDL-C predicted lesion area independent of non-HDL-C.32 In 
the latter study, the combination of niacin and simvastatin reduced non-HDL-C beyond the 
level reached by simvastatin monotreatment and largely explained why niacin added to the 
anti-atherosclerotic effects of simvastatin. 
4.1.2 Peroxisome proliferator-activated receptor (PPAR) agonists
PPARs are transcription factors involved in regulation of target gene expression. The effects 
of PPAR isoforms (α, γ) on glucose and lipid metabolism have led to the development of 
PPAR agonists for the treatment of hyperglycemia and dyslipidemia.86, 87
4.1.2.1 PPAR-α agonists
PPAR-α activation by fibrates increases lipoprotein lipase-mediated lipolysis, VLDL 
remnants clearance, β-oxidation,88 apolipoprotein A-I/II expression and cholesterol efflux 
from macrophages.86, 87 In addition, the HDL-C-raising effects of fibrates were ascribed 











































In NZW rabbits and F1B hamsters, fenofibrate reduced atherosclerosis progression 
and induced regression.33, 34 In the rabbit model, the beneficial effects of fenofibrate 
were ascribed to an increase in HDL-C or potential pleiotropic effects of fibrates, since no 
significant change in LDL-C was observed. 
4.1.2.2 PPAR-γ agonists
PPAR-γ agonists (glitazones) mainly mediate glucose homeostasis,86 but pioglitazone also 
weakly activates PPAR-α which explains the small increase in HDL-C.90 Similar to fibrates, 
glitazones exert anti-inflammatory and anti-oxidant effects independent of its metabolic 
activities. The atheroprotective effects of glitazones in preclinical studies were mostly 
independent of lipid modulation and according to our knowledge no studies reported an 
increase in HDL-C.
4.1.2.3 PPAR-α/γ agonists
PPAR-α/γ agonists (glitazars) were developed to more effectively improve lipid and glucose 
metabolism.86 In APOE*3Leiden.CETP mice, tesaglitazar prevented progression of pre-
existing atherosclerosis.35 A strong reduction in non-HDL-C was observed, as well as an 
increase in HDL-C. The latter was not accompanied by a rise in apolipoprotein A-I, suggesting 
an increase in particle size rather than the number of particles.
4.1.3 Cholesteryl ester transfer protein (CETP) inhibition
In 1989, markedly increased HDL-C led to the discovery of the first mutation in the CETP 
gene in two Japanese subjects.91 CETP facilitates the transfer of cholesteryl esters from 
atheroprotective HDL to atherogenic V(LDL) and has become a target to increase HDL-C.92 
In an early study, antisense oligonucleotides against CETP suppressed atherosclerosis 
with a reduction in LDL-C and a small increase in HDL-C in JW rabbits.36 Several studies have 
confirmed a reduction of lesion development after treatment with anti-CETP vaccines in 
NZW rabbits37-40 and small molecule inhibitors, torcetrapib and anacetrapib in NZW rabbits43 
and APOE*3Leiden.CETP mice.44, 45 In the rabbit study, aortic lesion area correlated with TC/
HDL-C ratio and a trend toward an inverse correlation between HDL-C and lesion size was 
found. It should be noted, however, that torcetrapib produced a pro-inflammatory, unstable 
plaque phenotype possibly related to an increase in aldosterone levels in APOE*3Leiden.
CETP mice,44 the latter is in line with data from clinical studies.23 Inconsistent data have been 
reported on the atheroprotective effects of dalcetrapib in JW rabbits41, 42 where a reduction 
in atherosclerosis was only found when accompanied by a decrease in non-HDL-C levels, 
the latter of which is in contrast to clinical findings.41 In the study by Huang et al., despite no 
effect of treatment on lesion size, TC and non-HDL-C, but not HDL-C correlated with lesion 
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with lesion area, however, only non-HDL-C and not HDL-C independently determined lesion 
size.45 
4.1.4 Scavenger receptor B-I (SR-BI) inhibitor and ATP-binding cassette A1 (ABCA1) 
degradation inhibitors
SR-BI mediates selective uptake of HDL-cholesterol esters by the liver and cholesterol efflux 
from other tissues. The SR-BI inhibitor, ITX5061 increased HDL-C without increasing (V)
LDL-C and reduced atherosclerotic lesion area in ldlr+/- mice expressing CETP.46 ATP-binding 
cassette (ABC) transporter, ABCA1 plays an important role in cholesterol efflux by mediating 
cholesterol transport to lipid-poor apolipoprotein A-I.10 In rabbits, pharmacological inhibition 
of ABCA1 degradation increased HDL-C and reduced atherosclerotic lesion area.47
4.2 Treatment strategies aimed at raising HDL-C and cardiovascular disease: randomized 
controlled clinical trials
The efficacy and cost-effectiveness of statins have assured its partaking in randomized 
controlled trials involving high risk patients. This has led to a noticeable decrease in baseline 
LDL-C when compared to previous trials. It is not surprising that in relevant clinical trials 
involving patients with a baseline LDL-C of < 100 mg/dL, on average 82% of the patients 
were on prior statin treatment. In a meta-analysis involving 8 statin trials and 38 153 
participants, HDL-C and apolipoprotein A-I levels, as well as the increase in apolipoprotein 
A-I were associated with reduced cardiovascular risk, however no association was found 
for the increase in HDL-C.22 This is in line with results from the current meta-analysis with 
other lipid-modulating therapies where we observed no association between between-
group differences in absolute or percentage change from baseline in HDL-C and non-fatal 
myocardial infarction, whereas a trend toward an association between absolute change 
from baseline in LDL-C levels and non-fatal myocardial infarction was found.
4.2.1 The effect of treatment on clinical outcomes in patient populations with high baseline 
LDL-C
Niacin reduced non-fatal myocardial infarction, whereas clofibrate/clofibric acid did not 
protect against cardiovascular disease in coronary heart disease patients in the CDP trial 
72 and in newly diagnosed diabetic patients in the DIS trial.70 In the WHO trial, clofibrate 
decreased non-fatal myocardial infarction in healthy subjects.71 LDL-C and HDL-C levels 
were not measured in these earlier trials. Gemfibrozil, a fibrate that decreases LDL-C and 
increases HDL-C, reduced non-fatal myocardial infarction in dyslipidemic patients in the 
HHS trial66 and in coronary heart disease patients in the VA-HIT trial,69 but failed to affect 
clinical outcomes in patients with suspected heart disease that were excluded from the 










































heterogeneity. In the VA-HIT trial, baseline LDL-C levels were much lower as compared to 
other trials without statins whereby no decrease in LDL-C was reported during the trial. In 
the BIP trial, bezafibrate had favorable effects on both LDL-C and HDL-C, but the reduction 
in cardiovascular events did not reach significance in patients with coronary artery disease,62 
whereas bezafibrate significantly reduced non-fatal myocardial infarction in patients with 
lower extremity arterial disease in the LEADER trial.68 The angiographic DAIS trial that 
investigated the effects of fenofibrate in diabetic patients was not designed to detect 
differences in events,63 but showed comparable reductions in clinical endpoints to that of 
post-hoc analyses in subgroups with diabetes.66, 69 In the FIELD trial, fenofibrate reduced non-
fatal myocardial infarction in diabetic patients.65 Fenofibrate decreased LDL-C in both trials, 
but the increase in HDL-C was not apparent at study closure in the FIELD trial. It should be 
noted that during the BIP, LEADER and FIELD trials, significantly more patients in the placebo 
group received lipid-modifying drugs, mostly statins. This could have contributed to the 
unexpected reduction in the cumulative probability of the primary endpoint after placebo 
treatment in the BIP trial, especially given the decline in LDL-C towards the end of the trial.
4.2.2 The effect of treatment on clinical outcomes in patient populations with low baseline 
LDL-C
The ACCORD and the FIRST trials were the only 2 trials that investigated the effects of a 
fibrate in combination with a statin in patients with diabetes29 and dyslipidemia.64 At the end 
of these trials, fenofibrate/fenofibric acid did not significantly affect LDL-C, had a small effect 
on HDL-C and failed to reduce cardiovascular outcomes. However, fenofibrate treatment in 
patient with high baseline TG and low baseline HDL-C appeared to be beneficial in post-hoc 
analysis.29 
Despite a decrease in LDL-C and an increase in HDL-C, the lack of efficacy of niacin 
in cardiovascular disease patients ascribed to insufficient power led to the premature 
termination of the AIM-HIGH trial.15 However, in the much larger HPS2-THRIVE study, niacin-
laropiprant also failed to reduce the risk of cardiovascular events in high risk patients.16 A 
potential adverse effect of laropiprant on the clinical outcome cannot not be fully excluded.
In the dal-OUTCOMES trial, dalcetrapib, a CETP inhibitor which only raises HDL-C without 
affecting LDL-C had no effect on cardiovascular events in patients with recent acute coronary 
syndrome and although not significant, the 0.6 mmHg rise in systolic blood pressure and 
18% increase in C-reactive protein certainly warrants attention, specifically with regards 
to other CETP inhibitors currently in clinical development.17 In the DEFINE trial, treatment 
with anacetrapib showed a non-significant 18% increase in C-reactive protein levels without 
affecting blood pressure and within the power limits of this trial, anacetrapib did not reveal 
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In aggregate, none of the studies with (reasonably) well-treated patients using statins 
showed additional beneficial effects on top of statin treatment with different classes of 
intervention (fenofibrate/fenofibric acid, niacin and dalcetrapib), perhaps with the exception 
of patients with high TG and low HDL levels at baseline. This indicates that using the current 
therapeutic options patients are treated well and that more powerful treatment modalities 
are needed to lower the residual cardiovascular risk.
4.2.3 The effect of treatment on clinical outcomes in trials excluded from the meta-analyses 
due to serious off-target cardiovascular adverse events
In the ILLUMINATE trial, torcetrapib favorably affected both LDL-C and HDL-C, but increased 
mortality most likely due to an off-target increase in aldosterone and blood pressure.23 
Interestingly, post-hoc analysis revealed lower risk of cardiovascular events in patients with 
a higher increase in HDL/apolipoprotein A-I from baseline to 1-3 month of treatment. Three 
imaging studies, the ILLUSTRATE, RADIANCE 1 and RADIANCE 2 trials also reported more 
serious clinical adverse events (cardiovascular and blood pressure-related events) after 
torcetrapib treatment in patients with coronary disease, familial hypercholesterolemia and 
dyslipidemia, although these trials were underpowered to detect differences in events.24-26 
Pioglitazone and aleglitazar increased both LDL-C and HDL-C and non-significantly 
reduced nonfatal myocardial infarction in diabetic patients in the PROactive27 and the 
AleCardio trials 28. In both trials, however, more patients in the treatment group suffered 
from heart failure, indicating adverse off-target effects. Development of other PPAR-α/γ 
agonists, muraglitazar and tesaglitazar were also stopped due to adverse events.93
4.3 Novel treatment strategies specifically targeting HDL on atherosclerosis: preclinical 
studies and clinical trials 
4.3.1 Purified, reconstituted and delipidated HDL
Badimon et al. demonstrated that administration of homologous HDL fraction not only 
inhibited aortic fatty streak formation, but also induced lesion regression in NZW rabbits 
48. Purified rabbit apolipoprotein A-I administration to NZW rabbits reduced aortic fatty 
streak progression without inducing regression.50 In these studies, the lack of plasma lipid 
modification and the reduction in aortic lipid accumulation suggested a direct role of HDL 
and/or apolipoprotein A-I on the vessel wall, possibly via an increase in reverse cholesterol 
transport. However, injection of reconstituted HDL failed to protect against fatty streak 
development and did not reduce aortic cholesterol content in JW rabbits.49 Results from a 
more recent study in NZW rabbits show that native or reconstituted HDL infusion reduced 
atherosclerotic lesion area and improved lesion stability to a similar extent as statins.51
In humans, infusions of reconstituted HDL, CSL-111 reduced atheroma volume from 










































a significant reduction in lipid content in the plaque after CSL-111 infusion versus placebo.95 
Both studies showed improved plaque characteristics. The reinfusion of delipidated plasma 
HDL, another potential approach to improve reverse cholesterol transport, non-significantly 
reduce atheroma volume in humans.96
4.3.2 Apolipoprotein A-I Milano
The therapeutic use of recombinant apolipoprotein A-I Milano originated from the 
observation that carriers of this mutation have low levels of HDL-C without increased 
atherosclerosis as observed in patients with hypoalhalipoproteinemia,97, 98 possibly due to 
accelerated binding and dissociation from lipids.99 In NZW rabbits, short-term administration 
of apolipoprotein A-I Milano reduced atherosclerosis progression,52, 53, 55 induced rapid 
regression and improved plaque stability.54, 56, 57 Interestingly, apolipoprotein A-I Milano 
showed similar effects on aortic cholesterol content with a greater reduction in intimal 
macrophage content as compared to phospholipid carrier alone.52 Other mechanisms 
besides reverse cholesterol transport were, therefore, suggested, including anti-oxidant, 
anti-inflammatory and vasodilatory effects. In another study, HDL Milano and HDL wild-type 
showed similar reductions in reverse cholesterol transport as evidenced by a reduction in 
aortic cholesterol content and up-regulation of ABCA1 and SRBI.56
In clinical trials, recombinant apolipoprotein A-I Milano, ETC-216 demonstrated rapid 
regression of atherosclerosis as seen by a reduction in atheroma volume from baseline100 
that was characterized by rapid remodeling with consequently no effect on lumen volume.101 
4.3.3 Apolipoprotein mimetic peptides
In NZW rabbits, the apolipoprotein AI mimetic peptides, D-4F and L-4F decreased 
atherosclerotic lesion area and reported a greater predictive value of inflammation markers 
as opposed to HDL-C levels.59 In WHHL rabbits, infusion of apolipoprotein A-I mimetic 
peptide/phospholipid complexes inhibited the progression of atherosclerosis mainly due 
to changes in LDL charge and by converting small, dense LDL into large, buoyant LDL.58 
According to our knowledge, the effects of other apolipoprotein A-I mimetic peptides, 6F 
and 5A, as well as an apolipoprotein E-derived HDL mimetic peptide, ATI-5261 were only 
investigated in animals lacking CETP.102, 103
In the CHI-SQUARE clinical trial, the HDL mimetic, CER-001 failed to reduce atheroma 
volume when compared with placebo and although not powered for clinical outcomes, 
revealed no differences in endpoints between groups.104
4.3.4 Apolipoprotein A-I inducer 
In preclinical development, the effects of the apolipoprotein A-I inducer, RVX-208 on 
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In the ASSURE trial, RVX-208 failed to reduce atheroma volume in statin-treated 
patients.103
Based on the present data, reconstituted HDL and apolipoprotein A-I-based treatment 
strategies seem promising in the protection against atherosclerosis development and 
cardiovascular disease. 
4.4 Limitations
To specifically investigate the role of non-HDL-C/LDL-C versus HDL-C, we pooled the effects 
of different compounds with different mechanisms of action. It is possible that these 
compounds also have different anti-atherosclerotic properties that are independent of their 
lipid-modifying effects. In addition, the studies that did not report lipid levels necessary to 
perform the analyses were excluded. Most compounds affected both LDL-C and HDL-C and 
it is, therefore, difficult to truly determine the contribution of each separate lipid fraction. 
In our preclinical studies with niacin32 and anacetrapib,45 we have tried to address this issue 
by performing statistical analyses (analysis of covariance) which suggested that anacetrapib 
mainly decreased atherosclerotic lesion development via a reduction in non-HDL-C, 
whereas the increase in HDL-C with niacin contributed to some extent to the reduction of 
atherosclerosis progression. 
4.5 Current status and future perspectives
Niacin and fibrates have been clinically available for many years. If indeed the baseline LDL-C 
levels in recent clinical trials were too low to detect reductions in clinical outcomes and after 
careful consideration of the reported adverse events in these trials, niacin and fibrates may 
still be feasible treatment options for certain patient populations, such as statin-intolerant 
patients, patients with familial hypercholesterolemia and dysbetalipoproteinemia, and 
patients with different forms of hypertriglyceridemia. In fact, a more potent PPAR-α 
agonist, K-877 is currently being investigated in phase II/III clinical trials.106 Despite failure of 
torcetrapib and dalcetrapib, the CETP inhibitors, anacetrapib and evacetrapib are currently 
being investigated in phase III clinical trials (the REVEAL and ACCELERATE trials) and TA-8995 
(DEZ-001) is in phase II clinical development (clinicaltrials.gov). 
Apolipoprotein A-I Milano (ETC-216, now MDCO-216) had manufacturing problems 
which limited its development.107 However, the compound is still in development. Phase 
II trials investigating the effects of reconstituted HDL and apolipoprotein A-I mimetic 
peptide infusions (CSL-112, CER-001, APL-180 (L-4F)) are ongoing (clinicaltrials.gov). 
Other apolipoprotein mimetic peptides, 5A, 6F and ATI-5261 are currently in preclinical 
development.102, 103 Another infusion therapy with recombinant human lecithin cholesterol 










































was shown to increase HDL-C in patients with coronary artery disease.103 LCAT esterifies 
cholesterol, thereby converting small lipid-poor nascent HDL into larger spherical HDL and 
may play a role in reverse cholesterol transport 102. A small molecule activator of LCAT in 
hamsters increased HDL-C, HDL particle size, plasma apolipoprotein A-I level and plasma 
cholesteryl ester (CE) to free cholesterol ratio and significantly reduced VLDL-C.108 In 
addition, phase II trials investigating the effects of an apolipoprotein A-I inducer (RVX208/
RVX000222) were recently completed (clinicaltrials.gov).
Other compounds in clinical development not yet discussed in this review due to lack of 
studies in CETP-expression animals or lack of efficacy (no increase in HDL-C), include PPAR-δ 
agonists, LXR agonists and miR-33 antagonism. Data from early phase II trials suggest that 
treatment with PPAR-δ agonists, GW501516 and MBX-8025 may be beneficial in patients 
with metabolic dysfunction.60 The clinical development of agonists of the transcription 
factor LXR is hindered due to its undesired effects on de novo lipogenesis and induction of 
CETP expression. The LXR agonist, LXR-623 also revealed central nervous system-related 
adverse events in phase I.102 Inhibition of miR33 improved ABCA1 expression and increased 
plasma HDL levels in preclinical studies and clinical trials should follow soon.103 Additional 
HDL-targeting compounds in preclinical development include endothelial lipase inhibitors 
and antisense oligonucleotides targeting CETP.10 
5. Conclusion
According to results from the current systematic review and meta-analysis, as well as 
supporting evidence obtained from the literature, we conclude that the protective role of 
lowering LDL-C and non-HDL-C is well-established, although occasionally LDL-C lowering 
compounds have failed due to (off-target) side effects. The contribution of raising HDL-C on 
inhibition of atherosclerosis and the prevention of cardiovascular disease remains undefined 
and may be dependent on the mode of action of HDL-C-modification. Nonetheless, 
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Cardiovascular disease (CVD) is the leading cause of death worldwide despite the successful 
development of several pharmaceutical interventions of which statin therapy is the 
dominating lipid-lowering treatment option.1 However, the treatment of CVD remains 
suboptimal due to; (i) a residual risk that persists after statin treatment,2 (ii) failure for 
some patients to reach low-density lipoprotein-cholesterol (LDL-C) targets despite statin 
treatment,3 and (iii) lack of adherence to statin treatment as a result of amongst others 
statin intolerance.4 Atherosclerosis, a chronic inflammatory disease of multifactorial origin,5, 
6 is a dominant contributor to the development of CVD.7 The research described in this 
thesis investigated the effects of innovative pharmaceutical interventions in experimental 
atherosclerosis, targeting hypertension and high blood cholesterol, more specifically high 
LDL-C and low high-density lipoprotein-cholesterol (HDL-C), as risk factors for CVD. We 
used APOE*3Leiden.CETP mice which express human cholesteryl ester transfer protein 
(CETP) under control of its natural flanking regions.8 These mice have impaired clearance of 
apolipoprotein B-containing lipoproteins and mimic the slow clearance observed in humans, 
particularly in patients with familial dysbetalipoproteinemia (FD).9 The APOE*3Leiden.
CETP mouse model is a well-established model for lipid and lipoprotein metabolism and 
atherosclerosis, because these mice; (i) develop diet-induced atherosclerosis, (ii) have 
a human-like lipoprotein metabolism and, (iii) respond in a human-like manner to lipid-
modifying treatment strategies, including LDL-C-lowering and HDL-C-raising compounds.10-15 
In view of the fact that hypertension is a leading risk factor for CVD and associated with 
the development of atherosclerosis,16, 17 we investigated the anti-atherosclerotic effects 
of aliskiren, the first commercially available, orally active, direct renin inhibitor approved 
for the treatment of hypertension in chapter 2.18 In this study in APOE*3Leiden.CETP 
mice, we demonstrated beneficial effects of aliskiren on atherosclerosis development 
and plaque stability when administered alone and in combination with atorvastatin. 
Aliskiren reduced systolic blood pressure and additionally reduced atherosclerotic lesion 
size and severity. Interestingly, the reduction in atherosclerosis development observed by 
aliskiren remained after correcting for blood pressure, suggesting that aliskiren had anti-
atherosclerotic properties beyond its blood pressure-lowering qualities. Aliskiren also 
improved plaque stability as evidenced by a decrease in macrophage and necrotic area, as 
well as by an increase in SMC content in the cap, possibly via a mechanism involving T cells. 
The combination of aliskiren and atorvastatin was more potent in reducing atherosclerotic 
lesion size, as well as markers of inflammation and in improving plaque stability. Clinical 
trials, including the ALLAY (Aliskiren in Left-Ventricular Hypertrophy),19 the ALOFT (Aliskiren 
Observation of Heart Failure Treatment)20 and the AVOID (Aliskiren in the Evaluation of 
Proteinuria In Diabetes) trials21 reported beneficial effects of aliskiren on various markers 
of organ damage. However, aliskiren in combination with angiotensin converting enzyme 










































cardiovascular benefit in diabetic patients at high risk of developing cardiovascular and renal 
complications in the ALTITUDE trial22 and in patients hospitalized for heart failure in the 
ASTRONAUT trial.23 Both these trials reported more adverse events, i.e. renal dysfunction, 
hyperkalemia and hypotension. In contrast, results from the prematurely terminated APOLLO 
trial that investigated the cardiovascular protective effects of aliskiren monotreatment 
and in combination with hydrochlorothiazide and amlodipine in elderly patients24 and the 
AQUARIUS trial that evaluated the effects of aliskiren on coronary atherosclerosis in patients 
with prehypertension, revealed potential for CVD reduction.25 The latter trial reported a 
non-significant trend towards a reduction in atheroma volume from baseline after aliskiren 
treatment. The ongoing ATMOSPHERE trial (NCT00853658) evaluating the efficacy and 
safety of aliskiren and aliskiren + enalapril combination treatment in patients with chronic 
heart failure will provide additional insight into the protective role of aliskiren and results 
are expected in 2015.
Cholesterol contained in LDL particles is well recognized as a primary causal risk factor 
for coronary heart disease (CHD) as evidenced by experimental, epidemiological and genetic 
data.26 Furthermore, intervention trials provided ample evidence that the lowering of LDL-C 
contributes to a reduction in CHD.27-29 However, despite the fact that epidemiological studies 
consistently reported an inverse association between HDL-C and CHD risk,30-32 the benefits 
of raising HDL-C remain less defined. In Chapter 3 to 6, we investigated the effects of novel 
lipid-modifying treatment strategies, i.e. LDL-C-lowering and/or HDL-C-raising compounds 
on atherosclerosis development in the APOE*3Leiden.CETP mouse model, since these mice 
respond to both LDL-C-lowering and HDL-C-raising compounds in a human-like manner.
The benefits of niacin on plasma lipids were first described in 1955 and led to the 
development of niacin for therapeutic purposes.33 In chapter 3,34 we aimed to address 
the discrepancy between the beneficial effects of niacin in initial clinical trials35-38 and 
the lack of effect of niacin on top of statin treatment on the reduction of CVD events in 
the large AIM-HIGH and HPS2-THRIVE clinical trials39, 40 by evaluating the effects of niacin 
alone and in combination with simvastatin on plasma lipid levels and atherosclerotic lesion 
size and composition. We demonstrated that niacin reduced (V)LDL-C and (V)LDL-TG and 
that the increase in HDL-C may be attributable to a decrease in hepatic and plasma CETP. 
Importantly, the extent of lipid-lowering observed with niacin in our study in E3L.CETP mice 
was comparable to that of FD patients.34, 41, 42 Moreover, we showed that niacin decreased 
atherosclerosis development mainly by reducing non-HDL-C with a modest HDL-C-raising 
and additional anti-inflammatory effects. We demonstrated that the additive effect of niacin 
on top of simvastatin was mostly dependent on its non-HDL-C-lowering capacities. Based 
on these findings and results from a reverse cholesterol transport (RCT) experiment, we 
conclude that the effects of niacin on HDL-C and HDL functionality may partially contribute 
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Therefore, data from our study suggested that clinical beneficial effects of niacin are largely 
dependent on its ability to lower (V)LDL-C on top of concomitant lipid-lowering therapy and 
may explain the failure of niacin in the AIM-HIGH and HPS2-THRIVE trials in hyperlipidemic 
patients subjected to aggressive LDL-C-lowering treatment with limited effects of niacin on 
(V)LDL-C.39, 40 
In 1989, markedly increased HDL-C led to the discovery of the first mutation in the 
CETP gene in two Japanese subjects.43 CETP facilitates the transfer of cholesteryl esters 
from atheroprotective HDL to atherogenic V(LDL) and has become a target to increase 
HDL-C. This has led to the development of several small molecule CETP inhibitors, including 
amongst others torcetrapib, dalcetrapib, anacetrapib and evacetrapib. However, despite 
favorable effects on both LDL-C and HDL-C, torcetrapib increased mortality in the large 
phase III ILLUMINATE trial, most likely due to an off-target increase in aldosterone which 
leads to activation of RAAS and an increase in blood pressure,44 potentially resulting in a 
more vulnerable plaque phenotype.13 In the large phase III dal-OUTCOMES trial, dalcetrapib 
which only raises HDL-C without affecting LDL-C had no effect on cardiovascular events 
in patients with recent acute coronary syndrome (ACS) and although not significant, the 
0.6 mmHg rise in systolic blood pressure and 18% increase in C-reactive protein certainly 
warrants attention, specifically with regards to other CETP inhibitors that are currently in 
clinical development.45 In chapter 4,46 we investigated the effects of a broad dose range of 
the novel CETP inhibitor, anacetrapib on CETP activity, lipid levels, atherosclerotic lesion size 
and composition, as well as HDL function and we examined possible additive/synergistic 
effects of anacetrapib on top of atorvastatin. In our study, anacetrapib dose-dependently 
reduced CETP activity, thereby decreasing non-HDL-C and increasing HDL-C. These lipid-
altering effects were comparable to findings from clinical trials.47-49 Moreover, anacetrapib 
dose-dependently reduced atherosclerosis development. This effect was mainly ascribed 
to a reduction in non-HDL-C despite a remarkable increase in HDL-C and without affecting 
HDL functionality. Interestingly, anacetrapib itself also contributed to the reduction of 
the lesion size by a hitherto unknown mechanism. In addition, anacetrapib improved 
lesion stability when given at a higher dose and a moderate dose anacetrapib added to 
the anti-atherogenic effects of atorvastatin. In phase II clinical trials, neither anacetrapib 
nor evacetrapib showed the side effects observed with torcetrapib treatment and both 
compounds were more potent in reducing LDL-C and increasing HDL-C when compared 
to torcetrapib and dalcetrapib.49-51 The effects of anacetrapib and evacetrapib on clinical 
outcomes are currently being investigated in the large phase III REVEAL (NCT01252953) 
and ACCELERATE (NCT01687998) clinical trials and results are expected in 2016/2017. 
We further explored the mechanism by which anacetrapib reduces (V)LDL-C and whether 
this effect is dependent on the inhibition of CETP activity in chapter 5. In this study, we 










































mechanisms; (i) inhibition of CETP activity, resulting in remodelled VLDL particles that 
are more susceptible to hepatic uptake, and (ii) a CETP-independent reduction in plasma 
proprotein convertase subtilisin/kexin type 9 (PCSK9) level that has the potential to increase 
LDL receptor (LDLR)-mediated hepatic remnant clearance. According to our knowledge, 
there are currently no clinical data describing the mechanism by which anacetrapib reduces 
non-HDL-C/LDL-C. However, a reduction in plasma PCSK9 levels after anacetrapib treatment 
was in accordance with findings in rhesus macaques52 and results from our study confirmed 
a CETP-independent decrease in plasma PCSK9 levels by anacetrapib as previously observed 
in C57BL/6 mice.53
In 2003, Abifadel et al. identified two French families with autosomal dominant 
hypercholesterolemia caused by mutations in PCSK9.54 PCSK9 is a serine protease responsible 
for LDLR degradation by preventing the recycling of the receptor to the cell membrane 
after internalization.55 The upregulation of the LDLR after statin treatment is accompanied 
by an upregulation of PCSK9 which in turn promotes LDLR degradation.56-58 Inhibition of 
PCSK9 is, therefore, a potential novel strategy in the treatment against CVD, especially in 
combination with statin treatment. We, therefore investigated the effects of 2 dosages of 
the fully human, monoclonal antibody against PCSK9, alirocumab alone and in combination 
with atorvastatin on hepatic LDLR protein levels and hepatic cholesterol metabolism, 
plasma lipid levels, atherosclerosis development and plaque morphology in chapter 6.59 
In this study, alirocumab dose-dependently increased hepatic LDLR protein levels without 
changes in hepatic cholesterol and TG levels and consequently decreased plasma cholesterol 
levels and reduced the development of atherosclerosis. Moreover, alirocumab improved 
lesion morphology and composition and enhanced the beneficial effects of a mild dose of 
atorvastatin. The anti-atherosclerotic effect was strongly dependent on the reduction of 
plasma TC levels, indicating that the majority of the effect was brought about by cholesterol-
lowering leaving limited/no space for other potential (pleiotropic) effects. This is the first 
study to show that a monoclonal antibody to PCSK9 reduces atherosclerosis development. 
It should be noted that this is a progression/prevention study which may pose as a potential 
limitation with respect to translation to the clinic where patients with existing lesions are often 
treated. Nonetheless, data from this study may also suggest beneficial effects on markers of 
atherosclerosis by reducing TC with alirocumab in the human situation where new lesions 
are formed alongside existing plaques. The dose-dependent cholesterol-lowering effects 
observed in our study were in accordance with results from phase I and II clinical trials.60-62 
No significant safety issues emerged from these short term trials. Results from phase III 
trials within the ODYSSEY programs will provide further insight regarding the long term 
efficacy, safety and tolerability of alirocumab in patients with familial hypercholesterolemia 
and in high CVD risk patients with hypercholesterolemia on lipid-modifying therapy.63 The 
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occurrence of cardiovascular events in patients with relatively recent ACS treated with high-
dose statins will reveal whether PCSK9 inhibition with alirocumab translates into clinical 
benefit and results are expected in 2018.  
In chapter 7, we reviewed the effects of established and novel treatment strategies, 
specifically targeting HDL, other than statins on inhibition of atherosclerosis development 
in preclinical studies in animals expressing CETP, a crucial gene involved in HDL metabolism 
and implicated in the mechanisms by which most therapies modulate HDL.64 In addition, we 
conducted a meta-analysis to evaluate the potential effects of these treatment strategies 
on the prevention of clinical events in randomized controlled trials. In the systematic 
review and meta-analysis, we focused specifically on the contribution of non-HDL-C/LDL-
C-lowering versus HDL-C-raising on inhibition of atherosclerosis and the prevention of CVD. 
Using data from relevant preclinical studies, we found significant correlations between 
both TC and non-HDL-C exposure and atherosclerosis, however, there was no significant 
association between HDL-C exposure and atherosclerosis. The meta-analysis of relevant 
clinical trials revealed no association between the absolute or percentage increase in 
HDL-C and non-fatal myocardial infarction, whereas a trend toward an association between 
the absolute decrease in LDL-C levels and non-fatal myocardial infarction was found. This 
is in line with results from a recent meta-analysis involving only statin trials (8 trials with 
38 153 participants), showing that HDL-C and apolipoprotein A-I levels, as well as the 
increase in apolipoprotein A-I were associated with reduced cardiovascular risk, however 
no association was found for the increase in HDL-C.65 The effects of other novel treatment 
strategies specifically targeting HDL, including reconstituted and delipidated HDL, as well as 
HDL mimetics, apolipoprotein A-I mimetic peptides, recombinant apolipoprotein A-I Milano 
and recombinant human lecithin cholesterol acyltransferase (LCAT) seem promising in the 
protection against atherosclerosis development and cardiovascular disease based on data 
from preclinical studies66-77 and clinical trials.78-81 In these studies, the lack of plasma lipid 
modification suggests a direct role of HDL and/or apolipoprotein A-I, possibly via an increase 
in reverse cholesterol transport and supports the view that HDL function rather than HDL-C 
may have a causal relation to atherprotection.82
Thus, according to results from our systematic review and meta-analysis, as well as 
supporting evidence obtained from the literature, it is evident that the protective role of 
lowering LDL-C and non-HDL-C is well-established, although occasionally LDL-C lowering 
compounds have failed due to (off-target) side effects. The contribution of raising HDL-C on 
inhibition of atherosclerosis and the prevention of cardiovascular disease remains undefined 
and may be dependent on the mode of action of HDL-C-modification. Nonetheless, 











































In conclusion, the research described in this thesis provides evidence for anti-atherogenic 
effects of several innovative pharmaceutical interventions that are currently being 
investigated in clinical trials, specifically targeting hypertension and hypercholesterolemia 
as risk factors for CVD. Our results further support additional benefit of these treatment 
strategies in combination with statin treatment which is currently the ‘gold standard’ 
therapy for the treatment of CVD. Most of these lipid-modifying treatment strategies 
affect both LDL-C and HDL-C and we demonstrate that the beneficial effects of these 
treatment strategies predominantly derive from their non-HDL-C/LDL-C-lowering abilities. 
Nonetheless, results from preclinical studies and clinical trials support the notion that 
treatment strategies aimed at improving HDL function and raising apolipoprotein A-I may 













































1. Laslett LJ, Alagona P, Jr., Clark BA, 3rd, Drozda JP, Jr., Saldivar F, Wilson SR, Poe C and Hart M. The 
worldwide environment of cardiovascular disease: prevalence, diagnosis, therapy, and policy 
issues: a report from the American College of Cardiology. Journal of the American College of 
Cardiology. 2012;60:S1-49.
2. Libby P. The forgotten majority: unfinished business in cardiovascular risk reduction. Journal of 
the American College of Cardiology. 2005;46:1225-8.
3. Davidson MH, Maki KC, Pearson TA, Pasternak RC, Deedwania PC, McKenney JM, Fonarow 
GC, Maron DJ, Ansell BJ, Clark LT and Ballantyne CM. Results of the National Cholesterol 
Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey 
and implications for treatment under the recent NCEP Writing Group recommendations. The 
American journal of cardiology. 2005;96:556-63.
4. Bitzur R, Cohen H, Kamari Y and Harats D. Intolerance to statins: mechanisms and management. 
Diabetes care. 2013;36 Suppl 2:S325-30.
5. Libby P, Okamoto Y, Rocha VZ and Folco E. Inflammation in Atherosclerosis. Circulation Journal. 
2010;74:213-220.
6. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. The New England 
journal of medicine. 2005;352:1685-95.
7. Galkina E and Ley K. Immune and inflammatory mechanisms of atherosclerosis (*). Annual 
review of immunology. 2009;27:165-97.
8. Westerterp M, van der Hoogt CC, de Haan W, Offerman EH, Dallinga-Thie GM, Jukema JW, 
Havekes LM and Rensen PC. Cholesteryl ester transfer protein decreases high-density lipoprotein 
and severely aggravates atherosclerosis in APOE*3-Leiden mice. Arteriosclerosis, thrombosis, 
and vascular biology. 2006;26:2552-9.
9. de Knijff P, van den Maagdenberg AM, Stalenhoef AF, Leuven JA, Demacker PN, Kuyt LP, Frants 
RR and Havekes LM. Familial dysbetalipoproteinemia associated with apolipoprotein E3-Leiden 
in an extended multigeneration pedigree. The Journal of clinical investigation. 1991;88:643-55.
10. Zadelaar S, Kleemann R, Verschuren L, de Vries-Van der Weij J, van der Hoorn J, Princen HM and 
Kooistra T. Mouse models for atherosclerosis and pharmaceutical modifiers. Arteriosclerosis, 
thrombosis, and vascular biology. 2007;27:1706-21.
11. van der Hoogt CC, de Haan W, Westerterp M, Hoekstra M, Dallinga-Thie GM, Romijn JA, Princen 
HM, Jukema JW, Havekes LM and Rensen PC. Fenofibrate increases HDL-cholesterol by reducing 
cholesteryl ester transfer protein expression. Journal of lipid research. 2007;48:1763-71.
12. van der Hoorn JW, de Haan W, Berbee JF, Havekes LM, Jukema JW, Rensen PC and Princen HM. 
Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester 
transfer protein in APOE*3Leiden.CETP mice. Arteriosclerosis, thrombosis, and vascular biology. 
2008;28:2016-22.
13. de Haan W, de Vries-van der Weij J, van der Hoorn JW, Gautier T, van der Hoogt CC, Westerterp 
M, Romijn JA, Jukema JW, Havekes LM, Princen HM and Rensen PC. Torcetrapib does not 
reduce atherosclerosis beyond atorvastatin and induces more proinflammatory lesions than 
atorvastatin. Circulation. 2008;117:2515-22.
14. de Haan W, van der Hoogt CC, Westerterp M, Hoekstra M, Dallinga-Thie GM, Princen HM, Romijn 
JA, Jukema JW, Havekes LM and Rensen PC. Atorvastatin increases HDL cholesterol by reducing 
CETP expression in cholesterol-fed APOE*3-Leiden.CETP mice. Atherosclerosis. 2008;197:57-63.
15. van den Hoek AM, van der Hoorn JW, Maas AC, van den Hoogen RM, van Nieuwkoop A, Droog 
S, Offerman EH, Pieterman EJ, Havekes LM and Princen HM. APOE*3Leiden.CETP transgenic 
mice as model for pharmaceutical treatment of the metabolic syndrome. Diabetes, obesity & 
metabolism. 2014;16:537-44.
16. Jankowski P, Bilo G and Kawecka-Jaszcz K. The pulsatile component of blood pressure: its role in 
the pathogenesis of atherosclerosis. Blood pressure. 2007;16:238-45.











































18. Kuhnast S, van der Hoorn JW, van den Hoek AM, Havekes LM, Liau G, Jukema JW and Princen HM. 
Aliskiren inhibits atherosclerosis development and improves plaque stability in APOE*3Leiden.
CETP transgenic mice with or without treatment with atorvastatin. Journal of hypertension. 
2012;30:107-16.
19. Solomon SD, Appelbaum E, Manning WJ, Verma A, Berglund T, Lukashevich V, Cherif Papst C, 
Smith BA and Dahlof B. Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor 
blocker losartan, or both on left ventricular mass in patients with hypertension and left 
ventricular hypertrophy. Circulation. 2009;119:530-7.
20. McMurray JJ, Pitt B, Latini R, Maggioni AP, Solomon SD, Keefe DL, Ford J, Verma A and Lewsey 
J. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. 
Circulation Heart failure. 2008;1:17-24.
21. Parving HH, Persson F, Lewis JB, Lewis EJ and Hollenberg NK. Aliskiren combined with losartan in 
type 2 diabetes and nephropathy. The New England journal of medicine. 2008;358:2433-46.
22. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, 
Persson F, Desai AS, Nicolaides M, Richard A, Xiang Z, Brunel P and Pfeffer MA. Cardiorenal 
end points in a trial of aliskiren for type 2 diabetes. The New England journal of medicine. 
2012;367:2204-13. 
23. Gheorghiade M, Bohm M, Greene SJ, Fonarow GC, Lewis EF, Zannad F, Solomon SD, Baschiera 
F, Botha J, Hua TA, Gimpelewicz CR, Jaumont X, Lesogor A and Maggioni AP. Effect of aliskiren 
on postdischarge mortality and heart failure readmissions among patients hospitalized for 
heart failure: the ASTRONAUT randomized trial. JAMA: the journal of the American Medical 
Association. 2013;309:1125-35.
24. Teo KK, Pfeffer M, Mancia G, O’Donnell M, Dagenais G, Diaz R, Dans A, Liu L, Bosch J, Joseph P, 
Copland I, Jung H, Pogue J and Yusuf S. Aliskiren alone or with other antihypertensives in the 
elderly with borderline and stage 1 hypertension: the APOLLO trial. European heart journal. 
2014;35:1743-51.
25. Nicholls SJ, Bakris GL, Kastelein JJ, Menon V, Williams B, Armbrecht J, Brunel P, Nicolaides M, Hsu 
A, Hu B, Fang H, Puri R, Uno K, Kataoka Y, Bash D and Nissen SE. Effect of aliskiren on progression 
of coronary disease in patients with prehypertension: the AQUARIUS randomized clinical trial. 
JAMA : the journal of the American Medical Association. 2013;310:1135-44.
26. Ridker PM. LDL cholesterol: controversies and future therapeutic directions. Lancet. 
2014;384:607-17.
27. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, 
Simes J and Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-
analysis of data from 170 000 participants in 26 randomised trials. The Lancet. 2010;376:1670-
1681.
28. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, 
Collins R and Simes R. Efficacy and safety of cholesterol-lowering treatment: prospective 
meta-analysis of data from 90 056 participants in 14 randomised trials of statins. The Lancet. 
2005;366:1267-1278.
29. Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, Voysey M, Gray A, Collins 
R and Baigent C. The effects of lowering LDL cholesterol with statin therapy in people at low 
risk of vascular disease: meta-analysis of individual data from 27 randomised trials. The Lancet. 
2012;380:581-590.
30. Castelli WP, Doyle JT, Gordon T, Hames CG, Hjortland MC, Hulley SB, Kagan A and Zukel WJ. HDL 
cholesterol and other lipids in coronary heart disease. The cooperative lipoprotein phenotyping 
study. Circulation. 1977;55:767-772.
31. Miller NE, Thelle DS, Forde OH and Mjos OD. The Tromso heart-study. High-density lipoprotein 
and coronary heart-disease: a prospective case-control study. Lancet. 1977;1:965-8.
32. Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, Wood AM, Lewington S, 
Sattar N, Packard CJ, Collins R, Thompson SG and Danesh J. Major lipids, apolipoproteins, and 









































General Discussion and Future Perspectives
189
8
33. Carlson LA. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. Journal of 
internal medicine. 2005;258:94-114.
34. Kuhnast S, Louwe MC, Heemskerk MM, Pieterman EJ, van Klinken JB, van den Berg SA, Smit 
JW, Havekes LM, Rensen PC, van der Hoorn JW, Princen HM and Jukema JW. Niacin Reduces 
Atherosclerosis Development in APOE*3Leiden.CETP Mice Mainly by Reducing NonHDL-
Cholesterol. PloS one. 2013;8:e66467.
35. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK and Grace KA. Arterial Biology for the Investigation of 
the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled 
study of extended-release niacin on atherosclerosis progression in secondary prevention 
patients treated with statins. Circulation. 2004;110:3512-7.
36. Taylor AJ, Lee HJ and Sullenberger LE. The effect of 24 months of combination statin and 
extended-release niacin on carotid intima-media thickness: ARBITER 3. Current medical research 
and opinion. 2006;22:2243-50.
37. Taylor AJ, Villines TC, Stanek EJ, Devine PJ, Griffen L, Miller M, Weissman NJ and Turco M. 
Extended-release niacin or ezetimibe and carotid intima-media thickness. The New England 
journal of medicine. 2009;361:2113-22.
38. Lee JM, Robson MD, Yu LM, Shirodaria CC, Cunnington C, Kylintireas I, Digby JE, Bannister T, 
Handa A, Wiesmann F, Durrington PN, Channon KM, Neubauer S and Choudhury RP. Effects 
of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a 
randomized, placebo-controlled, magnetic resonance imaging study. Journal of the American 
College of Cardiology. 2009;54:1787-94.
39. Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride 
R, Teo K and Weintraub W. Niacin in patients with low HDL cholesterol levels receiving intensive 
statin therapy. The New England journal of medicine. 2011;365:2255-67.
40. Landray MJ, Haynes R, Hopewell JC, Parish S, Aung T, Tomson J, Wallendszus K, Craig M, Jiang L, 
Collins R and Armitage J. Effects of extended-release niacin with laropiprant in high-risk patients. 
The New England journal of medicine. 2014;371:203-12.
41. Carlson LA and Oro L. Effect of treatment with nicotinic acid for one month on serum lipids in 
patients with different types of hyperlipidemia. Atherosclerosis. 1973;18:1-9.
42. Hoogwerf BJ, Bantle JP, Kuba K, Frantz ID, Jr. and Hunninghake DB. Treatment of type III 
hyperlipoproteinemia with four different treatment regimens. Atherosclerosis. 1984;51:251-9.
43. Brown ML, Inazu A, Hesler CB, Agellon LB, Mann C, Whitlock ME, Marcel YL, Milne RW, Koizumi 
J, Mabuchi H and et al. Molecular basis of lipid transfer protein deficiency in a family with 
increased high-density lipoproteins. Nature. 1989;342:448-51.
44. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca 
L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR and Brewer B. Effects 
of torcetrapib in patients at high risk for coronary events. The New England journal of medicine. 
2007;357:2109-22.
45. Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, 
Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC and 
Wright RS. Effects of dalcetrapib in patients with a recent acute coronary syndrome. The New 
England journal of medicine. 2012;367:2089-99.
46. Kuhnast S, van der Tuin SJ, van der Hoorn JW, van Klinken JB, Simic B, Pieterman E, Havekes 
LM, Landmesser U, Luscher TF, Willems van Dijk K, Rensen PC, Jukema JW and Princen HM. 
Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, 
improves lesion stability and adds to the beneficial effects of atorvastatin. European heart 
journal. 2014;doi:10.1093/eurheartj/ehu319.
47. Krishna R, Bergman AJ, Jin B, Fallon M, Cote J, Van Hoydonck P, Laethem T, Gendrano IN, 3rd, Van 
Dyck K, Hilliard D, Laterza O, Snyder K, Chavez-Eng C, Lutz R, Chen J, Bloomfield DM, De Smet M, 
Van Bortel LM, Gutierrez M, Al-Huniti N, Dykstra K, Gottesdiener KM and Wagner JA. Multiple-
dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester 











































48. Krishna R, Anderson MS, Bergman AJ, Jin B, Fallon M, Cote J, Rosko K, Chavez-Eng C, Lutz R, 
Bloomfield DM, Gutierrez M, Doherty J, Bieberdorf F, Chodakewitz J, Gottesdiener KM and 
Wagner JA. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins 
in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: 
two double-blind, randomised placebo-controlled phase I studies. The Lancet. 2007;370:1907-
1914.
49. Bloomfield D, Carlson GL, Sapre A, Tribble D, McKenney JM, Littlejohn TW, 3rd, Sisk CM, Mitchel 
Y and Pasternak RC. Efficacy and safety of the cholesteryl ester transfer protein inhibitor 
anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. 
American heart journal. 2009;157:352-360 e2.
50. Johns DG, Duffy J, Fisher T, Hubbard BK and Forrest MJ. On- and off-target pharmacology of 
torcetrapib: current understanding and implications for the structure activity relationships 
(SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors. Drugs. 
2012;72:491-507.
51. Nicholls SJ, Brewer HB, Kastelein JJ, Krueger KA, Wang MD, Shao M, Hu B, McErlean E and Nissen 
SE. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination 
with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA: the journal of the 
American Medical Association. 2011;306:2099-2109.
52. Roddy TP, McLaren DG, Chen Y, Xie D, Dunn K, Kulick A, Szeto D, Forrest G, Albanese K, Donnelly 
M, Gai C, Gewain A, Lederman H, Jensen KK, Ai X, Vachal P, Akinsanya KO, Cleary MA, Previs SF, 
Dansky HM and Johns DG. Effects of anacetrapib on plasma lipids, apolipoproteins and PCSK9 in 
healthy, lean rhesus macaques. European journal of pharmacology. 2014;740:410-6.
53. Dong B, Singh AB, Fung C, Kan K and Liu J. CETP inhibitors downregulate hepatic LDL receptor and 
PCSK9 expression in vitro and in vivo through a SREBP2 dependent mechanism. Atherosclerosis. 
2014;235:449-62.
54. Abifadel M, Varret M, Rabes JP, Allard D, Ouguerram K, Devillers M, Cruaud C, Benjannet S, 
Wickham L, Erlich D, Derre A, Villeger L, Farnier M, Beucler I, Bruckert E, Chambaz J, Chanu B, 
Lecerf JM, Luc G, Moulin P, Weissenbach J, Prat A, Krempf M, Junien C, Seidah NG and Boileau 
C. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nature genetics. 
2003;34:154-6.
55. Lambert G, Sjouke B, Choque B, Kastelein JJ and Hovingh GK. The PCSK9 decade. Journal of lipid 
research. 2012;53:2515-24.
56. Dubuc G, Chamberland A, Wassef H, Davignon J, Seidah NG, Bernier L and Prat A. Statins 
upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated 
convertase-1 implicated in familial hypercholesterolemia. Arteriosclerosis, thrombosis, and 
vascular biology. 2004;24:1454-9.
57. Mayne J, Dewpura T, Raymond A, Cousins M, Chaplin A, Lahey KA, Lahaye SA, Mbikay M, Ooi 
TC and Chretien M. Plasma PCSK9 levels are significantly modified by statins and fibrates in 
humans. Lipids in health and disease. 2008;7:22.
58. Careskey HE, Davis RA, Alborn WE, Troutt JS, Cao G and Konrad RJ. Atorvastatin increases 
human serum levels of proprotein convertase subtilisin/kexin type 9. Journal of lipid research. 
2008;49:394-8.
59. Kuhnast S, van der Hoorn JW, Pieterman EJ, van den Hoek AM, Sasiela WJ, Gusarova V, Peyman 
A, Schafer HL, Schwahn U, Jukema JW and Princen HM. Alirocumab inhibits atherosclerosis, 
improves the plaque morphology, and enhances the effects of a statin. Journal of lipid research. 
2014;55:2103-12.
60. Stein EA, Gipe D, Bergeron J, Gaudet D, Weiss R, Dufour R, Wu R and Pordy R. Effect of a 
monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein 
cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin 
dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. The Lancet. 
2012;380:29-36.
61. McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand AC and Stein EA. Safety and efficacy 
of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, 
SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable 








































General Discussion and Future Perspectives
191
8
62. Roth EM, McKenney JM, Hanotin C, Asset G and Stein EA. Atorvastatin with or without an 
antibody to PCSK9 in primary hypercholesterolemia. The New England journal of medicine. 
2012;367:1891-900.
63. Stein EA and Swergold GD. Potential of proprotein convertase subtilisin/kexin type 9 based 
therapeutics. Current atherosclerosis reports. 2013;15:310.
64. Chapman MJ, Le Goff W, Guerin M and Kontush A. Cholesteryl ester transfer protein: at the 
heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl 
ester transfer protein inhibitors. European heart journal. 2010;31:149-64.
65. Boekholdt SM, Arsenault BJ, Hovingh GK, Mora S, Pedersen TR, Larosa JC, Welch KM, Amarenco 
P, Demicco DA, Tonkin AM, Sullivan DR, Kirby A, Colhoun HM, Hitman GA, Betteridge DJ, 
Durrington PN, Clearfield MB, Downs JR, Gotto AM, Jr., Ridker PM and Kastelein JJ. Levels and 
changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events 
among statin-treated patients: a meta-analysis. Circulation. 2013;128:1504-12.
66. Badimon JJ, Badimon L and Fuster V. Regression of atherosclerotic lesions by high density 
lipoprotein plasma fraction in the cholesterol-fed rabbit. The Journal of clinical investigation. 
1990;85:1234-41.
67. Mezdour H, Yamamura T, Nomura S and Yamamoto A. Exogenous supply of artificial lipoproteins 
does not decrease susceptibility to atherosclerosis in cholesterol-fed rabbits. Atherosclerosis. 
1995;113:237-46.
68. Miyazaki A, Sakuma S, Morikawa W, Takiue T, Miake F, Terano T, Sakai M, Hakamata H, Sakamoto 
Y, Natio M and et al. Intravenous injection of rabbit apolipoprotein A-I inhibits the progression 
of atherosclerosis in cholesterol-fed rabbits. Arteriosclerosis, thrombosis, and vascular biology. 
1995;15:1882-8.
69. Nicholls SJ, Cutri B, Worthley SG, Kee P, Rye KA, Bao S and Barter PJ. Impact of short-term 
administration of high-density lipoproteins and atorvastatin on atherosclerosis in rabbits. 
Arteriosclerosis, thrombosis, and vascular biology. 2005;25:2416-21.
70. Ameli S, Hultgardh-Nilsson A, Cercek B, Shah PK, Forrester JS, Ageland H and Nilsson J. 
Recombinant apolipoprotein A-I Milano reduces intimal thickening after balloon injury in 
hypercholesterolemic rabbits. Circulation. 1994;90:1935-1941.
71. Soma MR, Donetti E, Parolini C, Sirtori CR, Fumagalli R and Franceschini G. Recombinant 
apolipoprotein A-IMilano dimer inhibits carotid intimal thickening induced by perivascular 
manipulation in rabbits. Circulation research. 1995;76:405-11.
72. Chiesa G. Recombinant Apolipoprotein A-IMilano Infusion Into Rabbit Carotid Artery Rapidly 
Removes Lipid From Fatty Streaks. Circulation research. 2002;90:974-980.
73. Parolini C, Marchesi M, Lorenzon P, Castano M, Balconi E, Miragoli L, Chaabane L, Morisetti 
A, Lorusso V, Martin BJ, Bisgaier CL, Krause B, Newton RS, Sirtori CR and Chiesa G. Dose-
related effects of repeated ETC-216 (recombinant apolipoprotein A-I Milano/1-palmitoyl-2-
oleoyl phosphatidylcholine complexes) administrations on rabbit lipid-rich soft plaques: in 
vivo assessment by intravascular ultrasound and magnetic resonance imaging. Journal of the 
American College of Cardiology. 2008;51:1098-103.
74. Ibanez B, Giannarelli C, Cimmino G, Santos-Gallego CG, Alique M, Pinero A, Vilahur G, Fuster 
V, Badimon L and Badimon JJ. Recombinant HDL(Milano) exerts greater anti-inflammatory and 
plaque stabilizing properties than HDL(wild-type). Atherosclerosis. 2012;220:72-7.
75. Ibanez B, Vilahur G, Cimmino G, Speidl WS, Pinero A, Choi BG, Zafar MU, Santos-Gallego CG, 
Krause B, Badimon L, Fuster V and Badimon JJ. Rapid change in plaque size, composition, and 
molecular footprint after recombinant apolipoprotein A-I Milano (ETC-216) administration: 
magnetic resonance imaging study in an experimental model of atherosclerosis. Journal of the 
American College of Cardiology. 2008;51:1104-9.
76. Van Lenten BJ, Wagner AC, Navab M, Anantharamaiah GM, Hama S, Reddy ST and Fogelman 
AM. Lipoprotein inflammatory properties and serum amyloid A levels but not cholesterol levels 
predict lesion area in cholesterol-fed rabbits. Journal of lipid research. 2007;48:2344-53.
77. Iwata A, Miura S, Zhang B, Imaizumi S, Uehara Y, Shiomi M and Saku K. Antiatherogenic effects 
of newly developed apolipoprotein A-I mimetic peptide/phospholipid complexes against aortic 










































78. Tardif JC, Gregoire J, L’Allier PL, Ibrahim R, Lesperance J, Heinonen TM, Kouz S, Berry C, Basser 
R, Lavoie MA, Guertin MC and Rodes-Cabau J. Effects of reconstituted high-density lipoprotein 
infusions on coronary atherosclerosis: a randomized controlled trial. JAMA: the journal of the 
American Medical Association. 2007;297:1675-82.
79. Shaw JA, Bobik A, Murphy A, Kanellakis P, Blombery P, Mukhamedova N, Woollard K, Lyon 
S, Sviridov D and Dart AM. Infusion of reconstituted high-density lipoprotein leads to acute 
changes in human atherosclerotic plaque. Circulation research. 2008;103:1084-91.
80. Waksman R, Torguson R, Kent KM, Pichard AD, Suddath WO, Satler LF, Martin BD, Perlman TJ, 
Maltais JA, Weissman NJ, Fitzgerald PJ and Brewer HB, Jr. A first-in-man, randomized, placebo-
controlled study to evaluate the safety and feasibility of autologous delipidated high-density 
lipoprotein plasma infusions in patients with acute coronary syndrome. Journal of the American 
College of Cardiology. 2010;55:2727-35.
81. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, Eaton GM, Lauer MA, Sheldon 
WS, Grines CL, Halpern S, Crowe T, Blankenship JC and Kerensky R. Effect of recombinant ApoA-I 
Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized 
controlled trial. JAMA : the journal of the American Medical Association. 2003;290:2292-300.


























































































Cardiovascular disease (CVD) is the leading cause of death worldwide despite the 
successful development of several pharmaceutical interventions of which statin therapy is 
the dominating lipid-lowering treatment option. Atherosclerosis, a chronic inflammatory 
disease of multifactorial origin, is a dominant contributor to the development of CVD. 
The research described in this thesis investigated the effects of innovative pharmaceutical 
interventions in experimental atherosclerosis, targeting hypertension and high blood 
cholesterol, more specifically high low-density lipoprotein-cholesterol (LDL-C) and low high- 
density lipoprotein-cholesterol (HDL-C), as risk factors for CVD. 
In view of the fact that hypertension is a leading risk factor for CVD and associated 
with the development of atherosclerosis, we investigated the anti-atherosclerotic effects 
of aliskiren, the first commercially available, orally active, direct renin inhibitor approved 
for the treatment of hypertension in chapter 2. In this study in APOE*3Leiden.CETP mice, 
we demonstrated beneficial effects of aliskiren on atherosclerosis development and plaque 
stability when administered alone and in combination with atorvastatin, possibly via a 
mechanism involving T cells. These results suggest a potential benefit of using aliskiren in a 
clinical setting, particularly in combination with statin treatment. 
Cholesterol contained in LDL particles is well recognized as a primary causal risk factor 
for coronary heart disease (CHD) as evidenced by experimental, epidemiological and 
genetic data and intervention trials. However, despite the fact that epidemiological studies 
consistently reported an inverse association between HDL-C and CHD risk, the benefits of 
raising HDL-C remain less defined. In Chapter 3 to 6, we investigated the effects of novel 
lipid-modifying treatment strategies, i.e. LDL-C-lowering and/or HDL-C-raising compounds 
on atherosclerosis development in the APOE*3Leiden.CETP mouse model, since these mice 
respond to both LDL-C-lowering and HDL-C-raising compounds in a human-like manner.
The benefits of niacin on plasma lipids were first described in 1955 and led to the 
development of niacin for therapeutic purposes. In chapter 3, we aimed to address the 
discrepancy between the beneficial effects of niacin in initial clinical trials and the lack 
of effect of niacin on top of statin treatment on the reduction of CVD events in the large 
AIM-HIGH and HPS2-THRIVE clinical trials by evaluating the effects of niacin alone and in 
combination with simvastatin on atherosclerosis development. We showed that niacin 
decreases atherosclerosis development mainly by reducing non-HDL-C with modest HDL-
C-raising and additional anti-inflammatory effects. The additive effect of niacin on top of 
simvastatin was mostly dependent on its non-HDL-C-lowering capacities. These data suggest 
that clinical beneficial effects of niacin are largely dependent on its ability to lower LDL-C on 
top of concomitant lipid-lowering therapy and may explain the failure of niacin in the AIM-










































In 1989, markedly increased HDL-C led to the discovery of the first mutation in the 
cholesteryl ester transfer protein (CETP) gene in two Japanese subjects. CETP facilitates 
the transfer of cholesteryl esters from atheroprotective HDL to atherogenic V(LDL) and has 
become a target to increase HDL-C. This has led to the development of several small molecule 
CETP inhibitors. In chapter 4, we investigated the effects of a broad dose range of the novel 
CETP inhibitor, anacetrapib on atherosclerosis development and we examined possible 
additive/synergistic effects of anacetrapib on top of atorvastatin. In our study, anacetrapib 
dose-dependently reduced CETP activity, thereby decreasing non-HDL-C and increasing 
HDL-C. Moreover, anacetrapib dose-dependently reduced atherosclerosis development. 
This effect was mainly ascribed to a reduction in non-HDL-C despite a remarkable increase 
in HDL-C and without affecting HDL functionality. In addition, anacetrapib improved lesion 
stability and added to the anti-atherogenic effects of atorvastatin. We further explored the 
mechanism by which anacetrapib reduces (V)LDL-C and whether this effect is dependent 
on the inhibition of CETP activity in chapter 5. In this study, we showed that anacetrapib 
reduces (V)LDL-C by increasing hepatic remnant uptake via two mechanisms: (i) inhibition 
of CETP activity, resulting in remodelled VLDL particles that are more susceptible to hepatic 
uptake; and (ii) a CETP-independent reduction in plasma proprotein convertase subtilisin/
kexin type 9 (PCSK9) level that has the potential to increase LDL receptor (LDLR)-mediated 
hepatic remnant clearance.
In 2003, Abifadel et al. identified two French families with autosomal dominant 
hypercholesterolemia caused by mutations in PCSK9. PCSK9 is a serine protease responsible 
for LDL receptor (LDLR) degradation by preventing the recycling of the receptor to the 
cell membrane after internalization. The upregulation of the LDLR after statin treatment 
is accompanied by an upregulation of PCSK9 which in turn promotes LDLR degradation. 
Inhibition of PCSK9 is, therefore, a potential novel strategy in the treatment against CVD, 
especially in combination with statin treatment. We, therefore investigated the effects of 2 
dosages of the fully human, monoclonal antibody against PCSK9, alirocumab alone and in 
combination with atorvastatin on atherosclerosis development in chapter 6. In this study, 
alirocumab dose-dependently increased hepatic LDLR protein levels and consequently 
decreased plasma cholesterol levels and reduced the development of atherosclerosis. 
Moreover, alirocumab improved lesion morphology and enhanced the beneficial effects of 
atorvastatin. The anti-atherosclerotic effect was strongly dependent on the reduction of 
plasma TC levels, indicating that the majority of the effect was brought about by cholesterol 
lowering leaving limited/no space for other potential (pleiotropic) effects. This is the first 
study to show that a monoclonal antibody to PCSK9 reduces atherosclerosis development. 
In chapter 7, we reviewed the effects of established and novel treatment strategies, 
specifically targeting HDL, other than statins on inhibition of atherosclerosis development 











































and implicated in the mechanisms by which most therapies modulate HDL. In addition, we 
conducted a meta-analysis to evaluate the potential effects of these treatment strategies 
on the prevention of clinical events in randomized controlled trials. We focused specifically 
on the contribution of non-HDL-C/LDL-C-lowering versus HDL-C-raising on inhibition of 
atherosclerosis and the prevention of CVD. According to results from our systematic review 
and meta-analysis, it is evident that the protective role of lowering LDL-C and non-HDL-C is 
well-established. The contribution of raising HDL-C on inhibition of atherosclerosis and the 
prevention of cardiovascular disease remains undefined and may be dependent on the mode 
of action of HDL-C-modification. Nonetheless, treatment strategies aimed at improving HDL 
function and raising apolipoprotein A-I may be worth exploring. 
In conclusion, the research described in this thesis provides evidence for anti-atherogenic 
effects of several innovative pharmaceutical interventions that are currently being 
investigated in clinical trials, specifically targeting hypertension and hypercholesterolemia 
as risk factors for CVD. Our results further support additional benefit of these treatment 
strategies in combination with statin treatment which is currently the ‘gold standard’ 
therapy for the treatment of CVD. Most of these lipid-modifying treatment strategies 
affect both LDL-C and HDL-C and we demonstrate that the beneficial effects of these 
treatment strategies predominantly derive from their non-HDL-C/LDL-C-lowering abilities. 
Nonetheless, results from preclinical studies and clinical trials support the notion that 
treatment strategies aimed at improving HDL function and raising apolipoprotein A-I may 






















































































Hart- en vaatziekten zijn wereldwijd doodsoorzaak nummer één ondanks succesvolle 
ontwikkeling van verschillende medicijnen, waarvan statines gelden als gouden standaard 
voor lipidenverlagende therapie. Atherosclerose is een chronische ontstekingsziekte, van 
multifactoriële origine, welke een grote bijdrage levert aan de ontwikkeling van hart- en 
vaatziekten. Het in dit proefschrift beschreven onderzoek bekeek de effecten van innovatieve 
farmaceutische interventies op experimentele atherosclerose. Deze interventies waren 
gericht tegen hypertensie of hyperlipidemie en, meer specifiek, tegen een hoog lage 
dichtheid lipoproteine- cholesterol (LDL-C) niveau en laag hoge dichtheid lipoproteine-
cholesterol (HDL-C) niveau, wat risico’s zijn voor hart- en vaatziekten. 
Gezien het feit dat hypertensie een belangrijke risicofactor voor hart- en vaatziekten is en 
geassocieerd is met de ontwikkeling van atherosclerose, werden de anti-atherosclerotische 
effecten van aliskiren onderzocht in hoofdstuk 2. Aliskiren is de eerste directe renineremmer 
op de markt voor de behandeling van hypertensie en is geschikt voor orale toediening. In 
deze studie werden in APOE*3Leiden.CETP transgene muizen positieve effecten gezien van 
aliskiren op de ontwikkeling van atherosclerose en de stabiliteit van atherosclerotische 
lesies. Dit was het geval in monotherapie, wanneer aliskiren alleen werd gegeven, en in 
combinatietherapie met atorvastatine, mogelijk via een mechanisme waarin T-cellen 
betrokken zijn. Deze resultaten suggereren een voordeel van het gebruik van aliskiren in de 
kliniek, met name in combinatie met een statinebehandeling.
Cholesterol verpakt in LDL deeltjes is erkend als een primaire en causale risicofactor 
voor coronaire hartziekten, bewezen door experimentele, epidemiologische en genetische 
data en interventie studies. Ondanks het feit dat epidemiologische studies consistent een 
omgekeerde associatie rapporteren voor HDL-C en coronaire hartziekten, blijven de voordelen 
van HDL-C verhoging onduidelijk. In hoofdstuk 3 t/m 6 werden de effecten onderzocht 
van nieuwe lipidenmodulerende behandelingsstrategieën, zoals LDL-C verlagende en/of 
HDL-C verhogende stoffen, op de ontwikkeling van atherosclerose in APOE*3Leiden.CETP 
transgene muizen. Deze muizen zijn responsief voor zowel LDL-C verlagende als HDL-C 
verhogende stoffen op een manier die lijkt op die van de mens.
De voordelen van niacine op plasmalipiden werden voor het eerst beschreven in 1955 
en leidden tot de ontwikkeling van niacine voor therapeutisch gebruik. In hoofdstuk 3 is 
getracht de discrepantie uit te leggen tussen de positieve effecten van niacine, gevonden 
in de eerste klinische studies, en de afwezigheid van een effect van niacine op hart- en 
vaatziekten wanneer het in combinatie met een statine werd gebruikt in de grote AIM-HIGH 
en HPS2-THRIVE klinische studies. Hiervoor werden de effecten van niacinebehandeling 
alleen of in combinatie met simvastatine op atherosclerose ontwikkeling onderzocht. Deze 










































door non-HDL-C te verlagen, met milde HDL-C verhogende en additionele anti-inflammatoire 
effecten. Het additive effect van niacine bovenop simvastatinebehandeling was voornamelijk 
toe te schrijven aan de non-HDL-C verlaging. Deze data suggereren dat positieve effecten 
van niacine in de kliniek voor een groot deel afhankelijk zijn van de LDL-C verlagende 
effecten bovenop de toegepaste lipidenverlagende therapie. Daarmee kunnen deze data 
het falen van niacine in de AIM-HIGH en HPS2-THRIVE studies verklaren, waarin patiënten 
een agressieve LDL-C verlagende behandeling ondergingen. 
In 1989 leidde een overduidelijk verhoogd HDL-C in twee Japanners tot de ontdekking 
van de eerste mutatie in het cholesteryl ester transfer proteine (CETP) gen. CETP faciliteert 
de overdracht van cholesterylester van het atheroprotectieve HDL naar het atherogene 
V(LDL) en is daardoor een doelwit geworden om HDL-C te verhogen. Dit heeft geleid tot de 
ontwikkeling van verschillende klein molecuul CETP remmers. In hoofdstuk 4, werden de 
effecten onderzocht van een grote doseringsreeks van de nieuwe CETP remmer anacetrapib 
op atheroscleroseontwikkeling. Tevens werden mogelijk additieve/synergistische effecten 
van anacetrapib in combinatie met statinetherapie beoordeeld. In deze studie verlaagde 
anacetrapib de CETP activiteit dosisafhankelijk en verlaagde daarbij het non-HDL-C en 
verhoogde het HDL-C. Anacetrapib remde de atheroscleroseontwikkeling dosisafhankelijk. 
Dit effect werd voornamelijk toegeschreven aan de verlaging in non-HDL-C ondanks een 
opmerkelijke verhoging van HDL-C, zonder daarbij de functionaliteit van HDL te veranderen. 
Anacetrapib verbeterde ook de stabiliteit van lesies en had een toegevoegde waarde voor 
de anti-atherogene effecten van atorvastatine. Vervolgens werd het (V)LDL-C verlagende 
werkingsmechanisme van anacetrapib onderzocht in hoofdstuk 5 en werd bekeken of dit 
effect afhankelijk is van de remming op CETP activiteit. De studie liet zien dat anacetrapib 
(V)LDL-C verlaagt door het verhogen van de hepatische opname van restpartikels via twee 
mechanismen: (i) remming van de CETP activiteit, wat resulteert in geremodelleerde VLDL 
deeltjes, die makkelijker op te nemen zijn door de lever; en (ii) een CETP-onafhankelijke 
afname in plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) niveau wat de LDL 
receptor (LDLR)- gemedieerde hepatische restdeeltjes klaring kan verhogen.
In 2003 identificeerde Abifadel et al. twee Franse families met autosomaal dominante 
hypercholesterolemie, wat veroorzaakt werd door mutaties in het PCSK9 gen. PCSK9 
is een serine protease welke LDLR degradatie promoot door recycling van de receptor 
na internalisatie terug naar het celmembraan te voorkomen. De verhoging van de LDLR 
expressie na statinebehandeling wordt vergezeld door een verhoging van PCSK9, wat 
daarop weer de LDLR degradatie bevordert. Remming van PCSK9 is daarom in potentie een 
nieuwe strategie in de behandeling tegen hart- en vaatziekten, vooral in combinatie met een 
statinebehandeling. De effecten van 2 verschillende doseringen alirocumab, een volledig 
humaan monoclonaal antilichaam tegen PCSK9, alleen en in combinatie met atorvastatine 











































alirocumab de hepatische LDLR eiwitexpressie dosisafhankelijk en daardoor verlaagde het 
de plasma cholesterolwaarden en de ontwikkeling van atherosclerose. Tevens verbeterde 
alirocumab de morfologie van lesies en versterkte het de positieve effecten van atorvastatine. 
Het anti-atherosclerotische effect was sterk gecorreleerd aan de verlaging van het plasma 
totaal cholesterol, wat suggereert dat het effect grotendeels werd veroorzaakt door 
cholesterolverlaging waarbij geen of weinig ruimte was voor andere mogelijke (pleiotrope) 
effecten. Dit is de eerste studie die laat zien dat een monoclonaal antilichaam tegen PCSK9 
daadwerkelijk atheroscleroseontwikkeling kan remmen.
In hoofdstuk 7 hebben we de effecten van reeds bestaande en nieuwe 
behandelingsstrategieën, specifiek gericht op HDL anders dan statines, op 
atheroscleroseontwikkeling in preklinische studies geëvalueerd. Voor dit systematische 
overzicht werden alleen studies bekeken waarin dieren werden gebruikt die CETP tot 
expressie brengen, omdat dit een cruciaal gen is voor het HDL metabolisme en veelal 
betrokken is in het werkingsmechanisme van de meeste HDL modulerende therapieën. 
Tevens werd een meta-analyse uitgevoerd om de potentiele effecten van deze behandelingen 
op de preventie van mortaliteit en morbiditeit in gerandomiseerde gecontroleerde studies 
te evalueren. Specifiek werd de bijdrage van de non-HDL-C/LDL-C verlaging ten opzichte 
van HDL-C verhoging op de remming van atherosclerose en de preventie van hart- en 
vaatziekten onderzocht. De resultaten van dit systematisch overzicht en deze meta-analyse 
bevestigen dat de beschermende rol van non-HDL-C/ LDL-C verlaging evident is. De bijdrage 
van HDL-C verhoging op de remming van atheroscleroseontwikkeling en de preventie 
van hart- en vaatziekten blijft echter onduidelijk en zou afhankelijk kunnen zijn van het 
werkingsmechanisme van HDL-C modificatie. Niettemin zouden behandelingen gericht op 
de verbetering van HDL functie en de verhoging van apolipoproteine A-I zeer waardevol 
kunnen zijn.
In conclusie, het in dit proefschrift beschreven onderzoek levert bewijs voor anti-
atherogene effecten van verschillende innovatieve farmaceutische interventies, die 
momenteel onderzocht worden in klinische studies, specifiek gericht tegen hypertensie en 
hypercholesterolemie wat risicofactoren zijn voor het ontstaan van hart- en vaatziekten. 
Deze resultaten onderschrijven de toegevoegde waarde van deze behandelingsstrategieën 
in combinatie met een statinebehandeling, wat momenteel de gouden standaard is voor 
de behandeling van hart- en vaatziekten. De meeste van deze lipidenmodulerende stoffen 
beïnvloeden zowel LDL-C als HDL-C. Onderzoek in dit proefschrift laat zien dat de positieve 
effecten van deze behandelingen voornamelijk toe te schrijven zijn aan de non-HDL-C/LDL-C 
verlagende effecten. Niettemin ondersteunen resultaten van preklinische en klinische studies 
de gedachte dat het verbeteren van HDL functie en het verhogen van apolipoproteine A-I 
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